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EXECUTIVE SUMMARY  
 
This report presents an independent review of the adequacy of New Zealand’s regulatory 
frameworks in dealing with manufactured nanomaterials (mNMs). In particular, it considers 
how regulatory oversight is triggered for mNMs, and identifies the existence of some 
potential regulatory gaps (a somewhat contested term which we discuss below). This project 
was completed by staff of the New Zealand Law Foundation Centre for Law and Policy in 
Emerging Technologies, Otago University, over the period March to December 2010. Our 
approach has closely followed that adopted in the report conducted by staff at Monash 
University in 2007, regarding Australia’s regulatory frameworks. 
 
In many ways, our overall conclusions are similar to those of the Monash Report, and indeed 
to other reports in this area.3 None of the areas of the New Zealand regulatory system that we 
have considered require wholesale changes in order to be applicable to mNMs. The regulatory 
mechanisms applicable to conventional products will, in broad terms, apply to mNMs, and to 
products containing and incorporating such products (though a possible gap was identified 
where the product actually creates nanoparticles, subsequent to sale.) 
 
In those areas where regulatory coverage is comprehensive for conventional products, it will 
usually be comprehensive for mNMs. The corollary, of course, is that areas of weakness in 
the regulatory frameworks will provide areas of weak regulation for mNMs too. We have, 
however, identified a number of possible regulatory gaps or weaknesses that are more specific 
to products containing mNMs. Our approach has distinguished between gaps that appear to 
occur at different levels: respectively, at the level of legislation, at the level of regulatory 
policy, and at the level of compliance and enforcement. The options for addressing those gaps 
will often depend upon which of these categories they are considered to fall within.  
 
We have also followed the methodology of the Monash Report in grouping the gaps under six 
headings, though our headings do not map precisely onto those utilised in the earlier report.  
 
Is a nanoform ‘new’? 
 
Identified by the Monash Report as ‘possibly the most significant potential gap’, we have also 
found points within New Zealand’s regulatory framework where the identification of 
nanoforms of existing products as new or ‘novel’ is potentially uncertain.  A safety 
assessment under the HSNO Act, for example, will only be triggered if ‘the hazards differ 
between the “conventional” substance and the nano substance’. Similarly, in many 
circumstances a food will be subject to a pre-market safety assessment only if it satisfies the 
criteria for a ‘novel food’ set out in Standard 1.5.1 of the FS Code.  
 
We have suggested that, with regard both to the HSNO and FSANZ Acts, these gaps could 
potentially be addressed by the regulators, without need to amend the legislation. ERMA 
could, for example, modify its Group Standards to require that nano-forms of existing 
                                                     
3 ‘“Regulatory gap” analyses have tended to conclude that the existing framework is capable of 
adaptation to make it fit for purpose in dealing with nanomaterials … After careful consideration, we 
agree.’ Royal Commission on Environmental Pollution, Novel Materials in the Environment; Then 
case of nanotechnology (2008), at paras 4.43 and 4.44. ‘We believe that for the foreseeable future, the 
present regulatory frameworks for protecting humans and the environment are sufficiently broad to 
encompass nanotechnologies and that a separate regulator or regulatory framework is unnecessary.’ 
The Royal Society and The Royal Academy of Engineering, Nanoscience and nanotechnologies: 
opportunities and uncertainties (2004) at 8.5. 
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substances could be subject to new assessments, or at least that they must be notified to 
ERMA. A partial precedent already exists in the form of the Cosmetic Products Group 
Standard, which requires notification of any cosmetic product containing nanomaterials. With 
regard to food, we have suggested that the least burdensome step for the regulator would be to 
stipulate unambiguously that all foods containing manufactured NMs should be submitted 
either to the Advisory Committee on Novel Foods for a recommendation as to novelty, or to 




Some questions have also arisen with regard to the remit of some of the regulatory bodies. For 
example, the applicability of the HSNO Act to nano-silver washing machines, and – in future 
– other items such as nano-silver fridges is an area of uncertainty, in view of the likely 
designation of such items as ‘manufactured articles’, which may render them ultra vires of the 
HSNO Act and of ERMA. 
 
The existence of such gaps is not attributable to the presence of mNMs; ERMA’s regulatory 
remit does not extend to manufactured items, whether or not they contain mNMs. However, 
the presence of mNMs may be thought to present new hazards, of a nature that would render 
greater regulatory oversight desirable. Furthermore, some of the potential gaps we have 
identified result in fairly arbitrary distinctions, e.g. between items designed to produce 
potentially hazardous substances, and items which already contain such substances.  
 
We have indicated that the potential solutions to such gaps may lie at the level of regulatory 
policy; as discussed below, for example, it may be open to ERMA to extend its remit to nano-
silver white goods by utilising s.96B(2)(d) of the HSNO Act. There may, however, be 
instances where the regulator’s remit can only be extended to certain items by means of 
amending the statute.  
 
Appropriateness of quantity-based triggers and conditions 
 
The existence of quantity-based regulatory triggers was identified in the Monash Report as a 
significant regulatory gap, and its conclusions have led NICNAS, the Australian industrial 
chemicals regulator, to revise some of its mass-based exemptions. As no analogous 
exemptions exist in New Zealand, this particular proposal is not applicable to the New 
Zealand regulatory framework. 
 
Quantity-based conditions, however, are present in the New Zealand regulatory scheme. For 
example, in terms of food regulation, some additives and contaminants are permitted only 
subject to quantitative restrictions. Doubts have been raised regarding the suitability of such 
limits to nanoforms. Again, it appears to us as though the regulator – in this case, FSANZ – 
has the capacity to vary these limits, either with regard to nanoforms of existing materials or 
new/novel nanoscale materials (see Section 3.7). It is to be hoped that regulators will keep the 
appropriateness of such quantitative restrictions under review if – as we strongly suspect – 




The European Union recently legislated for compulsory labelling of cosmetics containing 
NMs, while a proposal to require nano-specific labelling of novel foods is currently the 
subject of conciliation proceedings involving the EU Parliament, Council and Commission. 
At present, there are no nano-specific labelling requirements in New Zealand, either for 
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






cosmetics or for any other products containing mNMs. This could be argued, in some 
contexts, to be a regulatory gap. In relation to food regulation, for example, we have noted 
that one of FSANZ’s objectives, as laid down in the FSANZ Act, is ‘the provision of 
adequate information relating to food to enable consumers to make informed choices’. On the 
other hand, as discussed later, the view has been expressed quite forcefully that the decision 
not to require nano-specific labelling is not a regulatory gap, but rather, a considered and 
appropriate decision made within the regulatory framework.  
 
Perhaps more than any other, we found this issue to be one that divided, even polarised, 
opinion. Clearly, before offering an opinion on the normative question as to whether food or 
other products containing mNMs should be labelled as such, a great many considerations 
would need to be weighed that we have not had the opportunity to evaluate here. We have 
therefore confined ourselves to the observation that some commentators view the status quo 
as inadequate, and as such, we consider it a suitable subject for inclusion in our report. Our 
suggestions as to how a labelling requirement could be introduced should, however, be read in 
that context, and should be taken to imply nothing either way about the quite separate 
question of whether it should be introduced. 
 
Insofar as this is properly seen as a regulatory gap, it may be one that could be addressed at a 
regulatory, as opposed to statutory level. FSANZ could, for example, vary the FS Code to 
require nano-specific labelling, while it would seem to be open to ERMA to use Group 
Standards to impose a similar condition on manufacturers of, e.g., cosmetics containing NMs. 
We note, finally, that due consideration would have to be paid to the appropriate wording of 
any such labels, if they are to impart genuinely useful information to prospective consumers 




The limited state of current knowledge about the risks posed by some mNMs presents a 
number of obstacles to any attempt to regulate in this area. In some cases, regulatory triggers 
require the identification of a product as being likely to present a risk. Under the Waste 
Minimisation Act, for example, the absence of documented cases of adverse environmental 
effects directly attributable to mNMs may mean that products containing mNMs may not be 
singled out as products likely to harm the environment when disposed of as waste.  
 
It is obviously important that regulators remain apprised of the most recent reliable 
information with regard to the possible hazards presented by mNMs; indeed, we are reassured 
that many of the regulators had already acknowledged this obligation. More challenging, 
however, is the question of how to proceed in situations of uncertainty. With regard to burden 
of proof, should regulators assume that a nanoform of an existing product is safe until reliable 
evidence shows otherwise? Or should they operate the contrary assumption: that a new 
product is unsafe until the contrary can be demonstrated? 
 
Some of the regulatory frameworks we have examined offer some guidance in this regard. 
The HSNO Act, for example, adopts a ‘precautionary approach’, which emphasises ‘the need 
for caution in managing adverse effects where there is scientific and technical uncertainty 
about those effects’. However, a range of opinions can be found as to how ‘caution’ is to be 
understood. ERMA’s view is that ‘while the HSNO Act provides for decisions to be 
precautionary where there is scientific or technical uncertainty … it does not empower ERMA 
to act when there are suspicions but little or no evidence.’ This understanding of the 
precautionary remit is likely to be controversial, not least because it may be thought that many 
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of the situations in which there is ‘scientific or technical uncertainty’ will arise precisely 
because ‘there are suspicions but little or no evidence’.  
 
This is far from a straightforward matter. As one leading commentator on the regulation of 
emerging technologies has said, ‘there is scope for endless argument about just how strong 
the evidence needs to be before precaution kicks in.’4 On one view, it seems inevitable that, 
when dealing with NMs about which the evidence of hazard is still uncertain, particular 
mNMs must either be presumed to be safe or unsafe. It is unclear what an approach avoiding 
either of those presumptions might look like, even in theory. However, it is also possible that 
more nuanced options may exist within those broad presumptions. For example, an approach 
could perhaps be adapted from criminal law, whereby anyone objecting to an NM would bear 
an evidentiary burden of demonstrating some risk of harm – of ‘putting the issue into play’, as 
it has been described – but having passed that threshold, the burden of proof would then 
transfer to the manufacturer to prove that the risk was unfounded or adequately managed. 
This could potentially avoid the possibility of an NM being banned because of a mere 
suggestion of hazard, but would perhaps avoid the danger of regulatory paralysis until some 
harm has actually occurred. 
 
The question of standard of proof has also been identified as an area of possible uncertainty, 
for example, the ‘likelihood’ trigger in Standard 1.4.3 of the FS Code, or the designation as 
‘hazardous’ in terms of the HSE or HSNO Acts. How compelling must the evidence be before 
such triggers are activated? Whether carbon nanotubes, for example, should be deemed 
‘hazardous substances’ within the terms of the HSNO Act seems at present to be uncertain.5 
For some of those with whom we have spoken, existing evidence about CNTs is sufficient to 
justify a moratorium on their use, or at least on certain uses to which they could be put, while 
for others, the studies published to date are preliminary and inconclusive. 
 
Insofar as existing regulations are not specific about the level of proof that would be required 
to trigger regulatory action, we agree with the Monash Report that these may be seen as 
potential regulatory gaps. 
 
Successive Generations of mNMs and Combination Products  
 
This report focuses on presently existing nano-products, and to an extent, on those which are 
foreseen as likely to enter the market in the near future. Therefore, we are primarily 
concerned with the first and second generation nanotechnologies and mNMs.6 We suspect 
that the conclusions that we offer here will require revision as and when successive 
generations of mNMs enter the market.  
 
Some reviews of this topic have suggested that subsequent generations of nanotechnologies 
are likely to present a much more significant challenge to existing regulatory structures.7 This 
report concludes that the second, and successive generations, of nanomedicines do, and will 
continue to, present challenges to the Medicines Act 1981. Many of the new generation 
nanomedicines combine medicines and devices into a single product. These ‘combination 
products’ are therapeutic or diagnostic products that combine a drug, device and/or biological 
                                                     
4 Roger Brownsword, Rights, Regulation, and the Technological Revolution. Oxford: Oxford 
University Press, 2008, at p.106 
5 As per correspondence with Sustainability Council, 30 November 2010,  and ERMA, 21 December 
2010.  
6 J. Clarence Davis ‘Oversight of Next Generation Nanotechnology’ (Project on Emerging 
Nanotechnologies, April 2009) at p. 8, available at http://www.nanotechproject.org 
7 Id.  
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product into a single entity. ‘Cosmeceuticals’, which combine cosmetics with medicines, may 
also present regulatory challenges.  
 
These next generation and combination nano-products (which may sit at the border or 
regulatory agencies and regulatory regimes) will require regulatory review as more such 





Compliance and enforcement 
 
Finally, it should be borne in mind that even the most comprehensive regulatory framework 
will be an ineffective safeguard of public health if no effective mechanism exists to monitor 
and enforce compliance with it. This is what we identified as a third level regulatory gap. For 
example, the notification requirement of the presence of NMs in cosmetics relies upon the 
voluntary compliance of manufacturers. It appears, however, that this requirement has, at least 
until recently, been widely ignored. This gap is far from unique to New Zealand; in Australia, 
a voluntary call for data by the National Industrial Chemicals Notification and Assessment 
Scheme (NICNAS) produced ‘disappointing’ results, while a voluntary reporting scheme 
operated by the UK’s DEFRA has yielded a similarly low number of reports.8 
 
We therefore make the general observation that, before implementing any rule or measure to 
address nano-safety concerns, consideration should perhaps be given to the practical necessity 
of monitoring, and where need be, enforcing compliance with that rule or measure. This may 
involve a range of measures, from merely reminding manufacturers in clear terms of their 
obligations, to invoking such legal sanctions as are considered appropriate. Where regulators 
are not empowered to conduct such monitoring and enforcement roles, amendment of their 
foundation statutes may be required. More often, we suspect, lack of monitoring and 
enforcement will result from policy decisions by the regulators themselves, and the resource 




It may be seen, then, that some of the potential gaps we have identified are quite specific to a 
particular regulatory area. Others – such as the challenge of deciding what burden and 
standard of proof is most appropriate in the face of uncertain evidence – are likely to be 
common to all regulators, and probably in all jurisdictions. Insofar as specific gaps have been 
identified, we have tried where possible to consider some possible strategies whereby they 
could be closed, or at least narrowed. Where we have done so, these should be seen merely as 
options for further consideration, rather than explicit recommendations on our part.  
 
As the Monash Report concluded, it is now for each of the regulatory agencies to consider in 
detail the potential gaps we have identified, and to consider whether these potential gaps 
require some action on their part. If some action is regarded as appropriate, detailed 
consideration should then be given to what form of action would be most appropriate to the 
gap in question, giving consideration to the scale an urgency of the possible problem, and to 
issues of proportionality. 
 
                                                     
8 Royal Commission on Environmental Pollution Novel Materials in the Environment, op. cit., at para. 
4.74. 
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This report, then, in no ways purports to be the last word on the subject of regulation of 
nanoproducts in New Zealand. It is hoped, however, that it will make a worthwhile 
contribution to clarifying the terms of the discussions that must follow. 
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The origins of this review lie with a Nanotechnology Workshop, hosted by MORST and 
others, in April 2009. The aim of that Workshop was to ‘raise awareness of opportunities and 
challenges that nanotechnologies are creating, identify what are the most important 
nanotechnology-related issues for New Zealand, and discuss appropriate ways to address 
them.’9 One outcome of this Workshop was an undertaking by MoRST to commission ‘a 
study to review New Zealand's regulatory landscape with respect to nanotechnologies … 
identifying potential regulatory gaps or weaknesses.’ Similar studies had already taken place 
in the UK,10 EU11, Australia,12 and the US.13 The stated intention was that the New Zealand 
study would follow a similar approach to that adopted in the Monash Report. 
 
In March 2010, responsibility for conducting this study was given to members of the newly 
established New Zealand Law Foundation Centre for Law & Policy in Emerging 
Technologies, at the University of Otago. An interim report, representing the results of the 
researchers’ meetings with regulators and provisional conclusions, was presented in 
September 2010. Following a teleconference meeting with regulators in October 2010, at 
which responses and suggestions were offered and discussed, a Final Report was prepared and 
submitted in January 2011.  
 
Although we are grateful for the contributions that various regulators, academics and other 
stakeholders have made to our understanding of this area, we stress that the content, and 
particularly the conclusions, of this report are our own, and not necessarily shared by any of 
those parties. 
 
1.2 Project aims 
 
The aims of this project are to produce a review of how regulatory oversight is triggered for 
mNMs in New Zealand, as well as to conduct an analysis of Australia’s proposed response to 
a similar review of their regulatory framework. More specifically, the objectives set out by the 
Ministry of Research, Science and Technology in the Statement of Work document were to: 
 
Assess New Zealand’s existing regulatory framework to determine if potential risks of 
manufactured nanomaterials are covered by existing regulatory frameworks;  
                                                     
9 http://www.morst.govt.nz/current-work/roadmaps/nanotech/workshop-2009/ 
10 The Royal Society & The Royal Academy of Engineering, Nanoscience and nanotechnologies. (July 
2004), Chapter 8; Chaudhry Q.; Boxall, A.;Aitken, R.; Hull, M. A Scoping Study into the Manufacture 
and Use of Nanomaterials in the UK. Sand Hutton, York: Central Science Laboratory, 2005; Royal 
Commission on Environmental Pollution, Novel Materials in the Environment: The case of 
nanotechnology (November 2008), Chapter 4. 
11 European Commission Regulatory Aspects of Nanomaterials: Summary of Legislation in Relation to 
Health, Safety and Environment Aspects of Nanomaterials, Regulatory Research Needs and Related 
Measures (Commission of the European Communities, Brussels, 2008); European Commission 
Regulatory Aspects of Nanomaterials (Commission of the European Communities, Brussels, 2008).  
12 Karinne Ludlow, Diana Bowman and Graeme Hodge. A Review of Possible Impacts of 
Nanotechnology on Australia’s Regulatory Framework. September 2007, henceforth referred to as the 
Monash Report.  
13 Food and Drug Administration, Nanotechnology – A Report of the US Food and Drug 
Administration Nanotechnology Task Force (FDA, Washington DC, 2007); Environmental Protection 
Agency EPA Nanotechnology White Paper (EPA, Washington DC, 2007).  
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Identify where manufactured nanomaterials may not be adequately covered by any existing 
regulatory framework; and 
Analyse whether the changes to the regulation of industrial nanomaterials proposed by 
NICNAS in Australia are relevant to provisions under the HSNO Act.  
 
For the purposes of this project, and in accordance with the MORST Statement of Work, 
nanotechnology has been defined as: ‘the understanding and control of matter at dimensions 
of roughly 1 to 100 nanometres, where unique phenomena enable novel applications.’ 
Manufactured nanomaterials are ‘intentionally produced, manufactured or engineered to have 
specific properties or specific composition, and one or more dimensions typically between 1 




Though very commonly accepted,15 the definition of ‘nanotechnology’ set out in the 
Statement of Work  is not uncontested.16 Indeed, the appropriateness of a size-based definition 
at all has been called into question.17 Other commentators seek to restrict the definition of 
nanotechnology to ‘the control and restructuring of matter at 1-100 nm to create materials, 
devices, and structures.’18 In view of the current state of technological development, most of 
what we discuss here would fail to meet that stricter definition; the nanoscale particles of 
silver or zinc that are found in certain consumer goods have not, after all, been ‘restructured’. 
Controversies around that definition, however, have little relevance to this report. As the title 
makes clear, we are concerned here with nanomaterials, rather than nanotechnologies; that is, 
with  manufactured materials with at least one dimension of less than 100nm, regardless of 
how they were manufactured. 
 
As noted above, and in accordance with the Statement of Work, our report is also limited to 
consideration of  materials ‘intentionally produced, manufactured or engineered to have 
specific properties or specific composition, and one or more dimensions typically between 1 
and 100 nanometres.’ Our remit, therefore, does not extend to consideration of nano-scale 
materials that may be produced as an unintended by-product of a manufacturing or other 
process. Again, that we do not address that issue within this report should not be taken to say 
that it is an issue of no importance.  
 
                                                     
14 Statement of Work, at para. 2. 
15 It is, for example, the definition adopted by the US National Nanotechnology Initiative 
(http://www.nano.gov/html/facts/whatIsNano.html), and in reports by, respectively, the UK’s Royal 
Society and Royal Academy of Engineering, and the Royal Commission on Environmental Pollution.   
16 ‘Currently the definition of what is “nano” is still under debate.’ SCENIHR, Risk Assessment of 
Products of Nanotechnologies, January 2009, p.7. See also Geoffrey Hunt, ‘Nanoscience and Complex 
Systems: The Case for Nanology’, in Hunt and Mehta, eds. Nanotechnology: Risk, Ethics and Law 
(London: Earthscan, 2006), and the Sustainability Council report, The Invisible Revolution.  
17 Auffan, et al. ‘Towards a definition of inorganic nanoparticles from an environmental, health and 
safety perspective’ Nature Nanotechnology 4, 634 - 641 (2009). It has also been noted in one of our 
predecessor reviews that ‘many believe that “nanotechnology” as a term will cease to exist within the 
next decade because increasingly researchers will select a material for its functionality, rather than for 
its size.’ Royal Commission on Environmental Pollution, Novel Materials in the Environment: The 
case of nanotechnology (November 2008), at para. 2.5. 
18 Mike Treder, ‘Risk Governance Report’, 11 July 2006, at 
 http://crnano.typepad.com/crnblog/2006/07/irgc.html, our emphasis. 
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Throughout this report, we make frequent reference to ‘regulatory gaps’. This terminology is 
common in reports of this kind,19 and indeed, the Statement of Work makes specific reference 
to it.20 However, as with previous reports on this topic, the use of this expression has at times 
generated a measure of controversy. It should therefore be made clear from the outset that, in 
identifying actual or potential regulatory gaps, we intend something analogous to the 
definition adopted in the Monash Report, i.e. ‘potential regulatory gaps were defined as 
occurring where the analysis suggested that Australia’s existing regulatory frameworks may 
not cover, or cover appropriately, nanotechnology-based materials, products and 
applications.’21 
 
In particular, it should be noted that, in identifying the existence of a regulatory gap, we imply 
nothing about whether such gaps arose as a result of regulatory oversight, or after considered 
deliberation. Neither do we imply anything about the appropriate response to such gaps; 
questions of whether, how and when they should be narrowed or closed involve a range of 
policy and perhaps resource considerations that lie outwith our remit. A regulatory gap is 
merely an area where it appears to us that existing regulatory frameworks may not apply to 
mNMs, or may not apply to mNMs in a manner that would generally be agreed to be 
adequate. Whether a particular gap is troubling enough to justify the cost and effort of closing 
it is a separate question. 
 
There have also been occasions when we have found the regulatory parameters to be 
insufficiently certain to enable us to state, with complete confidence, whether or not they 
would extend to mNMs. This may be because a particular statutory provision is open to a 
number of alternative interpretations, and has never been definitively interpreted by a court. 
Or it may be because a particular item that contains or incorporates mNMs has not yet been 
introduced into New Zealand, leading to a degree of uncertainty as to whether it would trigger 
particular regulatory mechanisms. In such circumstances, we have flagged up these 
uncertainties as potential regulatory gaps, reflecting the current state of uncertainty as to 
whether existing regulatory mechanisms will prove adequate.  
 
On other occasions, we have encountered a lack of consensus as to whether something is or is 
not properly designated a gap. To take one example, the absence of any provision requiring 
labelling of foodstuffs containing manufactured NMs is, to some observers, a gap in the 
regulatory framework. To others (including at least some of the regulators with whom we 
have worked), it is the result of a considered decision within that framework, and should not 
be designated a ‘gap’ at all. In such circumstances, we have attempted, in our use of language, 
to indicate this diversity of opinions. However, we hope that consideration of the substantive 
content of this report does not come to be eclipsed by a debate about semantics.  
 
Our approach identifies three possible levels of regulatory gaps, which seem to require 
different strategies if they are to be closed. The first is at the statutory level. If some of the 
legislation we have been charged to evaluate does not, for whatever reason, apply to mNMs, 
then this is a gap that would presumably require to be addressed by amending the relevant 
statutory provision.  
 
The second level of regulatory gap is at the level of interpretation and application; thus, 
some gaps may be thought to exist because regulators have interpreted a piece of legislation 
                                                     
19 In addition to the Monash Report, see, for example, The Royal Society & The Royal Academy of 
Engineering, Nanoscience and nanotechnologies. (July 2004); Royal Commission on Environmental 
Pollution, Novel Materials in the Environment: The case of nanotechnology (November 2008). 
20 At paragraph 15. 
21 Monash Report, at para 1.2 
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in a particular manner, or because they have adopted a particular policy when applying it or 
operating within it. A regulatory gap at this level could also be closed by modifying the 
relevant legislation (so as to render its wording less open to interpretation, or to require a 
particular course of action by the regulators). Alternatively, it could be altered by a policy 
change on the part of the regulators. 
 
The third level at which potential regulatory gaps might exist would be with regard to 
enforcement and compliance. Here, we may find that the relevant legislation contains 
adequate provisions for regulation, and that the regulators charged with implementing it have 
a policy that encompasses mNMs; however, for whatever reason, compliance with the 
regulatory framework is inadequate. This may be because importers or manufacturers are 
neglecting to comply with, or are unaware of, a voluntary reporting scheme. Alternatively, it 
may be because the regulator is insufficiently resourced to monitor such compliance, or that 
they have not regarded such monitoring as a priority. The manner in which gaps at this level 
could be closed will depend ultimately in the reason for their existence, with tighter rules (for 
example, replacing voluntary with compulsory compliance), more effective monitoring or 
differing regulatory priorities perhaps being better suited to different situations. 
 
In a recent article, Robert Lee and Elen Stokes pointed out that ‘an analysis of regulatory 
coverage may ignore issues of regulatory application and overlook completely the question of 
regulatory effectiveness. The fact that existing regulation can extend to cover 
nanotechnologies offers little indication of the actual extent of protection.’22 Although we in 
no way claim that this report addresses all of the areas to which Lee and Stokes refer, we hope 
that in at least considering these second and third level regulatory gaps, we are addressing 
some of their concerns about reviews of this nature. 
 
While we may, at times, suggest possible mechanisms by which regulatory gaps could be 
closed, these should be treated merely as contributions to the range of options available to 
policy makers. We reiterate that identifying something as a regulatory gap should be taken 
neither as an attribution of blame for its existence, nor to venture into the realm of policy or 
resource prioritisation. 
 
1.4 Remit and limitations 
 
As with the Monash Report which we were asked to take as our model, we should make it 
clear that this report comprises an academic review of the applicability of various regulatory 
frameworks to manufactured nanomaterials, and should not be regarded as legal advice. It is, 
to borrow a phrase from that Report, an exercise in ‘regulatory terrain mapping’, and does not 
purport to be a definitive or wholly comprehensive study of every area of law that could 
potentially impact upon nanotechnologies and mNMs.  
 
It is also important to be clear from the outset that the remit of this report has limited us to a 
consideration of whether ‘and under what conditions, nanotechnology-based materials, 
products or applications, and their manufacture, use and handling, are covered by existing 
regulatory frameworks’. In particular, it has not been our task to make recommendations 
regarding the proper policy to be adopted with regard to manufactured NMs, and certainly not 
to nanotechnology more generally. Where mNMs have been found not to be covered by 
existing regulatory frameworks, we have noted this. Where we have concluded that existing 
regulatory mechanisms are triggered by the presence of mNMs, this should be taken to imply 
no conclusion either way as to the substantive adequacy of those mechanisms. Whether they 
                                                     
22 Lee, R and Stokes, E. ‘Twenty-first Century Novel: Regulating Nanotechnologies’ Journal of 
Environmental Law (2009); 21(3): 469-482, at pp.472-473 
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currently strike the correct balance between, for example, progress and precaution, is an 
important question, but not one that we were asked to consider in this report. 
 
Specifically, we have not addressed the question of whether a separate regulatory strategy or 
regulatory body should be set up to deal with mNMs or nanotechnologies. We note, however, 
that while some jurisdictions may be moving towards closer scrutiny of mNMs,23 there does 
not seem to have been a move towards the creation of nano-specific regulatory bodies; 
indeed, some reviews of this area have expressed skepticism as to the utility of a nano-
specific regulatory approach.24  
 
Finally, we note that our report has focused on presently existing nano-products, and to an 
extent on those which are foreseen as likely to come ‘on-stream’ in the near future. 
Essentially, then, we are concerned with the products of what have been described as first and 
second generation nanotechnologies.25 Our research has revealed highly disparate estimates as 
to how nanotechnologies are likely to evolve in the medium and long term, and it may be that 
the conclusions that we offer here will require to be revised as and when more is learned 
about successive generations of nanotechnologies (a caveat that the authors of the Monash 
Report have also been careful to emphasise). It should perhaps be noted that some reviews of 
this topic have suggested that subsequent generations of nanotechnologies are likely to 
present a much more significant challenge to existing regulatory structures.26 
 
In all, though it is hoped that this report makes a valuable contribution to decisions as to 
‘whether changes to the current regulatory frameworks are required’, it was neither asked to, 
nor does it purport to, provide exhaustive coverage of the sort of information and evidence 
that should inform such decisions.  
 
Nanotechnologies: an overview 
 
As noted above, the definition of ‘nanotechnologies’ is contested. Most commentators, 
however, agree that the term refers to a multidisciplinary and heterogeneous field involving 
nanostructures and devices which are generally sized between 1 to 100 nanometers.27 One 
nanometre is one billionth of a metre. A human hair is approximately 80,000 nanometres 
wide. It would take eight hundred 100-nanometer particles side by side to match the width of 
a human hair.28 Scientists have been working with nanoscale materials for centuries, but the 
                                                     
23‘Nanomaterials: MEPs call for more prudence’, 24 April 2009, 
http://www.europarl.europa.eu/sides/getDoc.do?type=IM-
PRESS&reference=20090422IPR54260&format=XML&language=EN 
24 ‘We have not seen convincing evidence of the need for a special regulatory regime for nanomaterials 
… There is no logical reason why size of particle should in itself provide the basis for new regulatory 
controls.’ Royal Commission on Environmental Pollution, Novel Materials in the Environment: The 
case of nanotechnology (November 2008), at para. 4.44. 
25 J. Clarence Davis, ‘Oversight of Next generation Nanotechnology’ (Project on Emerging 
Nanotechnologies, April 2009), at p.8, Available at 
http://www.nanotechproject.org/process/assets/files/7316/pen-18.pdf,  
26‘nothing less than a completely new system will suffice to deal with the next generations of 
nanotechnology.’ ‘Oversight of Next generation Nanotechnology’, ibid, at p.8,  
27 We say ‘generally’ because although 1 to 100 nanometers is the commonly accepted metrology, it is 
not uncontested. For example, see SCENIHR, Risk Assessment of Products of Nanotechnologies, 
(SCENIHR, EU, January 2009) 7; Melanie Auffan and others ‘Towards a Definition of Inorganic 
Nanoparticles from an Environmental, Health and Safety Perspective’ (2009) 4 Nature Nanotechnology 
634.  
28 Understanding Nano: Introduction to Nanotechnology 
http://www.understandingnano.com/introduction.html viewed 16 October 2010. 
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relatively recent development of special microscopes,29 capable of displaying small particles 
such as atoms, has improved researchers’ ability to work with these tiny materials. 
   
NMs can be categorised as natural or engineered/manufactured. Naturally occurring NMs 
include particles in our atmosphere such as volcanic ash. Manufactured NMs are 
manufactured to have regular shapes which may contribute to their toxicity. As we explain in 
the Introduction, this report is concerned only with manufactured NMs.  
 
A broad range of applications, materials and products fall under the term ‘nanotechnologies’. 
Details of the various ‘nanotechnology families’ can be found in the Monash Report.30 
Therefore, this report does not repeat that discussion, but provides a brief explanation of 
nanotechnology applications, materials and products. Nanotechnology allows manipulation of 
properties at the nanoscale and it can have many applications in, for example, medicine, 
energy, food, environmental air and water quality, and electronics.  
 
Examples of mNMs include metal oxides, nanotubes, quantum dots and fullerenes (C60 or 
Buckyballs).   Engineered NMs have greater surface area to volume ratios than at larger sizes. 
The considerably larger surface area per unit mass increases their potential for biopersistence 
and reactivity. The nano features of these materials include not only size, but also other 
parameters such as shape, surface chemistry, composition, solubility and aggregation.  
 
NMs exhibit different physical, chemical and biological properties from their equivalent 
macro counterparts. For instance, gold as a bulk material is nontoxic, but gold particles below 
2 nanometres have shown unexpectedly high toxicity in a variety of cell lines.31   
 
Not all NMs are the same, nor are they all potentially harmful to human and environmental 
health and safety.  There are deficiencies in our scientific understanding of nanotoxicity, but 
there is growing evidence that the novel properties of some NMs may bring unforeseen 
human and environmental health and safety risks.32 Research on carbon nanotubes, for 
example, suggests that their size and fibre shape may lead to health effects similar to 
asbestos.33 Detailed discussions about the health risks, toxicity34 and exposure routes35 of 
NMs have been conducted in the academic literature. 
                                                     
29 The Scanning Tunnelling Microscope was invented in 1981 
30 Monash Report, at pp.13-20.  
31 Jahnan-Dechent, W. and Simon, U. ‘Function Follows Form: Shape Complementarity and 
Nanoparticle Toxicity’ (2008) 3 Nanomedicine 601, 602.  
32 Kandlikar, M.; Ramachandran, G. and Maynard, A. ‘Health Risk Assessment for Nanoparticles: A 
Case for Using Expert Judgment’ (2007) 9 Journal of Nanoparticle Research 137; Maynard, A. 
‘Nanotechnology: The Next Big Thing or Much Ado About Nothing?’ (2007) 51 The Annuals of 
Occupational Hygiene 1; Andrew Maynard and others ‘Safe Handling of Nanotechnology’ (2006) 444 
Nature 267; Oberdorster, G., et al ‘Nanotoxicology: An Emerging Discipline Evolving from Study of 
Ultrafine Particles’ (2005) 113 Environmental Health Perspectives 823.  
33 Poland, C. and others, ‘Carbon Nanotubes Introduced into the Abdominal Cavity of Mice Show 
Asbestos-like Pathogenicity in a Pilot Study’ (2008) Nature Nanotechnology 423; Knowles, EE. 
‘Nanotechnology: Evolving Occupational Safety, Health and Environmental Issues’ (2006) 
Professional Safety 20, 24; Service, R. ‘Nanotechnology’s Public Health Hazard?’ (2008) Science Now 
http://news.sciencemag.org/sciencenow/2008/05/20-01.html viewed 11 August 2010.   
34  Aitken, RJ; Creely, KS; Tran, CL. Nanoparticles: An Occupational Hygiene Review (Institute of 
Occupational Medicine for the Health and Safety Executive, London, 2004); Therapeutic Goods 
Administration A Review of the Scientific Literature on the Safety of Nanoparticulate Titanium Dioxide 
and Zinc Oxide in Sunscreens (Therapeutic Goods Administration, Canberra, 2006); Donaldson, K and 
others ‘Nanotoxicology’ (2004) 61 Occupational Environmental Medicine 727; Oberdorster, E. 
‘Manufactured Nanomaterials (Fullerenes, C60) Induce Oxidative Stress in the Brain of Juvenile 
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The ability to use nanotechnologies across many industry sectors has ensured the rapid 
commercialisation of products produced by nanomanufacturing processes or incorporating 
manufactured NMs. NMs are used in a broad range of consumer products such as cosmetics, 
sunscreens, food packaging, paints, textiles, herbal remedies, medical devices and 
pharmaceuticals.36    
 
Mike Roco’s influential approach conceives of nanotechnologies in terms of generations. 
First generation nanoproducts are ‘passive nanostructures, illustrated by nanostructured 
coatings, dispersion of nanoparticles, and bulk materials - nanostructured metals, polymers, 
and ceramics.’ Second Generation nanoproducts are ‘active nanostructures’, such as 
‘nanobiosensors and devices, tools for molecular medicine and food systems, multiscale 
hierarchical modeling and simulation, energy conversion and storage, nanoelectronics beyond 
CMOS, 3-D nanoscale instrumentation and nanomanufacturing, R&D networking for remote 
measurement and manufacturing, converging technologies (nano-bio-info-cogno) and their 
societal implications.’ 
 
The Third Generation will involve ‘3-D nanosystems and systems of nanosystems with 
various syntheses and assembling techniques, such as bioassembling; networking at the 
nanoscale and multiscale architectures,’ while the Fourth Generation of nanotechnologies 
will see the development of ‘heterogeneous molecular nanosystems, where each molecule in 
the nanosystem has a specific structure and plays a different role. Molecules will be used as 
devices and from their engineered structures and architectures will emerge fundamentally new 
functions.’37 
 
We will provide a brief explanation of one group of products, nanomedicines, in order to 
provide readers with a case study example of one nanotechnology family. We have chosen 
nanomedicines as our case study because research and development on nanotechnologies for 
medical products is one the fastest growing areas. Commentators predict that by 2014, the 
market for health applications of nanobiotechnology will be US$18 billion per year.38 
‘Nanobiotechnology’ is a narrower application of nanotechnology in which nanotechnology 
and biotechnology converge. There is no legislative definition, but academic literature defines 
nanobiotechnology as:39 
                                                                                                                                                        
Largemouth Bass’ (2004) 112 Environmental Health Perspective 1058; Powell, MC and Kanarek, MS. 
‘Nanomaterial Health Effects – part 1: Background and Current Knowledge’ (2006) 2 Wisconsin 
Medical Journal 16; Powell, MC and Kamarek, MS. ‘Nanomaterial Health Effects – part 2: 
Uncertainties and Recommendations for the Future’ (2006) 2 Wisconsin Medical Journal 18;  D’Silva, 
J and van Calster, G. ‘Taking Temperature – A Review of European Union Regulation in 
Nanomedicine’ (2009) 16 European Journal of Health Law 249;  Maynard, A. Nanotechnology: A 
Research Strategy for Addressing Risk (Woodrow Wilson Project on Emerging Technologies, 
Washington DC, 2006); Maynard, A and Kuempel, ED. ‘Airborne Nanostructured Particles and 
Occupational Health’ (2005) 7 Journal of Nanoparticle Research 587.    
35 For example, see Karinne Ludlow ‘One Size Fits All? Australian Regulation of Nanoparticle 
Exposure in the Workplace’ (2007) 15 JLM 136, 140-142. 
36 For further examples of products containing NMs see Woodrow Wilson International Center for 
Scholars Consumer Products: An Inventory of Nanotechnology-based Consumer Products Currently 
on the Market http://www.nanotechproject.org/inventories/consumer/ viewed 17 September 2010.  
37 Roco, MC. ‘Nanoscale Science and Engineering: Unifying and Transforming Tools’, AIChE Journal 
(2004); 50(5):  890–897 
38 Drew, H and Raj, B. ‘The Carbon NanoTube Patent Landscape in Nanomedicine: An Expert 
Opinion’ (2007) 17 Expert Opinion Therapeutic Patents 1.  
39 Roco, MC. ‘Nanotechnology: Convergence with Modern Biology and Medicine’ (2003) 14 Current 
Opinion in Biotechnology 337, 337.  
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a field that applies the nanoscale principles and techniques to understand and 
transform biosystems (living or non-living) and which uses biological 
principles and materials to create new devices and systems integrated from 
the nanoscale. 
 
Examples of products currently on the US and EU markets, and which are produced by 
nanobiotech manufacturing processes or incorporating manufactured NMs, include 
Rapamune® immunosuppressant for prevention of organ rejection in renal transplant 
patients,40 Epaxal® Hepatitis A vaccine,41 Estrasorb topical estrogen therapy,42 Vitoss® bone 
graft substitute,43 TiMesh tissue reinforcement, EnSeal™ tissue sealing system for 
laparoscopic surgery,44 and CellTracks® Analyser II in vitro diagnostic device,45 and 
Abraxane®. NZ has approved two nanomedicines: Rapamune46 and Abraxane.47 Rapamune is 
an immunosuppressant for prevention of organ rejection in renal transplant patients. Abraxane 
is a nanoparticle albumin-bound paclitaxel which is indicated for the treatment of metastatic 
breast cancer. 
 
Many nanomedical products are currently in the third phase of clinical trials. Many of the new 
generation nanomedicines combine medicines and devices into a single product. These 
‘combination products’ are therapeutic or diagnostic products that combine a drug, device 
and/or biological product into a single entity.  
 
Another type of combination product is the cosmeceutical. ‘Cosmeceutical’ is a term used by 
the cosmetics industry to refer to cosmetics that have medicinal benefits. They are typically 
products that combine cosmetics and medicines. Legislation in the US, EU and NZ does not 
use the term ‘cosmeceutical’. ‘Nanocosmeceutical’ refers to cosmeceuticals which contain 
materials at the nanoscale.  
 
These next generation combination nanoproducts (which may sit at the border of regulatory 
agencies and regulatory regimes) will require regulatory review as more such products are 






                                                     
40 See Wyeth Pharmaceuticals (which is now part of Pfizer) www.wyeth.com/products viewed 18 
October 2010 
41 See Crucell-Berna Biotech www.crucell.com/Products-Epaxal viewed 1 November 2010 
42 See Espirit-Pharma www.estrasorb.com viewed 1 November 2010. 
43 See Orthovita http://www.orthovita.com/vitoss/ viewed 1 November 2010. 
44See Project on Emerging Technologies 
http://www.nanotechproject.org/inventories/medicine/apps/medical_tools/enseal_laparoscopic_vessel_f
usion_system/ and http://www.surgrx.com viewed 1 November 2010.  
45 The Project on Emerging Technologies 
http://www.nanotechproject.org/inventories/medicine/apps/diagnostic_tests/celltracks/ viewed 1 
November 2010. 
46 See the datasheet information: 
http://www.medsafe.govt.nz/profs/Datasheet/r/Rapamunetaboralsoln.pdf viewed 25 November 2010.   
47 Medsafe Product Detail http://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=14039 viewed 
18 October 2010; Medsafe Abraxane Product Information 
http://www.medsafe.govt.nz/profs/Datasheet/a/abraxaneinj.pdf viewed 18 October 2010.  
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2 REGULATORY FRAMEWORKS  
 
This section outlines the relevant regulatory frameworks for seven New Zealand regulatory 
bodies. Following the Monash Report, we conceptualise ‘regulatory framework’ as including 
a ‘range of activities, from legislation through to relevant regulations, codes, standards and 
guidelines.’48 A summary of the sources of power (the legislative instruments) of the relevant 
regulatory bodies is shown in the table below. 
   
 
Regulatory Agency  Legislative Instruments  
Department of Labour  Health and Safety in Employment Act.  
Approved Code of Practice for the Management of 
Substances Hazardous to Health in the Place of 
Work. 
MedSafe, Ministry of Health  Medicines Act 1981 
Ministry for the Environment & 
ERMA 
Waste Minimisation Act 2008 (MfE). 
Hazardous Substances and New Organisms Act 
1996 (ERMA). 
Ministry of Consumer Affairs Consumer Guarantees Act  
 Fair Trading Act  
New Zealand Customs Service  Customs and Excise Act 1996  
New Zealand Food Safety Authority & 
Food Standards Australia and New Zealand 
Food Act 1981  





The DoL’s primary role is to improve the performance of the labour market. The DoL 
administers the HSE Act in most workplaces. The DoL’s roles include coordinating the 
development of codes of practice, enforcing compliance with the Act and regulations made 
under it, through inspectors employed by the DoL. The DoL acts as the principal prosecuting 
authority for offences under the Act.   
 
Under section 20 of the HSE Act, the Minister may approve codes of practice. These codes 
are the result of consultation between the DoL and affected industry members, including 
employers and employee organisations. Compliance with codes of practice is not mandatory. 
However, codes of practice have ‘powerful persuasive authority’.49 In any proceedings under 
the HSE Act, the Court may have regard to the code of practice that was in force at the time 
of the alleged offending.50  
 
The Approved Code of Practice for the Management of Substances Hazardous to Health in 
the Place of Work is relevant to nanotechnology. This code of practice and the HSE Act are 
considered in this review.  
 
                                                     
48 Monash Report, at p.21. 
49 Richard Rudman New Zealand Employment Law Guide (CCH, Auckland, 2009) at ch 11, p.234.  
50 HSE Act, s 20(9).  
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






One of the DoL’s roles is to ensure that the HSNO Act is complied with in workplaces. The 
DoL is working with ERMA and the MfE to identify the best ways to inform employees and 




The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) is a business 
unit of the Ministry of Health (MOH). Medsafe is responsible for the regulation of therapeutic 
products in New Zealand. Medsafe’s mission is ‘to enhance the health of New Zealanders by 
regulating medicines and medical devices to maximise safety and benefit’.52  
 
Medsafe administers the Medicines Act 1981 and the regulations promulgated under this Act, 
most notably the Medicines Regulations 1984 and the Medicines (Standing Order) 
Regulations 2002. The MOH has identified several proposed amendments to these 
regulations.53 However, changes to the Meds Act itself are not being considered at this 
stage.54 
 
The objective of the medicines legislation is to manage the risk of avoidable harm associated 
with the use of medicines. The legislation is designed to ensure that:55 
• medicines meet acceptable standards of safety, quality and efficacy; 
• personnel, premises and practices used to manufacture, store and distribute medicines 
comply with requirements designed to ensure that products meet acceptable standards 
right up until they are delivered to the end-user; and 
• information about the selection and safe use of medicines is provided to health 
professionals and consumers. 
 
The proposal to establish a joint Australia and New Zealand therapeutic products regulatory 
agency (ANZTPA) has been postponed.56 The Therapeutic Products and Medicines Bill (the 
legislation that would implement the ANZTPA) has not progressed. The Medicines Act, 
therefore, remains in force and has been examined for this review.  
 
2.3 MfE  
 
New Zealand’s primary agency for protecting the environment is the Ministry for the 
Environment. The MfE’s vision is for a prosperous New Zealand where a healthy 
environment enhances social and economic wellbeing.57 Their mission is environmental 
stewardship for a prosperous New Zealand.58 The MfE was established under the 
Environment Act 1986. The MfE has specific functions under the RMA and the HSNO Act.  
 
The MfE works on a range of environmental and resource management issues such as waste 
minimisation. The Waste Minimisation Act 2008 is administered by the MfE. The New 
                                                     
51 DoL, www.osh.dol.govt.nz/about/initiatives 
52 Medsafe www.medsafe.govt.nz  
53 MOH Consultation on Proposed Amendments to Regulations under the Medicines Act (26 February 
2010) www.moh.govt.nz  
54 Id.  
55 Medsafe www.medsafe.govt.nz  
56 Australia New Zealand Therapeutic Products Authority http://www.anztpa.org/ For information 
about the advantages of establishing a trans Tasman therapeutic products agency see 
http://www.anztpa.org/about.htm#why 
57 MfE www.mfe.govt.nz 
58 Id.  
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Zealand Waste Strategy’s vision of ‘zero waste and a sustainable New Zealand’59 is the 
background against which the Waste Minimisation Act 2008 was passed.60 This Act is 
relevant because this review is concerned with the possible impact of nanotechnology on New 




The Hazardous Substances and New Organisms (HSNO) Act 1996 was enacted ‘because of 
the need for a more integrated and consistent approach to managing hazardous substances and 
new organisms in New Zealand.’61 The Act’s stated purpose is ‘to protect the environment, 
and the health and safety of people and communities, by preventing or managing the adverse 
effects of hazardous substances and new organisms.’62  
 
Section 14 of the HSNO Act provides for the establishment of the Environmental Risk 
Management Authority (ERMA), ‘an independent, quasijudicial authority set up by the 
HSNO Act to decide on applications to introduce hazardous substances and new organisms.’63 
ERMA’s overall mission is to ‘[a]chieve effective prevention or management of risks to the 
environment, public health and safety associated with importing or manufacturing hazardous 
substances and introducing new organisms, and their use.’ 64 
 
More specifically, it exists to: 
 
• assess and decide on applications to introduce hazardous substances and new organisms into 
New Zealand 
• place controls, where appropriate, on hazardous substances and new organisms 
• maintain a publicly available register of applications and approvals 
• approve test certifiers and codes of practice. 
• monitor compliance with and enforcement of the Act 
• where appropriate, enquire into incidents or emergencies involving a new organism or 
hazardous substance 
• report to Parliament annually on incidents caused by inadequate management of hazardous 
substances or new organisms, and the extent to which the Act has contributed to the health 




The MCA is part of the Ministry of Economic Development. The main role of the MCA is to 
promote information flows between suppliers and consumers so that consumers can transact 
with confidence.66 The MCA has various functions such as investigating unsafe consumer 
products and developing consumer policy including consumer protection and product safety.  
                                                     
59 The New Zealand Waste Strategy: Towards Zero Waste and a Sustainable New Zealand (March 
2002 with reviews in 2003, 2006) at http://www.mfe.govt.nz/publications/waste/waste-strategy-
mar02/index.html (accessed 1 June 2010).  
60 Wagener, H. ‘The Waste Minimisation Act 2008 and the Ability of Territorial Authorities to Manage 
Solid Waste’ (2009) NZJEL 295 at 299.  
61
 ERMA, ‘A guide to the Hazardous Substances and New Organisms Act’, April 2006, available at 
http://www.ermanz.govt.nz.ezproxy.otago.ac.nz/resources/index.html 
62 Section 4 
63 ERMA, ‘A guide to the Hazardous Substances and New Organisms Act’, April 2006, p.12 
64 http://www.ermanz.govt.nz/about/whatwe-do.html 
65 ERMA, ‘A guide to the Hazardous Substances and New Organisms Act’, April 2006, p.13 
66 MCA http://www.consumeraffairs.govt.nz/about-mca/what-we-dont-do-and-who-can-help/about-
the-ministry accessed 27 May 2010 
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The MCA can:67  
• investigate unsafe products;  
• suggest modifications to make a product safe;  
• request that unsafe products be removed from sale;  
• give advice to companies recalling unsafe products; and  
• help develop self-regulation options. 
 
Where circumstances require this, the Minister of Consumer Affairs can: 
• recall unsafe products;  
• ban an unsafe product; or  
• make mandatory standards. 
 
In addition, misleading conduct and false representations are investigated and enforced by the 
Commerce Commission.  
 
New Zealand’s consumer protection law is contained primarily in the FTA and CGA. Both 
the FTA and CGA are analysed in this review. Consumer protection law is relevant to 
nanotechnology. For example, the misleading and deceptive conduct, and safety, provisions in 
relation to goods can cover goods containing NMs.   
 
New Zealand’s consumer protection law overlaps with other areas of law such as contract and 
tort law. For example, the misleading and deceptive conduct prohibited by the FTA is at the 
core of the torts of deceit, passing off and negligent misstatement.68 
 
The MCA administers the Fair Trading Act 1986 (FTA) and the Consumer Guarantees Act 
1993 (CGA). However, the MCA does not investigate breaches of the CGA as it is self-
enforcing.69 The Commerce Commission is responsible for enforcing the FTA and 
investigating breaches of the FTA. The Commerce Commission enforces product safety 
standards and product bans made under the FTA.  
 
The MCA liaises and consults with other government agencies that may have an interest in 
government intervention.70 MCA investigates all product safety issues except those relating to 
food, medicines, or vehicles.71 NZFSA and Medsafe deal with product safety issues relating 
to food and medicine respectively. The New Zealand Customs Service can also enforce the 
safety provisions under the Customs and Excise Act 1996. Hazardous substances and 
organisms are dealt with by ERMA and hazardous products and products used in the 




The NZCS is the government agency that facilitates the legitimate movement of goods and 
people across the border. The focus of the NZCS is protecting the security of New Zealand’s 
borders.72 The NZCS has various functions such as enforcing import and export prohibitions 
                                                     
67 MCA http://www.consumeraffairs.govt.nz/about-mca/what-we-dont-do-and-who-can-help/about-
the-ministry accessed 1 June 2010 
68 Laws of New Zealand (online ed) at [1].  
69 MCA http://www.consumeraffairs.govt.nz/about-mca/what-we-dont-do-and-who-can-help/what-we-
dont-do-and-who-can-help accessed 27 May 2010  
70 MCA www.consumeraffairs.govt.nz  
71 Id.  
72 NZCS www.customs.govt.nz/about/Our+history.htm 
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and restrictions. The NZCS works closely with other agencies such as the NZFSA, Ministry 
of Economic Development and ERMA.  
 
The primary statute which regulates the movement of goods, craft and people crossing New 
Zealand’s border is the Customs and Excise Act 1996. This Act is administered by the NZCS.  
 
The NZCS also enforces import and export prohibitions and restrictions under other statutes 




2.6 NZFSA & FSANZ  
 
The Food Standards Australia New Zealand Act 1991 (FSANZ Act) is intended to ‘ensure a 
high standard of public health protection throughout Australia and New Zealand’.73 The 
FSANZ Act ‘establishes the mechanisms for the development and variation of joint food 
regulatory measures (a food standard or a code of practice) and creates Food Standards 
Australia New Zealand (the Authority) as the agency responsible for the development and 
maintenance of a joint Australia New Zealand Food Standards Code (the Code).’74 The Code 
‘is a collection of individual food standards’,75 which sets out quality or composition and 
labelling requirements for food prepared and sold in, or imported into, Australia and New 
Zealand. It is an offence in New Zealand to supply food that does not comply with relevant 
food standards. 
 
FSANZ is ‘a bi-national Government agency’, whose ‘main responsibility is to develop and 
administer the Australia New Zealand Food Standards Code (the Code)’,76 setting food 
standards for both countries. Standards or variations to standards developed and approved by 
the Authority are subject to review by the Australia and New Zealand Food Regulation 
Ministerial Council (ANZFRMC), which comprises Health Ministers from all Australian 
States and Territories, the Australian Government and New Zealand. 
 
Interpretation and enforcement of the Code is not the responsibility of FSANZ, but of the 
relevant departments and food agencies within Australia and New Zealand. In New Zealand, 
that responsibility falls to the New Zealand Food Safety Authority (NZFSA). NZFSA exists 
‘to protect consumers by providing an effective food regulatory programme covering food 
produced and consumed in New Zealand as well as imports and exports of food products.’77  
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3 APPLICATION  
This section of our report examines each regulatory framework and its adequacy to manage 
the possible impacts of mNMs. Following the Monash Report, the adequacy of each 
regulatory framework was analysed with reference to the five criteria adopted in that Report:78  
1. Trigger and scope;  
2. Requirement for regulatory approval;  
3. Human safety assessment;  
4. Environmental safety assessment and;  
5. Post-market monitoring.  
A summary of the application of the regulatory frameworks to mNMs can be found in the 
table below. This table follows the table adopted in the Monash Report,79 but we have 
included the Australian and the New Zealand findings in the table below to enable 
comparison of the two jurisdictions. A more detailed table summarising the adequacy of New 
Zealand’s regulatory frameworks to mNMs (including a summary of potential gaps) can be 



























0  0  
NZ: DoL 0  0  
AUS: TGA   0  













AUS:DEW     
NZ: MfE 
(WMA) 
(limited)  (limited) 0  
AUS:N/A N/A N/A N/A N/A 
NZ:MCA 0 0 0 FTA:(limited) 
 
                                                     
78 Monash Report, para 4.1, p.28. A description of the five criteria can be found in the Monash Report 
at paras 1.4 and 4.1.  
79 Monash Report, para 4.2, p.29. 
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AUS:Customs  0 0 0 













AUS: FSANZ   0  
NZSFA & 
FSANZ 




3.1 DoL  
The Department of Labour’s primary role is to improve the performance of the labour 
market.80 The DoL administers the HSE Act in most workplaces. The DoL’s roles include 
coordinating the development of codes of practice, enforcing compliance with the Act and 
regulations made under it, through inspectors employed by the DoL. The DoL acts as the 
principal prosecuting authority for offences under the Act.   
 
Section 21 empowers the Governor-General to make regulations imposing duties relating to 
the health or safety of employees. Regulations made under the HSE Act (The Health and 
Safety in Employment Regulations 1995 and The Health and Safety in Employment 
(Prescribed Matters) Regulations 2003) extend the scope and detail of the Act itself. The 
regulations set out the general requirements for all employers and specific requirements for 
certain industries.81  
 
Under section 20 of the HSE Act, the Minister may approve codes of practice. These codes 
are the result of consultation between the DoL and affected industry members, including 
employers and employee organisations.82 Compliance with codes of practice is not 
mandatory. However, codes of practice have ‘powerful persuasive authority’.83 In any 
proceedings under the HSE Act, the Court may have regard to the code of practice that was in 
force at the time of the alleged offending.84  
 
The Approved Code of Practice for the Management of Substances Hazardous to Health in 
the Place of Work is relevant to nanotechnology. This code of practice and the HSE Act are 
considered separately below.  
 
Dangerous goods law is also relevant to nanotechnology. The Dangerous Goods Act 1974 
was replaced by the HSNO Act. The importation, manufacture and use of explosives are now 
regulated under the HSNO Act. Both dangerous goods and explosives are now regulated 
under the HSNO Act and, therefore, they are considered in the analysis of the HSNO Act. The 
HSNO Act’s provisions relating to hazardous substances have the most significance for 
                                                     
80 Department of Labour <www.dol.govt.nz/about>  
81 Rudman, R. New Zealand Employment Law Guide (CCH, Auckland, 2009) at ch. 11.  
82 Rebecca Keenan (ed) Health Care and The Law (Brookers, Wellington, 2010) at [14.3.7].  
83 Rudman, New Zealand Employment Law Guide, op. cit. at ch. 11.  
84 HSE Act, s 20(9).  
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occupational health and safety. 85  The HSNO Act takes an integrated approach to the control 
of hazardous substances and new organisms. The Act applies to everyone who imports, 
manufactures, uses or stores hazardous substances.    
 
3.1.1 HSE Act 1992  
 
Scope and Triggers  
 
The HSE Act enacts an extensive statutory regime to ensure the health and safety of 
employees and other people in the workplace. The Act is less concerned with prescribing how 
to make workplaces safe and more concerned with putting obligations on employers and 
employees to ensure that workplaces and work practices meet defined standards of health and 
safety.86 New Zealand has a ‘no fault’ scheme for dealing with accidental injury.  
 
The HSE Act’s object is to promote the prevention of harm to all persons at work as well as 
others in, or in the vicinity of, a place of work.87 The Act seeks to achieve this goal by: 
• promoting excellence in health and safety management, in particular through 
promoting the systematic management of health and safety;88  
• comprehensively defining hazards and harm, including harm caused by work-related 
stress and hazardous behaviour caused by certain temporary conditions;89   
• imposing various duties on persons who are responsible for work and those who do 
the work;90  
• setting flexible requirements that relate to taking all practicable steps to ensure health 
and safety;91  
• recognising that volunteers who are engaged in work activities should have their 
health and safety protected;92  
• recognising that successful management of health and safety issues is best achieved 
through good faith cooperation in the workplace;93   
• providing a range of enforcement methods to enable an appropriate response to a 
failure to comply with the Act;94   
• prohibiting persons from being indemnified (or indemnifying others) against the 
costs of these enforcement measures.95  
 
The Act covers places of work. ‘Place of work’ is given a broad definition in section 2:  
 
a place (whether or not within or forming part of a building, structure, or vehicle) where any 
person is to work, is working, for the time being works, or customarily works, for gain or 
reward; and, in relation to an employee, includes a place, or part of a place, under the control 
of the employer (not being domestic accommodation provided for the employee), - 
(a) where the employee comes or may come to eat, rest, or get first-aid or pay; or  
                                                     
85 Rudman, New Zealand Employment Law Guide, op.cit. at p.258.  
86 Rudman, New Zealand Employment Law Guide, op.cit. at ch. 11.  
87 HSE Act, s 5.  
88 HSE Act, s 5(a).  
89 HSE Act, s 5(b).  
90 HSE Act, s 5(c). 
91 HSE Act, s 5(d).  
92 HSE Act, s 5(e).  
93 HSE Act, s 5(f).  
94 HSE Act, s 5(g).  
95 HSE Act, s 5(h).  
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(b) where the employee comes or may come as part of the employee’s duties to report in 
or out, get instructions, or deliver goods or vehicles; or  
(c) through which the employee may or must pass to reach a place of work.  
 
This definition applies to places which people move through in the course of their work, and 
to places which themselves move.96 It covers buildings, other structures, mobile plant, 
vehicles and outdoor workplaces. People are ‘at work’ if they are ‘present, for gain or reward, 
in their place of work’. A person is in a workplace ‘whenever and wherever the person 
performs work’. Therefore, the HSE Act will apply to places of employment whether or not 
those workplaces involve employees working with NMs.  
 
The Act binds the Crown.97 The HSE Act applies to employers, employees, self-employed 
people, contractors and subcontractors.98 The Act also specifically applies, with some 
modifications, to persons working on ships or aircraft, volunteers, persons receiving on the 
job training, persons gaining work experience and loaned employees.99 The HSE Act will, 
therefore, apply to all these people whether or not they work with NMs.  
 
The Act imposes duties on employers to ensure the safety of employees at work. Most duties 
under the HSE Act are not absolute, but require ‘all practicable steps’100 to have been taken. 
This phrase recurs throughout the Act. The ‘all practicable steps’ requirement is interpreted 
strictly.101 It is reasonable to expect an employer to do anything that is practicable to do.102 
Employers are expected to be proactive in identifying both existing and potential hazards and 
taking steps to prevent harm to workers.103 Employers may be expected, therefore, to be 
proactive in identifying potential hazards associated with NMs and nanoparticles.    
 
An assessment of whether or not all reasonable steps have been taken analyses:  
• the nature and severity of the harm that may be suffered if the result is not achieved; 
• the current state of knowledge about the likelihood that harm of that nature and 
severity will be suffered if the result is not achieved; 
• the current state of knowledge about harm of that nature; 
• the current state of knowledge about the means available to achieve the result and the 
likely efficacy of those means; and  
• the availability and cost of each of those means available.104  
 
A person required by the Act to take all practicable steps is required to take those steps only 
in respect of circumstances that the person knows or ought reasonably to know about.105 
Therefore, a person is required to take all practicable steps to ensure the safety of employees 
working with NMs only in respect of circumstances that the person knows or ought 
reasonably to know about.  
 
                                                     
96 OSH, A Guide to the Health and Safety in Employment Act 1992 Including the Health and Safety in 
Employment Amendment Act 2002 (2nd ed, DoL, Wellington, 2003) at p.12.  
97 HSE Act, s 3.  
98 HSE Act, s 2.  
99 HSE Act, ss 3A-3F.  
100 HSE Act, ss 2A and 6.  
101 Rudman, New Zealand Employment Law Guide, op.cit. atp.242.  
102 Id.  
103 Id.  
104 S 2A definition of ‘all practicable steps’.  
105 HSE Act, s 2A(2).  
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There is a potential regulatory gap in that the “current state of knowledge”106 regarding harm 
attributed to many NMs is deficient. Although many of the OSH implications of NMs and 
nanoparticles are unknown, scientific studies indicate that adverse health consequences are 
possible from NM and nanoparticle use and exposure.107 For some nanoparticles, such as 
carbon nanotubes, the small size and fibre shape has led to speculation that carbon nanotubes 
may have similar adverse health effects to asbestos fibres.108 Workers in workplaces are 
potentially being exposed to nanoparticles, hazardous substances and dangerous goods 
containing NMs. The main exposure routes are inhalation and dermal absorption.  
 
Section 6 requires employers to take all practicable steps to ensure the safety of employees. In 
particular, an employer must take all practicable steps to: 
• provide and maintain a safe working environment; 
• provide and maintain facilities for the safety and health of employees while 
they are at work; 
• ensure that plant at work is arranged, designed, made and maintained so that it is 
safe for the employees to use; 
• ensure that while employees are at work they are not exposed to hazards arising 
out of the arrangement, disposal, manipulation, organisation, processing, storage, 
transport, working, or use of things in the workplace or that are near the workplace 
and under the employee’s control;  
• develop procedures for dealing with emergencies that may arise while employees 
are at work.  
 
These obligations are expressed in general terms. The Act also imposes specific duties on 
employers in relation to protective clothing and equipment,109 information for employees,110 
and training and supervision.111  
 
The HSE Act sets out specific duties on employers in relation to hazards in the workplace. 
Employers must identify hazards;112 take all practicable steps to eliminate them;113 and if they 
cannot be practicably eliminated, isolate hazards.114 If hazards cannot be isolated, they must 
be minimised.115 Employees exposed to them must be monitored.116  
 
The general language of the Act requires a broad approach by employers to potential 
hazards.117 It is clear that employers must identify specific hazards and then do whatever they 
can to ensure that the hazards do not cause harm.118 
                                                     
106 HSE, s 2A.  
107 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) Risk Assessment 
of Products of Nanotechnologies (European Commission, Brussels, 2009); SCENIHR Opinion on the 
Appropriateness of the Risk Assessment Methodology in Accordance with the Technical Guidance 
Documents for New and Existing Substances for Assessing the Risks of Nanomaterials (European 
Commission, Brussels, 2007); Ludlow, K. ‘One Size Fits All?’, loc. cit. at p.137; Safety of Nano-
Materials Interdisciplinary Research Centre (SnIRC) http://www.snirc.org/ 
108 Knowles, E. ‘Nanotechnology, Evolving Occupational Safety, Health and Environmental Issues’ 
Professional Safety (2006) 20; Ludlow, ‘One Size Fits All?’, loc. cit., at p.139 
109 HSE Act, s 10. 
110 HSE Act, ss 11, 22.  
111 HSE Act, s 13.  
112 HSE Act, s 7.  
113 HSE Act, s 8.  
114 HSE Act, s 9.  
115 HSE Act, s 10.  
116 Id.  
117 Keenan, Health Care and The Law, op. cit., at 14.3.1.  
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The concept of hazard is vital to the working of the Act.119 Hazard means any activity, 
arrangement, circumstance, event, occurrence, phenomenon, process, situation, or substance 
that is an actual or potential cause or source of harm, whether it arises or is caused within or 
outside a workplace.120 ‘Substance’ means a thing that is an organic material, whether living 
or not.121 The definition of hazard in the HSE Act is broad and may be physical, biological or 
mental.122  
 
‘Significant hazard’ means a hazard that is an actual or potential cause or source of: 
• serious harm; 
• harm (that is less than trivial) for which the severity of the effect on a person 
depends on the extent or frequency of the person’s exposure to the hazard; or  
• harm that does not usually occur or that is not easily detectable until a significant 
time after the exposure to the harm.123  
 
‘Harm’ means illness, injury, or both and includes physical or mental harm caused by work-
related stress.124 ‘Serious harm’ means death, or some other harm declared to be serious harm 
by the Governor-General.125 Any illness, injury, physical or mental harm, or death, whether or 
not attributable to exposure to nanoparticles, may be caught by these definitions.   
 
‘Safe’ is defined narrowly to mean not exposed to any hazards and free from hazards.126 
‘Health’ and ‘healthy’ have restricted meanings; they simply mean unharmed.127 The 
definition of health under the HSE Act is different from the broad World Health Organisation 
definition of health. Health, according to the WHO, is a state of complete physical, mental 
and social well-being and not merely the absence of disease or infirmity.128  
 
The HSE Act drafters wanted to separate regulating safety at work from general regulation of 
product liability issues.129 Therefore, the regulation of product liability issues (including 
products containing NMs) falls outside the scope of the HSE Act. 
 
However, the HSE Act applies to places of work in which hazards (which means inter alia, 
substances) and/or significant hazards are identified, whether or not those hazards and/or 
significant hazards involve NMs.   
 
 
Approval Prior to Regulated Activity  
 
There are no provisions for formal approval or authorisation from the DoL prior to the 
regulated activity. However, there are prevention and control measures in the HSE Act130 and 
                                                                                                                                                        
118 Rudman, New Zealand Employment Law Guide, op.cit.  at p.242.  
119 OSH Guide at p.28.  
120 HSE Act, s 2.  
121 Id.  
122 OSH Guide at p.30.  
123 HSE Act, s 2.  
124 Id.  
125 Id.  
126 Id.  
127 Id.  
128 World Health Organisation www.who.int  
129 We are grateful to John Hughes (who has written extensively on the HSE Act) for making this 
important point. Email from John Hughes to Jennifer Moore regarding the HSE Act (26 May 2010).  
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The Code (see the discussion of The Code below under the heading ‘approval prior to 
regulated activity’).  
 
 
Human and Environmental Safety Assessment  
 
Human safety assessment occurs through identifying and managing hazards and monitoring 
workers’ exposure to hazards. Employers must have effective methods for identifying hazards 
to employees, if possible before the hazard arises.131  
 
Employers must regularly assess whether each hazard is significant.132 As outlined under 
‘scope and triggers’ above, when a hazard is assessed as significant, the employer must take 
all practicable steps to eliminate it.133 If the hazard cannot be eliminated or isolated, 
employers must take all practicable steps to minimize the likely harm to employees.134  
 
Employers must monitor employees’ exposure to a significant hazard135 and, with their 
informed consent, also monitor employees’ health in respect of their exposure to a hazard.136  
 
Pursuant to sections 7 to 10 of the HSE Act, employers must identify and manage hazards and 
monitor workers’ exposure to hazards, whether or not those hazards contain, or are 
attributable to, NMs. Nanoparticles and NMs may be covered by the hazard identification 
process. However, the identification of hazards may require the employer to know or suspect 
nanoparticles are a potential risk to human health. Deficiencies in current knowledge may 
preclude the identification of nanoparticles as a hazard. These potential statutory gaps may be 
covered by the language in section 7 in that hazards may be: previously existing,137 new,138 or 
potential.139  
 
The HSE Act does not specify a particular method of hazard identification. Various hazard 
identification methods are used in industry.140 Four commonly used hazard identification 
methods are:141  
1. Physical inspections: walking around the workplace with a checklist to identify 
hazards. 
2. Process analysis: following the production or service delivery process from start to 
finish and identifying hazards at each stage.  
3. Task analysis: examine the tasks in each job and observe the actions of employees 
while identifying the hazards involved.  
4. Analysis of accident investigation details: section 7(2) of the HSE Act makes this 
method mandatory. Where harm or an accident occurs, the employer is required to 
take all practicable steps to investigate.  
 
                                                                                                                                                        
130 HSE Act, ss 7-10.  
131 HSE Act, subss 7(1)(a) and (b).  
132 HSE Act, subs 7(1)(c).  
133 HSE Act, s 8.  
134 HSE Act, s 10.  
135 HSE Act, s 10.  
136 HSE Act, s 10(2)(e).  
137 HSE Act, subs 7(1)(a).  
138 HSE Act, subs 7(1)(b). 
139 HSE Act, s 2.  
140 OSH Guide at p.29.  
141 Ibid at pp.29-30.  
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Information from manufacturers, designers, safety data sheets, product labelling should be 
reviewed as part of the hazard identification process.142 Employers should produce a list of 
hazards in the workplace.143 
 
Risk assessment, including hazard identification methods, may not be appropriate for NMs. It 
may be necessary to amend the SDS and labelling systems to recognise that NMs have unique 
properties. Current processes may not consider the high surface area and increased reactivity 
of NMs. Therefore, the current methods and procedures may be inadequate for the safety of 
workers. Hazard assessment for nanoparticles needs to consider shape, chemical properties, 
the role of particle size, functionality and dose. 
 
There are further difficulties in protecting New Zealand workers from adverse health effects 
of nanoparticle exposure.144 First, there is no national or international agreed definition to 
describe nanoparticles. Second, equipment and methods to enable routine measurements of 
nanoparticles are not yet available.   
 
Assessment is concerned only with risks to people. Ecotoxicology does not have to be 
assessed. Risks to the environment are not directly addressed in the HSE Act. This deliberate 
gap is the result of the boundaries and scope of the regulatory regime. These aspects are 
covered by the HSNO Act, which dovetails with the HSE Act with respect to workplace 
management of hazardous substances.  
 
Post-Market Monitoring  
 
The HSE Act includes provisions for recording, reporting, reviewing and monitoring hazards 
in workplaces and workers’ health and safety. For example, Workplace Exposure Standards 
enable monitoring. When sufficient nanotoxicological and exposure data become available, 
nano-specific workplace exposure standards could be developed, if necessary.  
 
The HSE Act requires monitoring of employees’ exposure to hazards. Where elimination and 
isolation are not practicable, there is a requirement to minimise the hazard and to monitor the 
employee’s exposure to the hazard.145 Section 10 focuses on the requirement to monitor an 
individual employee’s exposure to hazards. There may be monitoring of general workplace 
levels of exposure, but monitoring is targeted at the degree of exposure individual employees 
are likely to experience.146  
 
Section 10 does not require the monitoring of hazards, whether or not they are NMs, which 
have been isolated. However, the OSH Guide indicates that this kind of monitoring is “worth 
considering as part of a process of regular revision”.147  
 
The HSE Act also requires monitoring of employees’ health. The purpose of monitoring is to 
identify any health effects and to provide the necessary medical care. Under section 36(a) and 
(b), a departmental medical practitioner may require employees to submit to a medical 
examination where the practitioner is satisfied that the employee has or may have been 
exposed to a significant hazard while at work. Monitoring of employees’ health is also a way 
to check the efficacy of measures taken to reduce exposure to hazards.  
                                                     
142 Ibid at p.30.  
143 Id.  
144 Ludlow, ‘One Size Fits All?’, loc. cit. at p.137.  
145 Section 10(2).  
146 OSH guide, at p.36.  
147 Id.  
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The HSE Act requires all employers, self-employed persons and principals to maintain a 
register of accidents and serious harm.148 A hazard register must systematically identify and 
manage hazards in the workplace.149 The register must contain details on every occurrence of 
serious harm to an employee while at work or as a result of a hazard to which the employee 
was exposed at work.150 The particulars that must be recorded are set out in the regulations.151 
An employer’s register must record particulars about every accident that harmed, or might 
have harmed, any employee at work or any person in a workplace controlled by the 
employer.152  
 
Trained health and safety representatives may issue hazard notices that describe a hazard 
identified in workplaces.153 Such notices must be in the prescribed form154 and may set out 
suggested steps to deal with the hazard.155  
 
The HSE Act confers powers on inspectors who may monitor conditions in workplaces.156 It 
is important that these monitoring and reporting procedures enable the timely and proper 
collection of information about exposure to nanoparticles which has caused harm, incidents 
and injuries.   
 




The HSE Act contains duties for any person who sells or supplies plant that can be used in a 
place of work.157 The section 2 definition of plant is broad and includes, but is not limited to, 
any: appliance, equipment, fitting, furniture, implement, machine, machinery, tool, or vehicle. 
The plant must be of a nature that can be used in a workplace. This definition will apply to 
plant, whether or not that plant contains NMs.  
 
Section 18A(6) provides that the duty contained in section 18A does not limit the Consumer 
Guarantees Act 1993. See the analysis of this Act on page 70. The Consumer Guarantees Act 
provides consumer protection for the purchase of goods and services other than in trade.   
 
Designers of plant have duties to take all practicable steps to design any plant in accordance 
with applicable ergonomic principles and design plant so that if the plant is manufactured and 
used appropriately there is no likelihood that the plant will be a cause or a source of harm to 
any person.158 Manufacturers and suppliers of plant have similar duties to take all practicable 
steps to ensure that any plant if manufactured, used and installed correctly is unlikely to cause 
harm.159  
 
                                                     
148 HSE Act, ss 25(1), (1A), (1B).  
149 HSE Act, s 25(1).  
150 HSE Act, s 25(1)(b).  
151 Health and Safety in Employment (Prescribed Matters) Regulations 2003.  
152 HSE Act, s 25(1)(a).  
153 HSE Act, s 46A(1)(a).  
154 See the Health and Safety in Employment (Prescribed Matters) Regulations 2003 SR 90 for the 
prescribed form.  
155 HSE Act, subss 46A(1)(b) and (c).  
156 HSE Act, s 33(1).  
157 HSE Act, s 18A. 
158 Health and Safety in Employment Regulations 1995 R66(1).  
159 Ibid, at R 67.  
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These regulations apply to designers, manufacturers and suppliers of plant, including plant 
with NMs. The issue, however, is whether designers, manufacturers and suppliers would or 
should be aware of the presence of NMs and their risks.   
 
 
3.1.2 The Code 1997 
 
Scope and Triggers  
 
The Code is a statement of preferred work practices and arrangements. The Code is a practical 
guide on how to comply with the applicable sections of the HSE Act and Regulations 1995 in 
order to minimise the risk of occupational illness or injury due to exposure to substances 
hazardous to health.160  
 
The Code applies to all workplaces in which substances hazardous to health are used or 
produced and to all persons with potential exposure to substances hazardous to health in those 
workplaces.161 The criteria for classification as a hazardous substance are discussed under the 
Human and Environmental Safety Assessment heading below.  
 
The Code applies to:162 
• Suppliers of substances hazardous to health for use at a place of work; 
• An employer or self-employed person at a place of work where a substance hazardous 
to health is used; and  
• An employee who may be exposed to a substance hazardous to health at a place of 
work.  
 
The Code does not apply to the following situations or materials:163  
• Asbestos and materials containing asbestos; 
• The carriage of hazardous substances;  
• The discharge or disposal of substances hazardous to health as covered by the RMA, 
except where such discharge or disposal may involve exposure to employees; 
• The use and handling of radioactive substances; 
• Hazards posed by non-ionising radiation;  
• The storage, transport and sale of motor fuel, aviation fuel, compressed natural gas, or 
liquefied petroleum gas; or  
• Micro-organisms.  
 
The Code does not apply to the following where the use of the product is not related to a work 
activity:164  
• Food or beverages; 
• Cosmetics; 
• Any product intended for use as a medicine for human use, or to any animal remedy 
intended for internal use; and  
                                                     
160 Approved Code of Practice for the Management of Substances Hazardous to Health in the Place of 
Work (The Code) 1997, at [8].  
161 Id.  
162 Id.  
163 Id. These situations or materials are excluded by The Code because they are covered by other 
regulatory instruments.   
164 Ibid, at p.9.  
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• Tobacco or products made of tobacco.  
 
A substance hazardous to health is defined as any substance, or product containing a 
substance, to be used or produced in a workplace that is known or suspected to cause harm to 
health.165 This includes:  
• Those substances that are classified as hazardous under the HSNO Act, excluding 
micro-organisms;  
• Scheduled toxic substances under the HSNO Act; and  
• Those substances that are listed in the Workplace Exposure Standards publication 
currently applicable in New Zealand.166  
 
Therefore, many substances that may be or may incorporate NMs such as paints, heavy metals 
and solvents will trigger The Code.  
 
 
                                                     
165 Ibid, at p.10.  
166 Workplace Exposure Standards published by OSH in 1994 and revised in 2002 www.osh.govt.nz  
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






Approval Prior to Regulated Activity  
 
Under The Code there is no provision for formal approval of hazardous substances from DoL 
prior to supply, sale, use or import because such approval is covered by the HSNO Act. In 
order to achieve compliance with sections 6 and 8 to 10 of the HSE Act, The Code provides a 
hierarchy of prevention and control measures.167 Where a significant hazard has been 
identified, the HSE Act requires that the hazard be managed by considering the following 
hierarchy of action:  
• Elimination;168 then  
• Isolation;169 and finally  
• Minimisation.170  
 
If NMs are identified as a significant hazard, they could be eliminated, isolated or minimised. 
A potential regulatory gap may exist if the deficiencies in nanotoxicology prevent a 
potentially harmful NM from being identified as a significant hazard. However, significant 
hazard is defined in the HSE Act as an actual or potential cause or source of serious harm.171 
If the NM is a potential cause of harm, it could be identified as a significant hazard and, 
therefore, trigger the hierarchy of action.  
 
Minimisation of the risk of substances hazardous to health may be achieved by a variety of 
practices such as personal protective equipment (PPE).172 However, it is likely that 
nanoparticles will be able to penetrate more readily the material from which the protective 
clothing is made than macro particles.173  
 




Under The Code there is no legal requirement for the supplier of a substance hazardous to 
health to provide specific health and safety information due to the requirements for labelling 
and SDS under the HSNO Regulations. The Code states that suppliers175 should176 have 
Safety Data Sheets (SDS) available for all substances hazardous to health that they supply.177 
The purpose of SDS is to provide the information required to allow the safe handling of 
hazardous substances at work.178  
 
The SDS describes the identity of the substance, relevant health hazard information, 
precautions for use and safe handling, disposal and emergency response information. 
                                                     
167 Ibid, at p.23.  
168 HSE Act 1992, s 8. 
169 HSE Act 1992, s 9.  
170 HSE Act 1992, s 10.  
171 HSE Act, s 2 our emphasis.  
172 The Code 1997, at pp.24 and 25.  
173 Ludlow, ‘One Size Fits All?’, loc. cit., at p.142.   
174 Safety Data Sheets were formerly known as Material Safety Data Sheets. The latter expression is the 
reference used in The Code 1997.  
175 ‘Supplier’ is defined as ‘the importer, manufacturer, wholesaler or distributor, but excludes the 
person who transports the substances hazardous to health’ (The Code, at p.10).   
176 ‘Should’ is defined as ‘a way of indicating preference. It does not indicate a mandatory 
requirement…’ (The Code, at p.10). 
177 The Code 1997, at p.34.  
178 Id. 
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Identification of the hazardous substance requires suppliers to detail the chemical identity and 
CAS Number of the substance. This identification will not necessarily reflect the fact that the 
chemical is in nanoform. The Code does not expressly distinguish between nano and 
conventional forms of substances.   
 
The physical and chemical properties of the substance are to be included. Particle size is not 
necessarily specifically noted as a relevant property. The SDS may also describe other 
information (at the supplier’s option). The supplier could describe the particle size of the 
substance in these sections of the SDS, but the supplier is not required to do so. 
 
Toxicological information is required. However, there are deficiencies in the toxicological 
data for NMs, particularly for chronic exposure.    
 
SDS could alert users to the presence of NMs and the risks posed by them, but there is no 
guarantee that this will occur. The Code, generally, and health hazard information, 
specifically, does not distinguish between nanoforms and conventional forms of chemicals. 
The SDS’s requirements could generally apply to substances whether or not they contain 
NMs, but the SDS does not expressly require information relevant to NMs. For instance, the 
SDS does not expressly require the supplier to note whether a substance is, or originated as, a 
NM and may, thus, have special properties. There is no obligation on suppliers to disclose 
such information. Given the deficiencies in current knowledge regarding the safety of NMs, 
SDS requirement that health effects and health hazard information should be included is 
unlikely to trigger the provision of nanotoxicological information. These gaps mean that users 
may not receive adequate information on the possible hazards of substances to workers.     
 
In addition to SDS, The Code states that suppliers should ensure that any container supplied 
for use in a place of work carries sufficient information for the safe use of the product it 
contains, and is labelled in a way that allows for positive identification of the product. Labels 
should be legible and must comply with all New Zealand legal requirements.179 The 
information on a label should contain the following minimum information:180 
• The product name and if necessary the product number or identifier; 
• The name and address of the manufacturer or importer;  
• A list of all substances hazardous to health contained in the product and their 
approximate concentrations;  
• Warning of any particular handling requirement or incompatibility; and  





In order to comply with section 12 of the HSE Act, The Code specifies the information about 
hazardous substances that the employer must provide to employees. However, the HSNO Act 
requirements on this aspect are now applicable.  SDS provided by the supplier may form the 
basis of the information, but this information may need to be configured for the particular 
workplace.181 Employers should ensure that all employees have access to SDS and have a 
clear understanding of safe handling requirements.182 Where a new substance is to be used in 
a place of work, the SDS should be obtained in advance to allow an assessment of the 
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controls required.183 This process will be triggered whether or not the new substance contains 
NMs.  
 
Containers of hazardous substances in workplaces should be labelled to allow the substances 
to be used safely.184 The HSNO Act requirements are now applicable and, therefore, this 
aspect is discussed in the section on the HSNO Act on page 51. Labelling requirements will 
apply to containers of hazardous substances whether or not they incorporate NMs. However, 
whether or not users are alerted of the presence of NMs depends on whether the product 
name, number or identifier used on the label references nano. 
 
 
Human and Environmental Safety Assessment  
 
As indicated under the scope and triggers heading above, a ‘substance hazardous to health’ is 
defined as any substance, or product containing a substance, to be used or produced in a 
workplace that is known or suspected to cause harm to health. Some substances hazardous to 
health that are or could be NMs, or incorporate NMs, or are produced using nanotechnology 
could be caught by this definition provided they are known or suspected to cause harm to 
health. The current deficiencies in nanotoxicology may mean that hazardous substances 
containing NMs may not be “known”, but they may be “suspected”, to cause harm to health.    
 
The Code describes an assessment process for employers to meet their duty to manage 
substances hazardous to health. The assessment aims to achieve compliance with section 7 of 
the HSE Act. The purpose of an assessment is to gain adequate information on the use of 
substances hazardous to health in the workplace.185 The emphasis in conducting an 
assessment is on determining the extent of the risk to employees and others that arises from 
the use or presence of the hazardous substances.186 The assessment process involves: 
1. Identifying substances hazardous to health in the workplace;  
2. Reviewing the information about the hazards they pose to health;  
3. Determining the degree of exposure;187  
4. Assessing the risk to health; and  
5. Reviewing the assessment.  
 
There are currently no effective methods available in the workplace to measure nanoparticles 
or exposure to nanoparticles, nor are there currently effective methods for assessing particle 
surface area.188 Therefore, the assessment process described in The Code will be difficult for 
hazardous substances that contain NMs or for nanoparticles.   
 
The Code describes a process if the outcome of an assessment is uncertain. If an assessment 
indicates that harm to health may result from exposure to substances hazardous to health, but 
there is some uncertainty about the degree and extent of the exposure, then further work such 
                                                     
183 Id.  
184 The Code 1997, at p.15.  
185 The Code 1997, at p.16.  
186 Id.  
187 ‘Exposure’ is defined as the conditions that are likely to result in a person absorbing a substance 
hazardous to health by ingestion, inhalation, or through the skin or mucous membranes (The Code 
1997, at p.10).  
188 Ludlow, ‘One Size Fits All?’, loc. cit. at p.145.   
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as monitoring (workplace exposure monitoring189 and biological exposure monitoring190) is 
required.  
 
Assessments should be revised at least every two years, or if:191 
• The process, plant or substance related to exposure to the substances hazardous to 
health is modified;  
• New information on the hazards of substances becomes available;  
• Monitoring indicates inadequate exposure control… 
 
Hazardous substances containing NMs may trigger a revision if the substance is modified or 
if new information on the substance becomes available. For instance, new epidemiological 
information on human exposure and nanotoxicological data may prompt a revision.   
 
As indicated under the ‘approval prior to regulated activity’ heading above, hazards must be 
managed by elimination, isolation, or minimisation. The generality of this hierarchy of action 
process means that it will apply to NMs. Whether it does so adequately, however, depends on 
the knowledge of risks.    
 
The Code also provides for health surveillance as a measure directed at controlling exposure 
to substances hazardous to health to ensure the health and safety of people at work.192 
Therefore, monitoring is required but this depends on the assessment showing that monitoring 
and surveillance is required. The current deficiencies in scientific knowledge about NMs 
means it is unclear whether assessments will identify NMs. Further, these deficiencies in 
knowledge mean that health surveillance and monitoring processes under The Code may not 
be suitable or adequate for NMs.   
 
Assessment is concerned only with risks to people in workplaces. Risks to the environment 
are not directly addressed. Environmental safety assessments are not required in The Code. 
This is an intentional ‘gap’ due to the scope of The Code and because such risks are covered 
by the HSNO Act assessments and controls. However, ecotoxicity193  information is typically 
required in SDS.   
 
Post-Market Monitoring  
 
The Code describes monitoring processes in order to achieve compliance with sections 
10(2)(c), (d) an (e) and section 11 of the HSE Act.194 The employer is responsible for 
ensuring that an assessment of the risks to health be conducted for any work involving 
potential exposure to any hazardous substances. As part of the assessment process, it may be 
necessary to monitor the employee’s exposure to hazardous substances and, with her or his 
informed consent, to monitor the employee’s health in relation to exposure to the hazardous 
substance.195  
 
                                                     
189 Workplace exposure monitoring may be either personal monitoring (achieved by sampling the air in 
the breathing zone of the worker); or static monitoring (using equipment that samples the air at a fixed 
point in the workplace) (The Code 1997, at p.29).  
190 Biological exposure monitoring involves, for instance, measurement and assessment of hazardous 
substances and their metabolites in blood, urine, or expired air (The Code 1997, at p.28).  
191 The Code 1997, at p.22.  
192 The Code 1997, at pp.27 and 39.  
193 Ecotoxicity refers to toxic effects on the environment.  
194 The Code 1997, at 27.  
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Monitoring includes the use of valid and suitable techniques to give a quantitative estimate of 
the exposure of employees to substances hazardous to health and their health in relation to 
exposure. For airborne substances, workplace exposure monitoring involves the periodic or 
continuous sampling of workplace atmospheres to derive a quantitative measure of exposure 
to hazardous substances. However, as outlined above, there are currently no effective methods 
available in the workplace to measure nanoparticles or exposure to nanoparticles. Therefore, 
monitoring will be difficult.  
 
Monitoring also includes biological monitoring, workplace exposure monitoring and health 
surveillance, all of which were described above. Whether the health surveillance is suitable 
for NMs is unclear.  
 
3.2 MEDSAFE  
 
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) is a business 
unit of the Ministry of Health (MOH). Medsafe is responsible for the regulation of therapeutic 
products in New Zealand. Medsafe administers the Medicines Act 1981 (Meds Act) and the 
regulations promulgated under this Act, most notably the Medicines Regulations 1984, the 
Medicines (database of Medical Devices) Regulations 2003 and the Medicines (Standing 
Order) Regulations 2002. The MOH has identified and consulted on several proposed 
amendments to these regulations.196 However, changes to the Meds Act itself are not being 
consulted on at this stage.197 
 
The proposal to establish a joint Australia and New Zealand therapeutic products regulatory 
agency (ANZTPA) has been postponed.198 The Therapeutic Products and Medicines Bill (the 
legislation that would implement the ANZTPA) has not progressed. The Medicines Act, 
therefore, remains in force.   
 
Medsafe is responsible for applying a framework designed to ensure that therapeutic products, 
when used appropriately, have greater benefits than risks.199 The main functions of Medsafe 
are exercised through two primary processes:  
• pre-market approval of products   
• post-market surveillance.   
 
 
Scope and Triggers  
 
The Meds Act is concerned with the law relating to the manufacture, sale, and supply of 
medicines, medical devices, and related products. The Act governs the distribution, supply 
and administration of medicines to humans for therapeutic purposes. The objective of the 
legislation is to manage the risk of avoidable harm associated with medicines.200 The Act is 
                                                     
196 MOH Consultation on Proposed Amendments to Regulations under the Medicines Act (26 February 
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about the advantages of establishing a trans Tasman therapeutic products agency see 
http://www.anztpa.org/about.htm#why 
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designed to ensure the quality, safety and efficacy of medicines, medical devices and related 
products.  
 
Medsafe regulates products used for a therapeutic purpose. Section 4 of the Meds Act defines 
therapeutic purpose to mean: 
• treating or preventing disease; or  
• diagnosing disease or ascertaining the existence, degree, or extent of a physiological 
condition; or  
• effecting contraception; or  
• inducing anaesthesia; or  
• altering the shape, structure, size or weight of the human body; or  
• otherwise preventing or interfering with the normal operation of a physiological 
function, whether permanently or temporarily, and whether by way of terminating or 
reducing or postponing, or increasing or accelerating, the operation of that function, 
or in any other way; or  
• cleaning, soaking, or lubricating contact lenses.  
 
Products deemed as used for a therapeutic purpose will be caught by this definition by virtue 
of their use for a therapeutic purpose, and not on the basis of whether or not they contain 
NMs.   
 
Medsafe regulates products used for a therapeutic purpose including: 
• medicines;  
• medical devices;  
• related products;  
• herbal remedies;  
• controlled drugs used as medicines.  
 
Pursuant to section 3(1)(a), medicine, new medicine, prescription medicine and restricted 
medicine (medicines) are defined as any substance or article, other than a medical device, that 
is manufactured, imported, sold, or supplied wholly or principally for administering to one or 
more human beings for a therapeutic purpose. Medicine is further defined in section 3(1)(b) 
and (c).  
 
The definition of medicine does not include substances used for dental cavities, or bandages, 
surgical dressings or radioactive material.201 Animal food and remedies are also excluded 
from the definition under the Act.202 Substances declared by regulations made under the Meds 
Act not to be medicine are also excluded from the definition of medicine.203   
 
New medicine, pharmacy-only medicine, prescription medicine and restricted medicine are 
further defined at length in section 3(3).  
 
Nanomedicines such as Caelyx or Abraxane,204 and medicines which contain active nano-
scale ingredients, will be defined as medicine whether or not they contain NMs. A product 
which falls within the definition will be a ‘medicine’ for the purposes of the Meds Act by 
                                                     
201 Meds Act, subss 3(2)(a), (b) and (c).  
202 Meds Act, subss 3(2)(d) and (e).   
203 Meds Act, subs 3(2)(f).  
204 Timothy Vines and Thomas Faunce ‘Assessing the Safety and Cost-Effectiveness of Early 
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virtue of being a medicine and not on the basis of the particle size of the active ingredients of 
the product.  
 
Under section 2 of the Meds Act medical device means any device, instrument, apparatus, or 
contrivance, including component parts and accessories thereof, that is manufactured, 
imported, sold, or supplied for use wholly or principally on or by one or more human beings 
for a therapeutic purpose; and includes bandages and other surgical dressings, except 
medicated dressings where the medication has a curative function that is not limited to 
sterilising the dressing. The definition of medical device does not include any ultrasonic 
therapy apparatus, any irradiating apparatus (except in section 38) or any article that is 
declared in the regulations as not being a medical device. 
 
Where products are defined as medical devices under the Meds Act, the products will fall 
within the regulatory scope of Medsafe. A product which falls within the definition will be a 
medical device by virtue of being a medical device and not on the basis of whether or not the 
device contains NMs. As combination therapies, such as nanotherapeutics, confuse the 
boundaries between ‘medicine’ and ‘medical device’, it is unclear whether the Meds Act 
definitions can manage the challenges posed by these combinations.  
 
The Meds Act definition is inconsistent with international definitions. For example, The Meds 
Act definition of medicine catches products such as pregnancy tests, which are regulated as 
devices in Europe, US, Canada and Australia.205 Redefinitions of medicine and medical 
devices were proposed in 1994,206 and again in the context of the proposed regulatory scheme 
to be administered by the ANTPA, but the change has not been adopted.  
 
‘Related product’ is defined in section 94 of the Meds Act. Related product means any 
cosmetic or dentifrice207 or food in respect of which a claim is made that the substance or 
article is effective for a therapeutic purpose. The definition of related product does not include 
any medicine or any substance or article of a kind or belonging to a class that is declared by 
regulations made under this Act to be a kind or class of substance or article that is not a 
related product. Fluoride toothpastes and some anti-dandruff products fall within the 
definition of related product. The planned regulation change would declare these not to be 
related products, leaving them to be regulated under the HSNO Cosmetic Group Standard 
administered by ERMA.   
 
Cosmetics that contain a hazardous substance are covered by a Cosmetic Products Group 
Standard under the HSNO Act.208  
 
Under section 2 of the Meds Act, herbal remedies are a subcategory of medicine. A herbal 
remedy is a medicine that does not contain a prescription medicine, or a restricted medicine, 
or a pharmacy only medicine and consists of any substance produced by subjecting a plant to 
drying, crushing, or any other similar process.   
 
Nanoparticles of silver, titanium dioxide, zinc and zinc oxide are used in nutritional 
supplements. These are most commonly regulated as Dietary Supplements under the Dietary 
Supplements Regulations 1985 (now administered by Medsafe). However, these regulations 
                                                     
205 Thank you to Dr Susan Martindale for this comment.  
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will be revoked if the planned Natural Health Products Bill is passed. This Bill is currently at 
the policy development stage.   
 
Products will be defined as related products or herbal remedies by virtue of falling within the 
statutory definitions and not on the basis of whether or not the products contain nano-scale 
materials.   
 
For medicines that are or contain new organisms, the requirements of the Meds Act are additional to 
the requirements in the HSNO Act.209 Medicines that are hazardous substances are excluded from 
the HSNO control.210  
 
 
Approval Prior to Regulated Activity  
 
Product quality standards are agreed during the pre-marketing approval process and enforced 
through monitoring.211 The structure of the Act is to impose a broad prohibition on the sale or 
distribution of medicines unless the publicly notified consent of the Minister of Health has 
been obtained, or an exemption applies.212 The aim is to ensure that the products available are 
those that can be expected to have greater benefits than risks if used appropriately. A key 
mechanism to achieve this aim is a pre-marketing approval system which requires products to 
be assessed for safety, quality and efficacy before use.213  
 
In particular, no person may sell, distribute, or advertise new medicines before the Minister of 
Health’s consent has been notified in the Gazette.214 A person who contravenes this provision 
commits an offence.215 An application for consent from the Minister of Health must be made 
in accordance with provisions of the Act.216 On receiving an application for consent, the 
Minister must consider all the particulars and information on the medicine and weigh the 
medicine’s likely therapeutic value against the risk of its use injuriously affecting a person’s 
health.217 If the Minister is not satisfied that consent for the medicine’s distribution should be 
given, s/he must refer the matter to the appropriate committee.218 After consideration, the 
committee must recommend what decision the Minister should make.219 The Act lays down a 
procedure for conditions to be imposed. Once approval is granted, the medicine may be 
distributed and administered on those conditions. The pre-marketing approval process applies 
to medicines, whether or not they contain NMs and whether or not they are nanomedicines.  
 
Every application for the Minister’s consent under section 20 must state the particulars 
specified in section 21(2). One of the particulars required by 21(1)(d) is a full statement of the 
ingredients named by the descriptive or non-proprietary names of the medicine, including 
details of the quantities in which they are present.220 Particle size could be included in the 
statement under section 21(2)(d). 
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Notwithstanding sections 20 to 22 of the Meds Act, the Minister may give provisional consent 
to the sale or supply or use of a new medicine where s/he is of the opinion that it is desirable 
that the medicine be sold, or used on a restricted basis for the treatment of a limited number of 
patients.221 Provisional consent could be granted whether or not the new medicine contains 
NMs or is a nanomedicine.  
 
The distribution of new medicines is prohibited unless the publicly notified consent of the 
Minister has been obtained, or an exemption applies. There are various exemptions covered in 
sections 25 to 34 of the Meds Act. For example, there are exemptions for practitioners222 and 
in respect of herbal remedies.223 Under section 28, the sale of herbal remedies is permitted 
without written recommendations about their use. However, if the herbal remedy is to be sold 
or distributed with a recommendation that it be used for a therapeutic purpose, then it may not 
be distributed until ministerial consent is granted under section 20.   
 
Under section 29, there is an exemption for a medicine required by a medical practitioner for 
the treatment of a particular patient. If the request for the section 29 exemption is successful, 
there will be no scrutiny of the medicine, whether or not it contains NMs. Accordingly, where 
an exemption applies to a medicine, that medicine (whether or not it contains NMs) will not 
be assessed by Medsafe prior to its supply in New Zealand.   
 
An exemption is created for clinical trials of new medicines, even those not generally 
approved for use in New Zealand.224 According to this exemption, clinical trials will be 
permitted when the trial investigators and the trial itself have been approved by the Director-
General, on the recommendation of the Health Research Council (HRC). The HRC has 
lawfully delegated its authority in this regard to the Standing Committee on Therapeutic 
Trials (SCOTT)225 or the Gene Technology Advisory Committee (GTAC) for biological 
products. Ethical approval for clinical trials is also required.226 The exemption for clinical 
trials will apply whether or not the trial involves medicines containing NMs or 
nanomedicines.  
 
Although most medicines require pre-market approval, some products which claim 
therapeutic benefits and have risks, do not. For example, the approval process outlined above 
applies to medicines. Medical devices, however, are not subject to any pre-market assessment 
or approval. In contrast to New Zealand, most developed countries require pre-market 
approval for medical devices.227 Medical devices are excluded from the definition of medicine 
in the Meds Act. Their distribution is not regulated by other legislation. 
 
SCOTT approval is not required for trials of new devices. However, medical devices are 
included in Medsafe’s Guidance Notes for Applicants for Consent to Distribute New and 
Changed Medicines and Related Products.228  
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These omissions regarding medical devices are deficiencies in the Meds Act. The 
inconsistency in product regulation was one issue which prompted proposals to review the 
Medicines Act.229 The Meds Act will struggle with the challenges presented by emerging 
technologies such as nanomedicines without safety and approval processes for medical 
devices.230 For example, it is unclear how the Meds Act will manage a nanomedical device 
designed to replace human blood.231 The Australian Therapeutic Goods Act provides the 
Agency with a range of regulatory controls in relation to the manufacturing of medical 
devices, which apply to these devices whether or not they contain NMs.232  
 
 
In New Zealand, the manufacture and distribution of medicines is regulated through an 
activities licensing system. Everyone who manufactures a medicine, sells a medicine by 
wholesale, packs or labels a medicine, or operates any pharmacy must do so in accordance 
with a licence unless an exemption applies.233 Licences are issued under Part 3 of the Act.234 
However, there are no product licences (approval for product) or activity licences required for 
medical devices.  
 
Access to medicines is controlled through a classification system which allows some 
medicines to be obtained only on prescription, while others may be purchased only from a 
pharmacist or in a pharmacy. The Minister of Health is responsible for appointing the 
Medicines Classification Committee, which must make recommendations to the Minister on 
the classification of medicines as prescription medicines, restricted medicines, or pharmacy-
only medicines.235 Medicines not restricted by the classification system may be purchased 
from any retail outlet. There is no comparable classification system for medical devices. 
Accordingly, unclassified medicines and medical devices, whether or not they contain NMs, 
will not be controlled through the classification system. For example, products such as nano 
colloidal silver dietary supplements and nano-silver hair straighteners are not subject to the 
classification system.236    
 
 
Human and Environmental Safety Assessment  
 
Risks assessments on products undertaken by Medsafe focus on the evaluation of the risks 
posed to human health. The human safety assessment must be favourable for the product to be 
approved.  
 
The Common Technical Document is accepted by Medsafe. If another agency accepts a 
particular product, Medsafe reviews the technical report issued by the other agency and 
conducts a truncated review of the section 21 data.237  
 
                                                     
229 Meds and Medical Devices at 10.  
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Section 22(1) of the Meds Act prescribes a procedure in respect of applications for the 
Minister’s consent. On receipt of an application for his or her consent to the distribution of a 
medicine for the purposes of section 20(2) of the Act, the Minister shall: 
• consider all the particulars and information relating to the medicine submitted under 
section 21 of this Act, and such other matters as appear to him or her to be relevant; 
and  
• as far as practicable, weigh the likely therapeutic value of the medicine against the 
risk (if any) of the use of the medicine injuriously affecting the health of any person.  
The human safety assessment under section 22 applies to medicines whether or not they 
contain NMs.  
 
A change in the manufacturing process, for example, the reduction of the particle size of 
active ingredients to the nanoscale, will trigger reassessment of the product.   
 
The human safety assessment process under the Meds Act is concerned with the principles of 
benefit/risk analysis, rather than solely the technology per se. This assessment method may 
not be appropriate for nanomedicines where there exists a deficiency of long-term exposure 
and nanotoxicology data. The potential adverse effects of nanoparticles may defy prediction 
from the known toxicity of the material of macroscopic size, and nanoparticles can 
accumulate in secondary organs. Therefore, some commentators argue that there may be long-
term effects which present benefit/risk assessments fail to consider.238  
 
If, after complying with the requirements in section 22(1), the Minister is not satisfied that 
s/he should give his/her consent to the distribution of the medicine, s/he will refer the matter 
to the appropriate committee. If the recommendation is to refuse consent, the applicant must 
be notified. The applicant can object.  
 
Accordingly, there is a human safety assessment for products defined as medicine under the 
Act. However, there is no human safety assessment for medical devices under the Meds Act. 
Whether or not medical devices contain NMs, Medsafe is not required to undertake a case-by-
case safety or hazard assessment of these devices.   
 
Medsafe does not currently perform environmental risk assessments. Although environmental 
safety assessment is not a focus, Medsafe reviews labels submitted under section 21(2)(o). If 
Medsafe considers that a warning or caution is needed, theoretically, they could ask for such a 
warning when conducting the review. In practice, however, New Zealand typically gets the 
labels that are used in other, bigger markets as companies rarely label for the small New 
Zealand market.239  
 
There are guidelines for DHBs on the disposal of unused, returned or expired medicines with 
adverse environmental effects.240 Medicines and devices should not be disposed of as part of 
normal household waste because of the potential for misuse and because municipal waste 
disposal in landfills is not the disposal method of choice for many pharmaceutical types.241 
 
The FDA requires that an environmental assessment accompany any New Drug Application 
(NDA) or Animal NDA for a drug with an expected environmental concentration greater than 
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239 Thank you to Dr Susan Martindale for alerting us to this important point.  
240 Disposal of Unused, Returned or Expired Medicines in Pharmacy Practice Handbook 2010 
Pharmaceutical Society of New Zealand <www.psnz.org.nz> 
241 Id.  
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one part per billion, as well as those known to cause adverse ecotoxicological effects at lower 
concentrations.242 The TGA does not require environmental data, although Australia is 
considering introducing this requirement.243. The EU consider environmental data, but this 
examination does not necessarily translate into label cautions.244 
 
Post-Market Monitoring  
 
The Meds Act provides Medsafe with various post-market monitoring powers over products 
used for a therapeutic purpose in order to ensure that the safety and efficacy of products is 
maintained. According to the regulator, post-market surveillance is conducted through 
activities such as: 
• monitoring adverse reactions to medicines used in New Zealand and monitoring the 
international literature and other information sources; 
• testing marketed medicines against product quality standards; 
• handling complaints and investigations; and 
• auditing and licensing medicine manufacturers.245 
Prescribers are advised about new safety information for products.246  
 
Sections 35-42 of the Meds Act govern quality and standards. Under section 35, the Minister 
may at any time, by notice in the Gazette, revoke, or suspend for such period as s/he may 
determine, any consent given under section 20 or 23 of the Act if s/he is of the opinion that:  
• the medicine can no longer be regarded as a medicine that can be administered or 
used safely for the purposes indicated in the application for consent; or 
• the specifications and standards with respect to the manufacture of the medicine that 
were included in the terms of consent can no longer be regarded as satisfactory; or  
• the efficacy of the medicine can no longer be regarded as satisfactory.  
 
The ability to remove products shown to be unsafe gives Medsafe power over the supply of 
products within the New Zealand.  
 
Section 36 provides the Director-General with powers to control established medicines. If the 
Director-General has reason to believe that any medicine (not being a new medicine) may be 
unsafe or ineffective for the therapeutic purpose for which it is sold, s/he may state the 
reasons for his/her belief and require the importer or manufacturer to satisfy him/her of the 
safety or efficacy of that medicine. The Minister may, by notice in writing to the importer or 
manufacturer, prohibit the importer or manufacturer from selling or supplying the medicine; 
or impose conditions on the sale or supply of the medicine by the importer or manufacturer.247 
The broad powers in section 36 cover any medicine, whether or not the medicine contains 
NMs and whether or not the medicine is a nanomedicine.    
 
The Minister has the power to prohibit the import, manufacture, packing, sale, possession, 
supply, administration, or other use of medicines of any specified description or medical 
devices of any specified kind, either absolutely or subject to such conditions as s/he thinks fit, 
for any specified period not exceeding 1 year.248 But the Minister shall not exercise this power 
                                                     
242 FDA www.fda.gov viewed 15 November 2010.  
243 Email from Dr Susan Martindale to Dr Jennifer Moore regarding the Medicines Act (14 June 2010). Email 
from Dr Susan Martindale to Dr Jennifer Moore regarding the Meds Act (14 June 2010). 
244 Id.  
245 www.medsafe.govt.nz  
246 Id.  
247 Meds Act 1981, subss 36(3)(a), (b).  
248 Meds Act, s 37. 
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more than once in respect of medicines or medical devices so specified.249 A person who 
contravenes this provision will commit an offence. Section 37 gives the Minister broad post-
market monitoring powers for medicines and medical devices, whether or not they contain 
NMs. Section 37 could be used for an immediate ban of a medicine, but this power has never 
been used.250   
 
Section 38 enables restrictions on the sale of medical devices, whether or not those devices 
contain NMs.  
 
These post-market monitoring provisions are designed to ensure that the quality and standards 
of medicines are maintained. The post-market monitoring provisions outlined apply to 
products whether or not they contain NMs. The post-market monitoring provisions are 
sufficiently broad to cover products containing NMs.   
 
Pursuant to sections 41, importers or manufacturers have a duty to report untoward effects of 
medicines. Failure to notify the Director-General of untoward effects of medicines, which 
may or may not contain NMs, will give rise to offences under the Act.    
 
Under section 42, importers and manufacturers have a duty to have and produce specifications 
of medicines. No importer or manufacturer may sell, or distribute any medicine unless s/he is 
in possession of a certificate of results of testing. Section 42 may provide a mechanism 
whereby a product containing NMs may be identified through the specifications of the 
medicine.   
3.3 MfE  
 
New Zealand’s primary agency for protecting the environment is the Ministry for the 
Environment. The New Zealand Waste Strategy’s vision of “zero waste and a sustainable New 
Zealand”251 is the background against which the Waste Minimisation Act 2008 (WMA) was 
passed.252 The WMA was passed in September 2008. The WMA provides for waste 
management and minimisation. The collection and disposal of waste in urban areas is 
traditionally a function and service of territorial authorities.253 Territorial authorities are 
compelled to have regard to the New Zealand Waste Strategy.254 The New Zealand Waste 
Strategy is currently under review. A revised Strategy is expected to be released later in the 
year, subject to Cabinet approval. Waste management and minimisation plans are to have 
regard to the New Zealand Waste Strategy.255 Many of the OECD’s recommendations in its 
Environmental Performance Review of New Zealand have been incorporated in WMA.256 
 
                                                     
249 Meds Act, s 37.  
250 Interview with Dr Susan Martindale, Principal Advisor, Regulation, Medsafe (Dr Jennifer Moore, 
Law Faculty, University of Otago, 17 May 2010).  
251 The New Zealand Waste Strategy: Towards Zero Waste and a Sustainable New Zealand (March 
2002 with reviews in 2003, 2006) at http://www.mfe.govt.nz/publications/waste/waste-strategy-
mar02/index.html (accessed 1 June 2010).  
252 Helgard Wagener, ‘The Waste Minimisation Act 2008 and the Ability of Territorial Authorities to 
Manage Solid Waste’ (2009) NZJEL 295 at p.299.  
253 Waste Management, Minimisation and Disposal, The Laws of New Zealand 
254 WMA, s 42(c). 
255 WMA, s 42(c). 
256 Wagener, ‘The Waste Minimisation Act 2008’, loc. cit., at p.315, and OECD Environmental 
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The Resource Management Act 1991 (RMA) and the Local Government Act 1974 (LGA) 
were the primary methods of dealing with solid waste management before the enactment of 
the WMA.257 The RMA deals with the environmental effects of activities such as solid waste 
disposal. The Health Act 1956 addresses the effects of solid waste where this creates a 
nuisance or any conditions likely to be injurious to health or offensive.258 The WMA is the 
first New Zealand statute that specifically regulates waste.259 
 
The WMA brings territorial authorities’ responsibilities for waste management into one 
statute. However, there are also provisions relating to waste in the RMA and the Hazardous 
Substances and New Organisms Act 1996 (HSNO). The RMA deals with the effects of 
activities such as waste disposal on the environment.    
 
The Basel, Stockholm and Waigani Conventions are New Zealand's international obligations 
relating to the management of hazardous wastes. Each one is implemented through domestic 
legislation and policy that is not covered in this report and could be useful instruments to 
manage NMs, particularly if internationally, NM waste and products becomes a higher 
priority. 
 
Scope and Triggers  
 
The purpose of the WMA is to encourage waste minimisation and a decrease in waste 
disposal in order to protect the environment from harm and to provide environmental, social, 
economic, and cultural benefits.260 The WMA continues the sustainability objectives set out in 
the RMA and LGA. The objective to protect the environment from harm has a link to the 
purpose of the RMA.261  
 
The WMA is not underpinned by the precautionary principle to the same extent as the RMA. 
However, some of the tools in the RMA (such as the regulation making powers) could be 
applied in a precautionary manner.262 
 
One of the main triggers of the WMA is the disposal of waste. Disposal means the final (or 
more than short-term) deposit of waste into or onto land set apart for that purpose; or the 
incineration of waste.263 Disposal facility means a facility, including a landfill, at which waste 
is disposed of; and at which the waste disposed of includes household waste; and that 
operates, at least in part, as a business to dispose of waste; and any other facility or class of 
facility at which waste is disposed of that is prescribed as a disposal facility. The disposal of 
waste will trigger the WMA, whether or not some of the constituents of the waste are NMs or 
produced using nanotechnology.  
 
The Act is also triggered by the actions of territorial authorities. For example, under section 
42 territorial authorities must promote effective and efficient waste management and 
minimisation within their districts.    
 
The provisions of the WMA include:  
                                                     
257 Wagener, ‘The Waste Minimisation Act 2008’, loc. cit., at p.309.  
258 Health Act 1956, ss 23, 29 & 63.  
259 Wagener, ‘The Waste Minimisation Act 2008’, loc. cit., at p.339. 
260 WMA, s 3.  
261 RMA, s 5. Wagener, ‘The Waste Minimisation Act 2008’, loc. cit., at p.327.  
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• introduction of product stewardship provisions264 to encourage (and in certain 
circumstances require) people and organisations involved in the life of a product to 
share responsibility for ensuring there is effective reduction, reuse, recycling or 
recovery of the product and managing any environmental harm arising from a product 
when it becomes waste; 
• impose a waste disposal levy to promote and achieve waste minimisation and also 
increase the cost of waste disposal in order to recognise its costs on the environment, 
society and economy;265 
• clarify the roles and responsibilities of territorial authorities with respect to waste 
minimisation;266 
• allow regulations to be made making it mandatory for territorial authorities and others 
to report on waste to improve information on waste minimisation;267 and 
• establish a Waste Advisory Board to give advice to the Minister for the Environment 
on waste minimisation issues.268   
 
Section 5 defines ‘waste minimisation’ as the reduction of waste and the reuse, recycling, and 
recovery of waste and diverted material. ‘Waste’ is defined in section 5 as any thing disposed 
of or discarded and includes a type of waste that is defined by its composition or source (for 
example, organic waste, electronic waste, or construction and demolition waste and includes 
any component or element of diverted material, if the component or element is disposed of or 
discarded. What constitutes waste is a contentious issue.269 There are different types of waste 
such as solid waste, organic waste and hazardous waste. Hazardous wastes contain 
explosives, are flammable, or able to cause oxidisation or corrosion and are toxic or 
ecotoxic.270  
 
Pursuant to this definition of ‘waste’, waste associated with NMs falls within the scope of the 
WMA. For example, the definition will include waste from the preparation and production of 
products containing NMs. Such waste will fall within the scope of ‘waste’ under the WMA by 
virtue of being ‘waste’, not as a consequence of incorporating NMs. The trigger for the 
application of the Act will not be whether or not the waste contains NMs. Rather ‘waste’ will 
be defined as such whether or not some of the constituents of the waste are NMs or produced 
using nanotechnology.  
 
‘Diverted material’ is distinguished from ‘waste’ and has a separate definition in the WMA. 
Diverted material is anything that is no longer required for its original purpose and, but for 
commercial or other waste minimisation activities, would be disposed of or discarded.271 
Diverted material will be defined as such whether or not some of the constituents of the 
diverted material are NMs.  
 
 
Approval Prior to Regulated Activity  
 
                                                     
264 WMA, Part 2 ss 8-24. 
265 WMA, Part 3 ss 25-41.  
266 WMA, Part 4, ss 42-64.  
267 WMA, s 41.  
268 WMA, Part 7, ss 89-99.  
269 Wagener, ‘The Waste Minimisation Act 2008’, loc. cit. at p.300.  
270 HSNO Act, s 2. See also the Hazardous Substances (Disposal) Regulations 2001 issued pursuant to 
s 76(1)(c) of the HSNO Act.  
271 WMA, s5(1).  
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The WMA does not provide the MfE with regulatory powers relating to the general approval 
of products prior to their importation, sale or use within NZ.  
  
However, Part 2 of the WMA establishes a framework for product stewardship. Product 
stewardship enables the “best means of minimising the environmental risks of a product to be 
considered at the most appropriate stage of its lifecycle.”272 Section 8 encourages (and, in 
certain circumstances, requires) people and organisations (including producers, brand owners, 
importers, retailers, consumers) to take responsibility for the environmental effects from the 
beginning to the end of the production process. ‘Producer’ is defined broadly to mean a 
person who –  
(a) manufactures a product and sells it in New Zealand under the person’s own brand; or  
(b) is the owner or licence holder of a trademark under which a product is sold in New 
Zealand; or  
(c) imports a product for sale in New Zealand; or  
(d) manufactures or imports a product for use in trade by the person or the person’s 
agent.  
A producer of products containing NMs would be considered a producer under the Act by 
virtue of falling within the definition in section 5(1) and not as a result of having products 
containing NMs.  
 
‘Product’ is defined in section 5(1) include packaging and a class of products such as fridges 
and freezers. Manufactured products, whether or not they contain NMs, will be caught by this 
definition.  
 
If that product is declared a priority product,273 a product stewardship scheme must be 
developed for a product as soon as practicable and that scheme must be accredited under the 
WMA.274 Under sections 5(1) and 9(1) a product is a priority product if it is so declared by the 
Minister for the Environment. The Minister can only declare a priority product when s/he is 
satisfied that: 
• the product’s waste will or may cause significant environmental harm; or  
• there are significant benefits from the reduction, reuse, recycling, recovery, or 
treatment of the product; and  
• the product can be effectively managed under a product stewardship scheme.    
 
The Minister for the Environment has not yet declared any priority products. Accordingly, no 
products containing NMs have been declared priority products. The MfE’s 2009 Discussion 
Document Waste Minimisation in New Zealand sought feedback on products that should be 
the initial focus for developing product stewardship schemes such as agricultural chemicals, 
used oil and refrigerant gases. Some of these products could contain NMs and may be 
declared priority products by virtue of their status as potential priority products, whether or 
not they contain NMs.  
 
Current deficiencies in knowledge about NMs and their eco-toxicity mean that there may not 
yet be adequate information to assess against the thresholds in section 9(2). These deficiencies 
in knowledge mean that it is currently difficult to show that the waste from products 
containing NMs will cause significant environmental harm. Recent research on silver sulfide 
nanoparticles in sewer sludge suggests that there is sufficient use of products which 
incorporate silver NMs to generate silver sulfide nanoparticles in wastewater treatment 
                                                     
272 www.mfe.govt.nz  
273 WMA, ss 9 and 10.  
274 WMA, s 15.  
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






plants.275 However, despite the use of products containing silver NMs, there are scientific 
knowledge deficiencies; more evidence is required to establish how NMs move from products 
into the environment and how the environment will be impacted.   
 
Before the Minister makes a declaration of priority products, s/he must provide the public 
with the opportunity to comment on the proposal.276 The Minister must obtain and consider 
advice from the Waste Advisory Board and also consider any public concerns about 
environmental harm associated with a product.277 There is no appeal process for the 
declaration of a priority product. However, the decision is open to judicial review.278 
 
There is also provision for the development and accreditation of voluntary product 
stewardship schemes.279 A number of voluntary product stewardship schemes already exist: 
whiteware, refrigerants, cell phones and paint. NMs are used in some paints and whiteware 
such as refrigerators. The voluntary schemes can seek to be accredited for a non-priority 
product. These schemes could be accredited for non-priority products, whether or not the 
products contain NMs.  
 
Also, the Act does provide the Governor-General with the power to make regulations to 
prohibit the sale of a priority product,280 and the power to control or prohibit the disposal or 
sale of products or waste whether or not priority products.281 As already outlined, the 
thresholds in section 9(2) must be met before a priority product can be declared.  
 
Human and Environmental Safety Assessment  
 
Under WMA, the Ministry for the Environment does not undertake safety assessments. 
However, safety assessments for hazardous substances are conducted by ERMA under the 
HSNO Act.   
 
Territorial authorities are required to undertake waste assessments for their districts before 
considering their waste management and minimisation plans.282 Territorial authorities must 
indicate how their proposals will, inter alia, ensure that public health will be adequately 
protected.283 The enquiry into how public health will be protected will occur irrespective of 
NMs. “It is unlikely that issues to do with nanotechnology would be specifically addressed in 
[waste] assessments”.284 Territorial authorities are compelled to consult with the local 
Medical Officer of Health when doing their waste assessments.   
 
Although the WMA does not have specific environmental safety assessment provisions, one 
of the objectives in the WMA is to protect the environment from harm.285 This objective is 
linked to the purpose of the RMA.286 Section 5 of the RMA integrates social, economic, 
cultural, health and safety considerations alongside the sustainable management of natural and 
                                                     
275 Bojeong Kim and others, ‘Discovery and Characterization of Silver Sulfide Nanoparticles in Final 
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physical resources. Assessments of environmental effects are required under the RMA.287 The 
definition of environment in the WMA has the same meaning as in section 2(1) of the 
RMA.288 The RMA’s definition of environment includes people and communities.    
 
 
Post-Market Monitoring  
 
The WMA includes monitoring, compliance and enforcement provisions in relation to 
managing environmental harm. However, few of the enforcement and auditing powers are 
likely to be applicable to products containing NMs.289  
 
The most relevant regulatory instrument which may cover products containing NMs is section 
23(1). Pursuant to section 23, the Governor-General may make regulations for:  
• controlling or prohibiting the disposal, or anything done for the purpose of disposing, 
of products or waste;290  
• controlling or prohibiting the manufacture or sale of products that contain specified 
materials…;291   
• the labelling of products.292  
 
Section 23(2) outlines when the Minister must not make regulations under section 23(1).  
Section 23(1)(b) concerns controlling or prohibiting the manufacture or sale of products that 
contain specified materials. This section could potentially cover products with NMs.293   
Regulations could be made for the labelling of products whether or not those products contain 
NMs.   
 
Under section 20(a), for example, the Secretary for the Environment may monitor the 
performance of accredited product stewardship schemes and recover the costs of doing so 
from the scheme manager. However, as already outlined, products (whether or not they 
contain NMs), would have to be declared a priority product, therefore requiring a product 
stewardship scheme, or have an industry-led non-priority product stewardship scheme.  
 
Pursuant to section 55 a Health Protection Officer294 may serve notice on a territorial 
authority if it provides a waste collection service to premises and s/he considers that: 
(i) the territorial authority has failed to collect waste from the premises promptly or 
efficiently; and  
(ii) the failure to do so is causing, or is likely to cause, a nuisance295.  
 
The territorial authority must comply with such a notice.296   
 
Section 18 gives the Minister the power to revoke the accreditation of any accredited scheme.  
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The Secretary for the Environment may request the New Zealand Customs Service to provide 
any information that Customs holds about the importers and importation of priority 
products.297 This statutory request could be made for priority products whether or not they 
contain NMs.  
 
Under section 48 the Governor-General may give directions to territorial authorities to 
include, omit, or amend 1 or more provisions in their waste management and minimisation 
plans. Such directions may be made whether or not the territorial authorities’ plans contain 
specific provisions on the disposal of products containing NMs.  
 
Section 86(1)(a), (b) and (c) give the Governor-General the power to make regulations to 
require: 
• the operator of a disposal facility to keep, and provide to the Secretary, records and 
information;  
• any class of persons to keep, and provide to the Secretary, records and information 
to assist the Secretary to compile statistics in order to measure progress in waste 
management and minimisation;  
• a territorial authority to keep, and provide to the Secretary each year, records and 
information about the territorial authority’s spending of levy money, performance in 
achieving waste minimisation and performance as measured against any 
performance standards set by the Minister under section 49.  
 
Under section 90(1), the Waste Advisory Board’s functions include providing advice to the 
Minister upon request about declaring a product to be a priority product, making guidelines 
about the contents and expected effects of product stewardship schemes for priority products, 
recommending the making of regulations prohibiting the sale of a priority product and 
recommending the making of regulations in relation to products (whether or not priority 
products), materials, and waste.   
 
There are provisions for offences under and enforcement of the provisions of the WMA, 
including fines from $20,000 to $100,000 and the seizure and disposal of property.298 For 
example, under section 65(1)(a) a producer who contravenes regulations made under section 
22(1)(a), relating to priority products, commits an offence and is liable on summary 
conviction to a fine not exceeding $100,000. In any prosecution for an offence such as in 
sections 65(1)(a), (c), (e) or section 66, strict liability is imposed. Under section 76, 






3.4 MfE/ ERMA  
 
The Hazardous Substances and New Organisms (HSNO) Act 1996 was enacted ‘because of 
the need for a more integrated and consistent approach to managing hazardous substances and 
new organisms in New Zealand.’299 The Act’s stated purpose is ‘to protect the environment, 
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and the health and safety of people and communities, by preventing or managing the adverse 
effects of hazardous substances and new organisms.’300  
 
Section 14 of the HSNO Act provides for the establishment of the Environmental Risk 
Management Authority (ERMA), ‘an independent, quasijudicial authority set up by the 
HSNO Act to decide on applications to introduce hazardous substances and new 
organisms.’301 ERMA’s overall mission is to 'achieve effective prevention or management of 
risks to the environment, public health and safety associated with importing or manufacturing 
hazardous substances and introducing new organisms, and their use.’302 
 
More specifically, it exists to: 
 
• assess and decide on applications to introduce hazardous substances and new 
organisms into New Zealand 
• place controls, where appropriate, on hazardous substances and new organisms 
• maintain a publicly available register of applications and approvals 
• approve test certifiers and codes of practice. 
• monitor compliance with and enforcement of the Act 
• where appropriate, enquire into incidents or emergencies involving a new organism or 
hazardous substance 
• report to Parliament annually on incidents caused by inadequate management of 
hazardous substances or new organisms, and the extent to which the Act has 
contributed to the health and safety of people and the environment.303 
 
As of 1 July 2011, ERMA will be ‘disestablished’, and a new Environmental Protection 
Authority will assume its role in terms of the HSNO Act.304 For the purposes of this review, 
however, it is the function of ERMA, as presently constituted, that will be considered. 
 
Scope and Triggers  
 
The HSNO Act applies only to ‘substances’ that are ‘hazardous’, and both of those criteria 
have been subject to interpretation and controversy. A ‘substance’ is defined as:  
 
(a) any element, defined mixture of elements, compounds, or defined mixture of 
compounds, either naturally occurring or produced synthetically, or any mixtures thereof; 
 
(b) any isotope, allotrope, isomer, congener, radical, or ion of an element or compound 
which has been declared by the Authority, by notice in the Gazette, to be a different 
substance from that element or compound; 
 
(c) any mixtures or combinations of any of the above; 
 
(d) any manufactured article containing, incorporating, or including any hazardous 
substance with explosive properties.305 
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 http://www.ermanz.govt.nz/about/whatwe-do.html 
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With the exception specified in (d), manufactured articles – even those containing or 
incorporating hazardous substances – are generally not considered to be ‘substances’ for 
purposes of the HSNO Act306  (subject to the partial exception in s.96B(2)(d)), discussed 
later). As discussed below, this has given rise to some controversy regarding ‘white goods’ 
that contain or produce nanoparticles. 
 
A substance will be considered ‘hazardous’ if it meets or exceeds one of the thresholds set 
down in the Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001 for any 
of the relevant properties.’307 These relate to 
(i) explosiveness; 
(ii) flammability; 
(iii) a capacity to oxidise; 
(iv) corrosiveness; 
(v) toxicity (including chronic toxicity); 
(vi) ecotoxicity, with or without bioaccumulation.308  
 
Where it is possible that a substance may trigger more than one threshold, it should be 
evaluated against the thresholds established for each hazardous property, e.g. a substance that 
may have both flammable and toxic properties must be evaluated against both relevant 
thresholds. 
 
As ERMA explains, ‘If a substance does not trigger any of the thresholds, it is not 
“hazardous” and does not need an approval from the Authority. However, if a substance does 
trigger a threshold level, then it cannot be imported or manufactured in New Zealand other 
than in accordance with an approval from the Authority.’309 The manufacture or importation 
of a hazardous substance without an approval is an offence.310  
 
Certain substances which might otherwise meet the relevant criteria are exempt from the 
terms of the HSNO Act, and hence, from the need for ERMA approval. Excluded substances 
include: food in a ready-to-consume form,311 and finished dose-form medicines.312  
 
                                                     
306 ERMA, ‘Interpretations and Explanations of Key Concepts’, paragraph 4.6; see also DSL Guide, 
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noted, however, that ‘[a]ny new ingredient used for formulating a medicine is not exempt and will 
require a HSNO approval.’ DSL, 2.4 
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






The relevant thresholds are set out in Hazardous Substances Regulations 2001.313 A threshold, 
for these purposes, is described as ‘the amount or concentration of a substance that is likely to 
cause an adverse effect on people or the environment.’314 The threshold level has been 
described as the ‘bottom rung on the classification ladder’,315 the least hazardous level at 
which controls can be triggered. A substance will not be considered hazardous if it does not 
meet this minimum threshold, while substances located higher up the hazard ladder may merit 
tighter controls. 
 
There are thirteen Hazardous Substances Regulations, covering, inter alia, minimum degrees 
of hazard, classification of hazards, packaging, identification and disposal.  As noted above, 
the minimum thresholds for hazardous properties – which determine whether a substance is 
hazardous - are contained in the Hazardous Substances (Minimum Degrees of Hazard) 
Regulations 2001,316 while the classification criteria for hazardous properties - which 
determine hazard levels for hazardous substances - are contained in the Hazardous Substances 
(Classification) Regulations 2001.317 As ERMA has pointed out, ‘The criteria in these 
regulations are based on those contained in the early version of the United Nations Globally 
Harmonised System of Classification and Labelling of Chemicals (GHS). This system is 
currently being implemented on a widespread basis around the world. The HSNO regulations 
are currently being updated to reflect the 2009 version of the GHS.’318 
 
A substance with toxic properties will not be treated as ‘hazardous’ for the purposes of the 
HSNO Act unless data indicates that it meets the minimum degrees of  hazard as stipulated in 
Schedule 4 of the Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001.  
Data, for these purposes, ‘includes values that are directly measured, calculated, or estimated 
for any of the measures given’.319 As ERMA has explained, ‘[t]his means it is not necessary 
to rely only on directly measured data to determine whether a substance exceeds any of the 
hazardous property threshold criteria’; rather, ‘a relevant parameter for a substance may be 
estimated based on the similarity of that substance to another substance for which the 
hazardous properties are known.’320 
 
If a substance is deemed to have properties that exceed one or more of these hazardous 
property thresholds, then an approval from ERMA will be required. The initial responsibility 
for deciding whether such an approval will be required rests with the importer, manufacturer 
or user.321   
 
The Monash Report identified a number of potential regulatory gaps with regard to quantity-
based assessment thresholds. For example, Australia’s industrial chemicals law allows for 
‘low volume permits’, described as ‘a simple means of by-passing the assessment 
certificate system in respect of a new industrial chemical if the total of the quantities of 
the chemical that are to be introduced by the person in any 12 month period will not exceed 
100 kilograms (or 1,000 kilograms in certain cases).’322 The Monash Report expressed 
                                                     
313 http://www.ermanz.govt.nz/resources/hsno-regs.html 
314 ERMA, Summary User Guide to HSNO Thresholds and Classifications, at 1.1.3. 
315 Id. 
316 Schedules 1 to 6. 
317 Schedules 1 to 6. 
318 Personal correspondence, For further information, see 
http://www.ermanz.govt.nz/hs/abouths/ghscriteria.html 
319 Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001, section 3 
320 ERMA, Summary User Guide to HSNO Thresholds and Classifications, at 1.1.4 
321 ERMA, Summary User Guide to HSNO Thresholds and Classifications, Preface 
322 Industrial Chemicals (Notification and Assessment) Act 1989, s.21Q 
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concern that ‘under this permit system, there is the potential for many products containing 
new industrial chemicals, including those produced at the nanoscale, to be imported or 
manufactured in Australia, and subsequently sold’ without having to go through the 
assessment system.323 NICNAS, the Australian chemicals regulator, has responded by 
proposing to ‘exclude nanomaterials which are new chemicals from low volume/low 
concentration exemptions, thereby shifting a post-market audit activity to a pre-market 
assessment’.324  
 
There is no analogous low volume exception under the HSNO Act. Hence, for the most part, 
this conclusion of the Monash Report – and this part of the NICNAS recommendations - has 
no relevance to New Zealand. The one permitted quantity-based exception under the HSNO 
Act relates to ‘small-scale use of hazardous substances in research and development or 
teaching’. Section 33 provides that the requirements of the HSNO Act do not apply to ‘any 
small-scale use of hazardous substances in research and development or teaching’, provided 
certain criteria are fulfilled, including  
• that such ‘use occurs in a laboratory that meets the prescribed requirements’;  
• the use does not create or involve a hazardous substance for which any application for 
approval has been declined under this Act; and 
• the importation, storage, and transportation of the hazardous substances each meets 
the prescribed requirements. 
R&D exemptions in Australia were identified by the Monash report as a potential gap. While 
acknowledging that ‘[t]hese gaps are not unique to NMs’, the Report’s authors nonetheless 
felt that ‘in light of the stage in development at which many NMs and products incorporating 
them currently are, this deliberate exception for research and development may be of greater 
significance for NMs and their products and therefore is included as a ‘gap’ for the purposes 
of this review.’325 NICNAS, however, have proposed that the R&D exemption be retained for 
mNMs, ‘due to their limited use (i.e. only in an R&D or analytical setting) and the assumption 
that they are handled only by trained personnel in a controlled environment.’326 
 
Whether New Zealand laboratory personnel are adequately trained in handling mNMs is an 
empirical question that we have not been able to investigate. However, research conducted by 
Canterbury University’s Sally Gaw for the MacDiarmid Institute in 2009 suggested that 
complacency in this regard should be avoided. Gaw’s report identified a number of issues of 
potential concern, specifically:  
 
• There is limited information on the effectiveness of engineering controls and personal 
protective clothing to minimise exposure to unbound nanomaterials. 
• Ensuring that researchers have access to best practice safety information for working 
with nanomaterials and that risk or safety assessments are completed. 
• A lack of documented training for new researchers in safe practices for working with 
nanomaterials. 
• Not all nanomaterials research is undertaken in dedicated facilities. A mechanism is 
needed to ensure that other researchers in shared facilities are aware of any hazards 
and associated  precautionary measures. 
                                                     
323 Monash Report, at p.83 
324 NICNAS, Proposal for Regulatory Reform of Industrial Nanomaterials: Public Discussion Paper 
(November 2009) 
325 Monash Report, at para. 5.1.5 
326 NICNAS, Proposal for Regulatory Reform of Industrial Nanomaterials, op. cit. 
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• The lack of readily available funding for upgrading research facilities to meet health 
and safety requirements. 327 
Is the substance ‘new’? 
Even if something is agreed to be a ‘hazardous substance’, an application will only be 
required if it has not already received approval. The question inevitably arises as to whether a 
nano-form of a previously approved substance would be regarded as a new substance, 
requiring its own approval, or alternatively, would be deemed to be covered by the existing 
approval. The Monash Report referred to this as ‘possibly the most significant potential gap’, 
pointing out that ‘uncertainty exists as to whether the nanoentity would be considered as 
“new” or “different” to or as the same as its’ [sic] conventional counterpart.’328  
Similar uncertainty may be said to apply to applications for nanoforms of substances already 
present in New Zealand. As ERMA has said, ‘if the hazards of the nanomaterial are the same 
as the “conventional” substance, then they are covered by the approval for the “conventional” 
substance.  It is only where the hazards differ between the “conventional” substance and the 
nano substance that the nano substance would need to be treated differently under HSNO.’329   
A question inevitably arises as to how a nanoform of an existing substance will be classified 
where there is uncertainty about the hazard profile. Should it be assumed that the hazards are 
identical, until data exists to prove otherwise? Or should the default position be that the nano-
form may have distinct hazardous properties, meriting a separate approval? The question of 
where the burden of proof should lie in questions of this nature – together with the appropriate 
standard of proof which should need to be satisfied - will be discussed later. 
 
Regulatory scope: manufactured items 
 
Some doubts surround the applicability of the HSNO Act to manufactured items that contain 
(or produce – as discussed later, the distinction may be of relevance) NMs. The recent 
Sustainability Council report,330 for example, expressed concern about Samsung’s SilverCare 
washing machines. As explained on Samsung’s website, the Silver Wash technology that 
these products employ ‘uses nano technology to electrolyze pure silver during wash and rinse 
cycles. Over 400 billion silver ions are released and penetrate deep into fabric for effective 
sanitization.’331 
 
Doubt may be said to exist as to whether nano-silver washing machines are ultra vires of 
ERMA’s regulatory remit. As explained earlier, the HSNO Act definition of ‘substance’ only 
extends to manufactured articles which they possess explosive properties.  332 
The potential difficulty lies in the fact that manufactured articles which do not possess 
explosive properties – even those containing or incorporating other hazardous substances – 
                                                     
327 Gaw, S. ‘Identification of Potential Health and Safety Issues Associated with MacDiarmid Institute 
Funded Nanomaterial Research in University Laboratories’ (2009) MacDiarmid Institute 
328 Monash Report, Para 5.5.1 
329 Personal correspondence with ERMA Chief Executive, 9 July 2010 
330 Sustainability Council, The Invisible Revolution, June 2010 
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http://www.samsung.com/sg/consumer/learningresources/silvernano/silvernano/wash_faq_popup.html 
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are not considered to be ‘substances’ for purposes of the HSNO Act.333  However, 
‘manufactured products’ – ‘such as glues, paints, pesticides, etc’ – are regarded as substances 
rather than manufactured articles, and can (if other criteria are met) be subject to regulation 
under the HSNO Act ‘regardless of how they are packaged or presented’. 
 
ERMA has issued detailed guidance on the criteria for determining whether an item will be 
considered a ‘substance’ or a ‘manufactured article’, with the latter being defined as 
‘something for which its intended use is primarily to do with its physical shape, rather than its 
chemical composition’. 334 Nonetheless, it has acknowledged that ‘there will continue to be 
“fuzziness” at the boundary when deciding what is a substance and what is an article. … no 
matter how precise the boundary definition is, there will continue to be room for 
interpretation.’335  
 
It may be that SilverCare washing machines could fall within this ‘fuzzy’ area around the 
boundary. On the one hand, it would seem strange to contend that a washing machine is a 
‘substance’ rather than a ‘manufactured article’; the function of a washing machine may 
certainly be thought to owe more to its ‘physical shape’ than its ‘chemical composition.’ This 
is certainly the view taken by ERMA’s Chief Executive: ‘Common sense dictates that a 
washing machine is a manufactured article.’336 Indeed, the Sustainability Council has 
conceded that ‘regulating a laundry appliance might at least seem to fall outside the scope of 
HSNO, which broadly speaking does not cover “manufactured articles”.337 
  
On the other hand, it could be argued that the unique selling point of Samsung’s SilverCare 
range relates to claims about a chemical substance released during its operation. The 
Sustainability Council has argued that ‘the use of the nanosilver as a pesticide could be 
regulated independent of the appliance’.338 ERMA’s position, though, appears to be that the 
‘nanosilver’ should be treated as a ‘component’ of the washing machine, rather than a 
substance meriting separate regulation, distinguishing this from the hypothetical scenario 
where ‘people needed to add “nanosilver” to the wash like they do powder or rinse aid.’339  
 
Does a ‘common sense’ approach dictate that these particles should be treated as chemical 
substances, potentially requiring ERMA approval, or as integral parts of the manufactured 
article, i.e. the washing machine? The triggering of regulatory oversight seems largely 
dependent on this classification. In either event, it may be seen that there is a potential 
regulatory gap with regard to pre-market assessment of products of this nature. Either the Act, 
as properly understood, does not extend to nano-silver used in this way (as ERMA contends), 
in which case there is a potential gap at a legislative level; the somewhat anomalous outcome 
would be that NMs that required to be added to an item such as a washing machine would be 
subject to regulatory oversight (as ERMA concede), but identical NMs that happen to be 
contained or produced within the item would escape such oversight. 
 
Alternatively (and we express no view either way on this point) it may be that ERMA’s 
understanding of its remit is overly restrictive, and that the HSNO Act does permit it 
jurisdiction over ‘substances’ such as nanosilver, even when contained or produced within a 
                                                     
333 ERMA, ‘Interpretations and Explanations of Key Concepts’, paragraph 4.6; see also DSL Guide, 
p.20 
334 ERMA Information Sheet, ‘Manufactured Articles’, May 2001 
335 Ibid, at p.2. 
336 Personal correspondence with ERMA Chief Executive, 9 July 2010. 
337 Sustainability Council, The Invisible Revolution, op. cit. 
338 Ibid, at p.15. 
339 Personal correspondence with ERMA Chief Executive, 9 July 2010. 
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manufactured item. If this is the case, then it may be that there exists a potential gap at the 
level of interpretation and application of the legislation. 
 
Whatever the better interpretation of the HSNO Act, it seems clear that items such as washing 
machines that contain or produce NMs are, in practice, being treated as ‘manufactured items’, 
and the NMs themselves as integral parts of those items, rather than as substances in 
themselves. Both the machines and the nano-particles, then, are treated as lying outwith the 
scope of the HSNO Act and of ERMA. If this interpretation of the Act, currently favoured by 
ERMA, is valid, then a regulatory gap may be identified with regard to such products. 
 
Other nano-silver products could present similar problems of interpretation. Samsung’s Silver 
Nano Refrigerators have a ‘Silver Nano coating’ applied to their inner surfaces, ‘for an 
overall antibacterial and antifungal effect.’340 Though it is not entirely clear from the 
company’s various descriptions of the technology, it appears as though the NMs here are 
intended not to leave the refrigerator, or to adhere to any of the food contained within it.341 If 
this is so, then the Silver Nano particles are likely to be regarded as intrinsic to the 
manufactured item (the refrigerator), and hence are unlikely to be regarded as falling within 
ERMA’s remit.342 If nanosilver particles within refrigerators or other manufactured articles 
are considered to be an appropriate subject for regulatory oversight, this may be viewed as a 
potential regulatory gap. 
 
By way of locating this issue within an international context, it may be of interest to note that 
the status of (certain) mNMs within electronic and electrical goods has been the subject of 
recent legislative debate within the EU. A recent Resolution from the European Parliament 
called for a ban on nanosilver, together with long multi-walled carbon nanotubes, in electrical 
and electronic products343 - though it should be noted that this proposed ban did not ultimately 
find its way into EU law.  
 
Approval Prior to Regulated Activity  
 
If a substance reaches one of the thresholds discussed above, an approval will be required 
before it can be imported, manufactured or used. ERMA will decide whether the substance’s 
likely benefits outweigh any risks and costs. With regard to mNMs, an example of this 
balancing exercise may be found in ERMA’s current position with regard to zinc oxide and 
titanium dioxide nanoparticles contained in sunscreens. As ERMA’s Chief Executive 
explained to us: ‘there are known and serious risks from UV radiation (including skin cancer) 
and the evidence against nano Zinc Oxide and Titanium Dioxide is scientifically unclear.  
Hence, given current knowledge, the known benefits of these products outweigh the potential 
risks.’344 
                                                     
340  
http://www.samsung.com/sg/consumer/learningresources/silvernano/silvernano/refigerator.html 
341 ‘Can the silver stick to my food? No, silver ions will not stick to the food.’  
http://www.samsung.com/sg/consumer/learningresources/silvernano/silvernano/refig_faq_popup.html 
342 Particles which ‘remain in their container during normal use of the item, and ... serve an intrinsic 
part of the end purpose of the item,’ would be ‘considered to be an integral part of the article.’ ERMA, 
‘Interpretations and Explanations of Key Concepts’ 
343 Draft European Parliament Legislative Resolution on the proposal for a directive of the European 
parliament and of the Council on the restriction of the use of certain hazardous substances in electrical 
and electronic equipment (recast), at 
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&reference=A7-2010-
0196&format=XML&language=EN#title2 
344 Personal correspondence with ERMA Chief Executive, 9 July 2010. Somewhat curiously, this 
statement was offered in response to a question regarding the exclusion of nano-form Zinc Oxide and 
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If the benefits are considered to outweigh the risks, the application may be approved, subject 
to the imposition of certain controls. These may be the default controls applicable to the 
substance’s hazard classification. Alternatively, ERMA may vary these default controls for 
the substance in question, making them either more or less stringent, as considered 
appropriate. In so doing, ERMA’s objective will be ‘to achieve the most cost-effective 
management of risks for the applicant and the community.’ 
 
Many of the controls are performance-based, specifying the outcomes that are desired, but not 
prescribing precisely how those outcomes are to be achieved. For example, controls may 
require that a substance be contained in a package that can withstand a drop from a certain 
height, or exposure to a certain temperature. This approach is intended to provide both 
certainty about what is required, and freedom to adopt new, potentially better and cheaper, 
methods of complying with these objectives.  Other controls are more specific; for example, 
conditions relating to labelling may specify the precise wording to be printed on the labels. 
 
Section 96A of the HSNO Act (as inserted by Hazardous Substances and New Organisms 
(Approvals and Enforcement) Amendment Act 2005) ‘enable[s] the Authority to issue, 
amend, and revoke standards (known as Group Standards) for groups of hazardous substances 
... that have a similar nature, are of a similar type, or have similar circumstances of use, so 
that the risks of the grouped hazardous substances can be effectively managed by 1 set of 
conditions.’ According to ERMA, these ‘provide for the efficient grouping of substances 
based on product type’.345 
 
Section 96B(1) stipulates that ERMA may use group standards to (a) identify the group of 
hazardous substances or products ... concerned; and (b) impose as conditions under this 
section any obligations and restrictions that the Authority thinks fit on the identified group of 
hazardous substances or products. A list of group standards issued to date can be found at the 
ERMA website.346 The possibility that a Group Standard could be issued for products 
containing NMs will be considered later in this section. 
 
As ERMA has explained, Group Standards apply to substances of a similar nature or type, or 
which have similar circumstances of use. The risks posed by all of the substances covered by 
the Group Standard must be capable of being managed by one set of conditions. Hence, a 
Group Standard may specifically exclude substances of a similar nature or type if those 
substances pose a significantly greater risk. A substance which is covered by the scope of an 
existing Group Standard will not require a separate application to ERMA for approval. 
Rather, its use will be subject to the conditions imposed by the relevant Standard. 
 
In the previous section, we considered the possibility that the introduction of the nano-form of 
a substance already present in New Zealand would not require a separate approval, if the 
substance was not deemed to be ‘new’. Our concern at that point was that a separate hazard 
                                                                                                                                                        
Titanium Dioxide from the notification requirements of the Cosmetic Products Group Standard, 
discussed below. Yet it is surely to be hoped that a similar statement could be made about the likely 
benefits and risks of any of the items that do require notification under that Standard. It has 
subsequently been explained to us by ERMA that another reason for the exclusion of these substances 
was that ‘it was already known that such substances existed in some cosmetics so further notification 
was not necessary. The notification provision was included so that ERMA would be aware when new 
types of nano-substances were being included in cosmetics.’ 
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profile would not be compiled for the nano-form of the substance. It is also worth 
considering, however, that the conditions applicable to the conventional form of the substance 
may not be appropriate for the nano-form. If the nano-form of a particular substance has no 
hazardous properties distinct from the conventional form of the substance, then this gap may 
be of little consequence. However, where uncertainty exists on this question, the application 




Group Standards and nanomaterials 
In 2006, ERMA issued the Cosmetic Products Group Standard (CPGS). ‘This group standard 
was created for products or preparations intended to be placed in contact with the various 
external parts of the human body (epidermis, hair system, nails, lips and external genital 
organs) or with the teeth and the mucous membranes of the oral cavity with a view 
exclusively or mainly to cleaning them, perfuming them, changing their appearance and/or 
correcting body odours and/or protecting them or keeping them in good condition.’ 347 
The group standard is of particular interest as it is unique in making specific reference to 
nanoparticles. Clause 23 stipulates that: 
Any person intending to import into, or manufacture in, New Zealand a cosmetic 
product containing nanoparticles other than zinc oxide or titanium dioxide, must at 
the time they first import or manufacture the substance, notify the Authority in 
writing of: 
(a) the name of the substance; and 
(b) the HSNO approval number and/or title of the Group Standard under 
which the substance has a deemed approval; and 
(c) the nature of the nanoparticles the substance contains.348 
 
It should be noted that this requirement is simply one of notification; it does not trigger any 
additional assessment nor impose any additional conditions (beyond the need to notify 
ERMA). Nonetheless, it is noteworthy that there is now precedent for the use of this 
regulatory mechanism to make specific provision for NMs. Assuming that ERMA has not 
acted ultra vires of its statutory authority in laying down this requirement, it may well be open 
to the Authority to impose similar conditions for other products that contain mNMs. 
Furthermore, since a prima facie case has been recognised for according a separate status to 
mNMs, it may also be open to ERMA to impose more onerous conditions if considered 
appropriate. (The challenge of monitoring and enforcing compliance with such conditions will 
be discussed later in this section). 
 
Group standards and manufactured articles 
 
While the CPGS applies to substances that contain mNMs, the possibility exists that group 
standards may also provide a statutory route by which ERMA’s regulatory oversight could be 
extended to manufactured articles containing mNMs, such as nano-silver washing machines. 
                                                     
347 http://www.ermanz.govt.nz/hs/groupstandards/standards/cosmetics/cosmetics.html 
348 ERMA, Cosmetic Products Group Standard 2006, as amended 24th July 2008, 28th July 2009 and 
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Section 96B(2)(d) of the HSNO Act allows a group standard to be applied to ‘a product 
(including, but not limited to, a manufactured article ...) that is, contains, incorporates, or 
includes a hazardous substance.’  
 
Whether or not ERMA is likely to use this statutory provision to extend its remit to 
manufactured articles containing mNMs will depend on various determinations by the 
Authority. First, it will require a determination that the included mNM qualifies as a 
‘hazardous substance’, a qualifying criterion that raises the same issues of uncertainty of 
evidence that were discussed above.  
 
Second, before issuing or amending any group standards, ERMA will require to be satisfied 
that:  
 
• the benefits associated with a reduction of environmental and health risks outweigh 
the economic costs associated with complying with the group standard; and 
• the issuing or amending (as the case may be) of group standards is the most efficient 
and effective way of managing the risks of all the products in the identified group, 
having considered matters including alternative methods of managing those risks; and 
• the group standard is only applied to the extent that it is reasonably necessary to 
manage the risks of the products.349 
 
Again, it is not the purpose of this Report to instruct ERMA on how it ought to interpret these 
determinations. It is noted only that, should ERMA form the opinion that imposing conditions 
on the manufacture or import of manufactured articles containing mNMs is justified, the 
amended Section 96 appears to provide a legislative mechanism allowing it to do so. 
 
One possible further reservation relates to the requirement that the product ‘contains, 
incorporates, or includes a hazardous substance’.350 With regard to nanosilver washing 
machines, however, their precise function may be seen closer to creating the nanoparticles; 
the machines, as imported or sold, contain not NMs but silver plates that, when electrolysed, 
gradually release ‘Silver Nano ions or Ag+’.351 While it may seem somewhat arbitrary for the 
law to distinguish between items designed to produce potentially hazardous substances, and 
items which already contain such substances, it may be that the wording of the legislation 
requires just such a regulatory distinction.352 
 
Ministerial call-in provisions 
 
The HSNO Act provides that the Minister for the Environment may ‘call in’ an application 
under the Act, to be decided by him/her, if s/he considers that the decision as to the 
application will have: 
 
• significant cultural, economic, environmental, ethical, health, international, or 
spiritual effects; or 
• significant effects in an area in which the Authority lacks sufficient knowledge or 
expertise.353  
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It has been observed, though, that there is an expectation that the Minister’s call-in power ‘is a 
power that would be exceptionally used.’354 Nonetheless, it is at least legally possible that this 
power could be used with regard to applications concerning NMs, should the Minister deem it 
appropriate to use it in this way.  
 
 
Labelling requirements and public register 
 
The Cosmetic Products Group Standard, then, is the first GS to make specific provision for 
manufactured nanomaterials. While it requires that newly introduced mNMs be notified to 
ERMA, it does not impose any additional restrictions or regulations thereon. Unsurprisingly, 
some campaigning organisations have called for significantly tighter regulation of products 
containing mNMs. In particular, calls have been made for nano-ingredients to be labelled as 
such.355 
 
The recently recast and consolidated European Union Cosmetic Products Regulation356 has 
introduced a requirement for labelling of NMs in cosmetics: ‘All ingredients present in the 
form of nanomaterials shall be clearly indicated in the list of ingredients. The names of such 
ingredients shall be followed by the word “nano” in brackets.’357 Additionally, in June 2010, 
the European Parliament’s Committee on the Environment, Public Health and Food Safety 
proposed an amendment to the Restriction of Hazardous Substances Directive, stating that 
‘Producers should label electrical and electronic equipment that contains nanomaterials that 
can lead to exposure of consumers, in order to enable consumers to make an informed 
choice.’358  
 
It should be noted that the version of the Directive finally accepted on 24 November 2010 
contained no such requirement.359 While the principle of nano-specific labelling seems to 
have been accepted by some industry spokespersons, it may be that this particular 
recommendation was seen to cast its net too widely:  
 
‘“Every transistor in a computer chip would then include a hazardous substance,” 
explains Steffi Friedrichs, director general of the international Nanotechnology 
Industries Association. “Labelling is an understandable consumer demand, but it 
needs to be practical, and labelling every computer chip would be nonsensical.”’360 
 
                                                     
354 Brookers Resource Management (2008), Volume II, at C68.03 
355 ‘Given that the public faces very intimate daily exposure to nano-cosmetics and personal care 
products it doesn’t seem unreasonable to demand rigour in their safety assessment and mandatory 
labelling to enable informed purchasing choices.’ Georgia Miller, ‘Science of the small may carry big 
risk’, The Age, 28 March 2009. See also Sustainability Council, The Invisible Revolution, op. cit. 
356 Regulation of the European Parliament and of the Council on cosmetic products (10 November 
2009), at http://register.consilium.europa.eu/pdf/en/09/st03/st03623.en09.pdf 
357 Regulation of the European Parliament and of the Council on cosmetic products (10 November 
2009), Article 19(1)(g), http://register.consilium.europa.eu/pdf/en/09/st03/st03623.en09.pdf 
358 ‘MEPs flag potentially hazardous substances in electrical and electronic equipment’, 2 June 2010, at 
http://www.europarl.europa.eu/en/pressroom/content/20100531IPR75278/ 
359 European Parliament legislative resolution of 24 November 2010 on the proposal for a directive of 
the European Parliament and of the Council on the restriction of the use of certain hazardous 
substances in electrical and electronic equipment (recast), at 
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2010-
0431&format=XML&language=EN#BKMD-6 
360 ‘EU Ministers Call For Nanomaterial Ban’, 14 June 2010, at 
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As discussed elsewhere in this Report, the issue of nano-specific labelling has become one of 
the most contentious in this area. It is beyond the remit of this report to consider in necessary 
detail the various considerations that should inform a decision as to the desirability of such 
labelling, or the form any such labels should take. However, it is worthy of note that there 
have been international moves in this direction with regard to cosmetics and electronic 
components, and that this is an issue that New Zealand will in all likelihood have to confront 
in the near future. 
 
In addition, the EU Cosmetic Products Regulation requires the European Commission to 
produce, by 11 January 2014,  a catalogue, regularly updated and publicly available, of ‘all 
nanomaterials used in cosmetic products placed on the market, including those used as 
colorants, UV-filters and preservatives in a separate section, indicating the categories of 
cosmetic products and the reasonably foreseeable exposure conditions.’361 Although the 
CPGS requires notification to ERMA of nano-ingredients, this information is not at present 
made publicly available in the form of a register or catalogue.  
 
As a letter to the editor of Nature Nanotechnology earlier this year suggested, ‘with the EU 
now starting to regulate nanomaterials, other jurisdictions might also be encouraged to 
“ratchet up” their own regulatory frameworks in the short-to-medium term.’362 Given that 
ERMA’s CPGS is closely based on the EU Cosmetics regulations, and is regularly updated to reflect 
changes in the EU regulation, it may be expected that these recent EU moves with respect to NMs in 
cosmetics will be considered for incorporation in the HSNO CPGS when next it is updated. 
 
Human and Environmental Safety Assessment  
 
The form of safety assessment which ERMA must conduct in its pre-market assessment is set 
out in the Hazardous Substances and New Organisms (Methodology) Order 1998. When 
evaluating assessment of risks associated with the substance or organism in an application, 
the Authority must take account of the following risk characteristics: 
(a) exposure to the risk is involuntary: 
(b) the risk will persist over time: 
(c) the risk is subject to uncontrollable spread and is likely to extend its effects 
beyond the immediate location of incidence: 
(d) the potential adverse effects are irreversible: 
(e) the risk is not known or understood by the general public and there is little 
experience or understanding of possible measures for managing the potential 
adverse effects.363  
A significant challenge to effective regulation of mNMs arises from the current uncertainty as 
to their likely effects. As the UK’s House of Lords Science and Technology said a year ago: 
‘Our current understanding of how they behave in the human body is not yet advanced 
enough to predict with any certainty what kind of impact specific nanomaterials may have on 
                                                     
361 Regulation (EC) No 1223/2009 (Cosmetics Regulation), Article 17(10)(a) 
362 Diana M Bowman, Geert van Calster and Steffi Friedrichs ‘Nanomaterials and regulation of 
cosmetics’  Nature Nanotechnology Vol. 5 | FEBRUARY 2010 
363 Hazardous Substances and New Organisms (Methodology) Order 1998, Section 33 
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human health.’364 An important question, then, relates to how New Zealand’s regulatory 
systems respond to uncertain risks. The HSNO Act provides for a ‘precautionary approach’, 
whereby ‘All persons exercising functions, powers, and duties under this Act ... shall take into 
account the need for caution in managing adverse effects where there is scientific and 
technical uncertainty about those effects.’365 As ERMA note, however, ‘the issue of “how 
cautious” is left open.’366 
The Methodology Order offers some guidance on this: 
29 Where the Authority encounters scientific and technical uncertainty relating to the 
potential adverse effects of a substance or organism, or where there is disputed scientific 
or technical information, the Authority— 
(a) must determine the materiality and significance to the application of the 
uncertainty or dispute taking into account the extent of agreement on the scope 
and meaning of the scientific evidence; and 
(b) may, where the uncertainty or dispute is material or significant, facilitate 
discussion between the parties concerned to clarify the uncertainty or dispute. 
The Order goes on to stipulate that, where the uncertainty or dispute is not resolved to its 
satisfaction, ERMA ‘must take into account the need for caution in managing the adverse 
effects of the substance’367 (though again, this does not answer the question as to ‘how 
cautious’). 
A current case study that may illustrate conflicting attitudes to precaution concerns CNTs. 
These are among the most controversial current uses of nanotechnology; indeed, as discussed 
earlier, the European Parliament passed a Resolution calling for them to be banned from 
electrical and electronic goods (though this did not find its way into EU law).  
 
Precisely how ‘precautionary’ an approach should be adopted towards CNTs is, 
unsurprisingly, a matter of dispute. According to some of the people to whom we have spoken 
in researching this report, a sufficient body of evidence currently exists to justify a 
precautionary ban on use or manufacture of CNTs. ERMA, on the other hand, appear to be 
less persuaded of the hazardous nature of CNTs, stressing that the studies published to date 
are of a ‘preliminary/scoping nature’ which ‘must be interpreted with great care as they have 
tended to use routes which are not of direct relevance to occupational and consumer exposure 
situations.’368 As yet, ERMA has not formally assessed the hazards or risks of CNTs as no 
application involving them has been under HSNO. 
 
                                                     
364 House of Lords Science & Technology Committee, Nanotechnologies and Food report, December 
2009. Q.v. ‘In spite of remarkable advances in the use of nanomaterials, there is a paucity of 
knowledge in understanding the toxicology of nanomaterials and a substantial gap between information 
obtained in the lab and how that information is applied to regulatory review. … The production and use 
of nanoparticles result in unknown risks since the exposures of biological systems to materials of this 
size have not been adequately studied.’ Stratmeyer, Goering, Hitchins, Umbreit. ‘What we know and 
don’t know about the bioeffects of nanoparticles’ Biomed Microdevices (2010); 12: 569-573 (All four 
authors are employees of the US FDA) 
365 HSNO Act, section 7 
366 Annotated Methodology, at 8.3.5 
367 Methodology Order, Section 30 
368 Shown to us in personal correspondence from the Sustainability Council, 13 October 2010. 
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






With regard to free CNTs, it appears as though an adequate regulatory framework exists to 
allow ERMA to impose such safety requirements as it sees fit - though the situation of CNTs 
intrinsic to manufactured goods may, as noted above, constitute a regulatory gap. 
Determining whether the regulator is adequately discharging its precautionary remit with 
regard to free CNTs would seem to depend on an evaluation of contested toxicological 
evidence, a task which lies beyond the scope of this review. We note, however, that in 
January 2010, NICNAS (for Safe Work Australia) commenced a formal hazard assessment on 
carbon nanotubes,369 ‘to clarify regulatory requirements.’370 ERMA has intimated that they are 
paying close attention to this review, and will respond to its findings if appropriate. 
 
Post-Market Monitoring  
 
Enforcement of the HSNO Act is the role of a number of enforcement agencies, ‘at both local 
and central government level.’371 The functions of these agencies include promoting and 
monitoring compliance with (i) the provisions of the Act itself, and (ii) controls set by 
ERMA. Although ERMA does not itself take a direct role in inspection and enforcement, it 
does have a supervisory role, which includes: 
• ensuring that the provisions of the HSNO Act are enforced in all premises likely to 
contain a hazardous substance or new organism; 
• advising the Minister for the Environment and relevant enforcement agencies if there 
is insufficient or unnecessary inspection; 
• appointing or authorising others to appoint enforcement officers; 
• enquiring into incidents and emergencies; 
• reporting on incidents caused by inadequate management of hazardous substances 
and new organisms; 
• advising the minister on levels of compliance with the HSNO Act; and 
• leading prosecutions in landmark cases (where appropriate).372 
 
The HSNO Act assigns enforcement roles to a number of agencies, some of which are 
discussed elsewhere in this report. ERMA has produced a chart showing how supervisory 
responsibility is allocated as between those agencies.373  
 
Enforcement agency Area of responsibility 
Ministry of Health In all places, to protect public health. 
Department of Labour In any place of work. 
Maritime New Zealand On any ship. 
Police and Land Transport New 
Zealand 
In and on roads, rail and vehicles. 
Civil Aviation Authority On any aircraft. 
Energy Safety Service, Ministry of 
Economic Development 
In, on or around any gas distribution system, 
installation or appliance. 
Local government (regional 
councils and territorial authorities) 
Responsibilities include: 
• premises not covered by the other agencies 
(e.g. private dwellings, public places) 
                                                     




371 DSL Guide, at 8.3.1 
372 DSL Guide, at 8.3.1 
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• enforcement during inspection of land use 
controls for hazardous substances under the 
RMA 
• functions transferred by other enforcement 
agencies. 
 
It has been noted that ‘[b]both overlaps and gaps exist in the areas of responsibility of those 
enforcement agencies’.374 
 
As previously indicated, we have taken the view that ‘regulatory gaps’ can occur at three 
distinct levels. With regard to nanosilver washing machines or refrigerators, it appears that 
any potential gaps appear at the level of the legislation itself or at the level of its interpretation 
and application by the regulators. The Sustainability Council Report,375 however, identified a 
potential ‘third level’ (by our classification) regulatory gap with regard to cosmetic products 
containing mNMs. As discussed in the previous section, the Cosmetic Products Group 
Standard requires that any cosmetic products intended for use on human skin which contain 
NMs must be notified to ERMA. Nonetheless, despite the commercial availability of several 
products that should, in principle, have been notified under this standard, not a single 
notification had been received by ERMA prior to the publication of the SC’s report (though 
we understand that several have now been received).  
 
This may well be an example of our third category of regulatory gap: a failure of enforcement 
or compliance. Rules applying to NMs are of limited utility if they are not adhered to, and 
even less so if there is no mechanism in place even to monitor whether they are being adhered 
to. This is to imply no criticism of ERMA, nor of any of the enforcement agencies, all of 
which operate with finite resources, and upon whom it is incumbent to make decisions about 
prioritisation. In those circumstances, it may well be that regulators had very good reasons to 
deploy those resources elsewhere than in pursuing non-notifying cosmetics 
manufacturers/importers. 
 
Nonetheless, we believe it is important to consider – particularly if new legislation or 
regulations are being considered – what the prospects may be for monitoring, ensuring and if 
need be, enforcing compliance with those rules. A significant regulatory gap may be thought 
to exist if regulations were routinely to be ignored, with no means in place to address this. 
 
3.5 MCA   
 
The main role of the Ministry of Consumer Affairs (MCA) is to promote information flows 
between suppliers and consumers so that consumers can transact with confidence.376 The 
MCA has various functions such as investigating unsafe consumer products and developing 
consumer policy including consumer protection and product safety. 
 
The MCA administers the Fair Trading Act 1986 (FTA) and the Consumer Guarantees Act 
1993 (CGA). However, the MCA does not investigate breaches of the CGA.377 The MCA 
                                                     
374 DSL Guide, at 8.3.1 
375 Sustainability Council, The Invisible Revolution, June 2010 
376 MCA http://www.consumeraffairs.govt.nz/about-mca/what-we-dont-do-and-who-can-help/about-
the-ministry accessed 27 May 2010 
377 MCA http://www.consumeraffairs.govt.nz/about-mca/what-we-dont-do-and-who-can-help/what-
we-dont-do-and-who-can-help accessed 27 May 2010  
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investigates product safety concerns where there are no product safety standards and the 
Minister can institute product safety bans, recalls and safety standards. The Commerce 
Commission investigates breaches of the FTA. The Commerce Commission enforces any 
breach involving misleading and deceptive conduct, false representations, product safety 
standards and product bans made under the FTA.   
 
In the context of the role of MCA, ‘product safety’ means risks to consumers that arise from 
their design, construction or normal usage.  This would include such things as choking 
hazards for young children in relation to toys, chemicals in the coatings of toys and the design 
and construction of pedal bicycles.  The remit does not cover products not designed for 
consumer (for example, industrial goods) nor does it generally cover safety issues that arise if 
goods are misused.378 
 
 
The MCA liaises and consults with other government agencies that may have an interest in 
government intervention.379 MCA investigates all product safety issues except those relating 
to food, medicines, or vehicles.380 NZFSA and Medsafe deal with product safety issues 
relating to food and medicine respectively. The New Zealand Customs Service can also 
enforce the safety provisions under the Customs and Excise Act 1996. Hazardous substances 
and organisms are dealt with by ERMA and hazardous products and products used in the 
workplace are dealt with by DoL.    
 
New Zealand’s consumer protection law is contained primarily in the FTA and CGA. New 
Zealand’s consumer protection law overlaps with other areas of law such as contract and tort. 
For example, the misleading and deceptive conduct prohibited by the FTA is at the core of the 
torts of deceit, passing off and negligent misstatement.381 
3.5.1 FTA 
Scope and Triggers  
 
The FTA is designed to prohibit certain conduct and practices in trade, to provide for the 
disclosure of consumer information relating to the supply of goods and services, and to 
promote product safety.382 The FTA prohibits misleading and deceptive conduct in trade and 
specifically prohibits particular types of misleading conduct and the making of false 
representations.383 The Act prescribes a broad standard of conduct by prohibiting any person 
in trade from engaging in conduct that is misleading or deceptive, or is likely to mislead or 
deceive.384 The FTA makes provision for the regulation and promotion of product safety.385  
 
The FTA applies within New Zealand but also extends to the conduct outside New Zealand of 
any person who is resident or carrying on business in New Zealand to the extent that such 
conduct relates to the supply of goods and services within New Zealand.386 
                                                     
378 There is currently a proposal to amend the Fair Trading Act regarding the introduction of power to 
ban or recall products which could reasonably foreseeably cause injury in Consumer Law Reform: A 
Discussion Paper www.consumeraffairs.govt.nz  
379 MCA www.consumeraffairs.govt.nz  
380 Id.  
381 Laws of New Zealand (online ed) at [1].  
382 FTA, Long Title.  
383 FTA, ss 9-26.  
384 FTA, s 9.  
385 FTA, Part 3.  
386 FTA, s 3.  
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‘Goods’ means personal property of any kind (whether tangible or intangible) and includes 
ships, aircraft, vehicles, animals, including fish, minerals, trees, crops, gas, electricity, water 
and computer software. NMs and products incorporating NMs would be included in the 
statutory definition of goods. These goods will be ‘goods’ for the purposes of the FTA 
whether or not they contain NMs.   
 
Trade means any trade, business, industry, profession, occupation, activity of commerce, or 
undertaking relating to the supply or acquisition of goods or services, or to the disposition or 
acquisition of any interest in land.387 The FTA provides that no person shall, in trade, engage 
in conduct that is misleading or deceptive, or is likely to mislead or deceive.388 Misleading 
conduct is the core of the Act and is particularly relevant to this nanotechnology analysis. For 
example, if a product states that it contains NMs, but it does not, then there may be a breach 
of the FTA. Also, if a product claims to contain ‘safe’ NMs, but it has not been tested, that 
would also be a breach of the FTA. With respect to products containing NMs, these breaches 
are likely to be more common than investigations into safety. Private transactions are not 
covered.    
 
The trigger for the FTA will not be whether the goods contain NMs, or whether the 
undertaking relates to the supply or trade of goods containing NMs, but whether the goods 
and trade meet the statutory definition. The Act will be triggered if a person in trade engages 
in conduct that is misleading or deceptive, whether or not that conduct is misleading or 
deceptive in relation to goods containing NMs.   
 
The FTA will also be triggered by ‘unsafe goods’389 whether or not those unsafe goods 
contain NMs.  
 
 
Approval Prior to Regulated Activity  
 
The MCA is not required to grant approval or authorisation prior to the regulated activity.  
 
However, the FTA allows the MCA to recommend the introduction of product safety 
standards. Product safety standards may be prescribed by the Governor-General by regulation 
on the recommendation of the Minister of Consumer Affairs in respect of any goods which 
can or may cause harm to consumers. The key element in any situation is that there must be 
good evidence that a product presents a significant safety risk.  MCA works on a ‘risk 
assessment’ basis with each issue assessed for the level and extent of risk presented. Some 
jurisdictions work on a hazard/precautionary basis in respect of consumer product safety. The 
Governor-General’s prescription is made for the purpose of preventing or reducing the risk of 
injury to any person.390 The product safety standard may cover:391 
• the nature of the product and its performance; 
• tests the product should go through during or after manufacture;392 
• the form and content of any markings, warnings or instructions on the product.  
 
                                                     
387 FTA, s 2.  
388 FTA, s 9.  
389 FTA, Part 3, s 31.  
390 FTA, s 29(1).  
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392 FTA, s 29(1)(b).  
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






There are currently six mandatory product safety standards. There is currently no nano-
specific product safety standard. Failure to comply with the requirements of product safety 
standards regulations is a breach of the FTA.  
 
 
Human and Environmental Safety Assessment  
 
The MCA has a lead responsibility for consumer product safety and is not directly responsible 
for harms to the environment or property.  Environmental hazards are covered by other 
agencies and legislation and there was no intention for the FTA to cover these issues.   
 
The MCA is not required to undertake a case-by-case safety or hazard assessment of goods 
prior to being placed on the New Zealand market. The onus for supplying safe goods lies 
squarely with manufacturers, importers, producers and suppliers.  
   
However, as already outlined, product safety standards can cover testing of goods during or 
after manufacture or processing.393   
 
Post-market Monitoring  
 
The FTA does not include post-market monitoring requirements akin to the other legislation 
considered in this report. As well as the reactive work it undertakes, the MCA does carry out 
a limited amount of proactive work on specific products or issues such as test purchases and 
sampling.  The MCA uses marketplace intelligence including overseas information to target 
resources.  
The Commerce Commission plays an important role in gathering post-market intelligence and 
conducting the enforcement. Members of the public and businesses are encouraged to contact 
the Commerce Commission and provide information about behaviour that appears to breach 
the FTA.394  The Commission assesses information it receives in this way, along with 
information it gathers from its own market monitoring and surveillance activities, to 
determine the investigations that it carries out into unfair or misleading trading practices.395 
Investigations are commenced according to a set of enforcement criteria.396 If the Commission 
considers that a breach of the Act may have occurred, it has a number of options open to it for 
resolving each investigation.397 The options include prosecuting the offending business where 
this is considered the most appropriate action. Only the courts can give an authoritative ruling 
as to whether behaviour breaches the Act and award appropriate penalties. 
With regard to NMs, there are difficulties testing for NMs.  A wide range of NMs are being 
used, and could be used, in a diverse range of applications. There are no agreed test methods 
established for NMs. This presents difficulties not only for regulators, but also for producers, 
who might be supplied products/components for incorporation into their products which may, 
unbeknown to them, contain NMs. 
 
Section 9 concerns misleading conduct generally. Section 10 concerns misleading conduct in 
relation to goods. No person may, in trade, engage in conduct that is liable to mislead the 
public as to the nature, manufacturing process, characteristics, suitability for a purpose, or 
                                                     
393 FTA, s 29(1)(b).  
394 Commerce Commission http://www.comcom.govt.nz/enforcement-of-the-fair-trading-act/ 
395 Id.  
396 Id.  
397 Id.  
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quantity of goods.398 The conduct in question must mislead or deceive, or be likely to mislead 
or deceive, the class of person who is affected by the conduct. This class of person may be the 
general public.399 Misleading conduct in relation to goods will be caught by the Act by virtue 
of meeting the statutory standard of conduct and not as a consequence of the goods 
incorporating NMs.  
 
False or misleading representations of various kinds are not permitted by any person in trade, 
in connection with the supply or possible supply of goods or with the promotion by any 
means of the supply or use of goods.400 For example, it must not be falsely or misleadingly 
represented that:  
• goods are of a particular kind, standard, quality, grade, quantity, composition, style, 
or model, or have had a particular history or particular previous use;401 
• goods are new, reconditioned, or that they were manufactured, produced, processed, 
or reconditioned at a particular time;402  
• goods have any sponsorship, approval, endorsement, performance, characteristics, 
accessories, uses, or benefits.403  
Such false or misleading representations in connection with the supply of goods will be 
caught by the statutory regime whether or not the goods contain NMs.  
 
Statements on labels and packaging are similarly subject to the prohibition against misleading 
or deceptive conduct by representations.404 Statements made about goods on packaging or 
labels are a factor in assessing whether goods supplied to a consumer are of acceptable 
quality.405 Products which contain hazardous or toxic substances, medicines and drugs have 
prescribed requirements as to the details and warnings required on their labels.406 Change of 
composition of a product over time so that it does not correspond with the representations as 
to composition on the label could result in the labelling being misleading and a breach of the 
FTA.407 These provisions concerning statements on labels and packaging apply whether or not 
the goods contain NMs.  
 
In relation to product safety, the FTA allows the Minister of Consumer Affairs to: 
• recommend the introduction of mandatory product safety standards;408 
• declare goods to be unsafe (a product ban);409 
• order a compulsory recall.410 
 
As outlined above under the heading ‘approval prior to regulated activity’, product safety 
standards may be prescribed under the FTA.411 If a product safety standard in respect of goods 
relates to a matter specified in section 29(1), a person must not supply, or offer to supply, or 
                                                     
398 FTA, s 10.  
399 Laws of New Zealand Consumer Protection (online ed) at [51]. 
400 FTA, s 13.  
401 FTA, s 13(a). 
402 FTA, s 13(d).  
403 FTA, s 13(d).  
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405 CGA, s 7(1)(h).  
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advertise to supply those goods unless that person complies with that product safety 
standard.412 The performance, composition, contents, manufacture, processing, design, 
construction, finish, or packaging of the goods may be the subject of product safety standards. 
Also, the testing of the goods during or after manufacturing or processing, and the form and 
content of markings, warnings or instructions to accompany goods may be subject to product 
safety standards.413  
 
There are currently no nano-specific product safety standards. The deficiencies in the current 
knowledge mean that there is inconclusive evidence as to whether there is product safety risk 
to consumers from products that contain NMs. The Minister is prohibited from 
recommending any (including a nano-specific) product safety standard regulation unless the 
Minister has consulted with those affected, given them an opportunity to comment, and the 
Minister has considered any comments.414  
 
The Minister of Consumer Affairs may declare goods ‘unsafe’ if it appears to the Minister 
that the goods will or may cause injury to any person.415 The declaration is made by notice 
published in the Gazette, and unless it is previously revoked by notice, the declaration will 
remain in force for 18 months from publication unless earlier revoked.416 Where, after the 
notice has been in force for 18 months, and no product safety standard relating to the goods 
has been declared, the Minister may, by further notice, prohibit the supply of the goods for a 
specified period or indefinitely.417 While a notice is in force, no one may supply, or offer or 
advertise to supply goods which are the subject of the notice.418 Goods that will or may cause 
injury to any person may be declared unsafe, by virtue of being deemed unsafe for the 
purposes of the Act, and not on the basis of whether or not those goods contain NMs.   
 
Where goods do not comply with a prescribed product safety standard, or are goods of a kind 
which may cause injury to any person, and the supplier has not recalled them, or taken 
satisfactory action to recall them, the Minister of Consumer Affairs may require the supplier, 
at its own expense, to provide one of several types of remedy.419 These remedies include: 
recalling the goods; disclosing to the public information on the characteristics of the goods 
which make them unsafe or the circumstances in which use of the goods is unsafe or any 
other matters; or repairing or replacing the goods; or refunding an appropriate amount of 
money to purchasers.420 The Ministerial recall powers under the FTA apply to any goods 
(whether or not they contain NMs) which do not comply with product safety standards or may 
cause injury to any person.  
 
It is prohibited to import into New Zealand, goods which do not comply with product safety 
standards or goods that are unsafe.421 Any such goods which are imported are deemed 
prohibited imports under the Customs and Excise Act 1996 and may be forfeited under that 
Act.422 The basis for the prohibition on importation of these goods will therefore be on the 
                                                     
412 FTA, s 30(1).  
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basis of whether the goods do or do not comply with the statutory provisions, and not whether 
the goods do or do not contain NMs.   
 
3.5.2 CGA 
Scope and Triggers  
 
The CGA implies mandatory guarantees as to title, quality, fitness, and performance in the 
supply in trade of goods and services normally acquired for household, domestic or personal 
use.423 Redress for breach of the guarantees is available against suppliers and manufacturers. 
The CGA amends the law relating to guarantees given, or deemed to be given, to consumers 
upon the supply of goods and services.424  
 
The guarantees in the Act only apply to goods or services of a kind ordinarily acquired for 
personal, domestic, or household use or consumption, but not to those goods and services 
acquired for resupply, consumption in production, or repairing goods or fixtures in trade.425 
The CGA only applies where the supplier of goods is in trade.426 ‘Trade’ includes any trade, 
business, industry, profession, occupation, activity of commerce, or undertaking relating to 
the supply or acquisition of goods or services.427 The CGA does not apply to goods supplied 
by auction or competitive tender.428 Accordingly, such goods are excluded by the Act, 
whether or not they contain NMs.  
 
The guarantees implied into contracts for the supply of goods and services by the CGA apply 
only to acquisitions of goods by a person who is a ‘consumer’. A ‘consumer’ is a person who 
acquires from a supplier, goods of a kind ordinarily acquired for personal, domestic, or 
household use or consumption.429  
 
‘Goods’ means personal property of every kind (whether tangible or intangible), other than 
money and choses in action; and includes personal property of any kind, goods attached to, or 
incorporated in, any real or personal property; ships, aircraft, vehicles; and animals, including 
fish and minerals, trees and crops, whether or, under, or attached to land or not, electricity and 
gas and water and computer software.430 Pursuant to this definition, goods containing NMs 
will fall within the definition of ‘goods’ for the purposes of the CGA.  
 
A ‘supplier’ is a person who, in trade, supplies goods or services to a consumer.431 In the case 
of goods, supply is achieved either by transferring ownership or possession of goods pursuant 
to a contract of sale, exchange, lease, hire, or hire purchase to which that person is a party, or 
by transferring ownership or possession of the goods as directed by an insurer.432  
 
A ‘manufacturer’ is a person who carries on the business of assembling, producing, or 
processing goods.433 
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Where goods are supplied to a consumer there is a guarantee that the goods will be of an 
acceptable quality.434 Goods are of acceptable quality if they are fit for all the purposes for 
which goods of the type in question are commonly supplied, and are acceptable in appearance 
and finish, free from minor defects, and safe and durable.435 Relevant to product safety is the 
guarantee that goods sold are of acceptable quality, including that goods are safe. This 
acceptable quality (safety) guarantee applies to all ‘goods’ that are supplied to a consumer, 
whether or not they contain NMs.  
 
Using the CGA provision that a product must be safe, the MCA “adopts the philosophy that 
voluntary national standards (NZ, Australian and European etc) provide a reasonable 
minimum benchmark for safety requirements”,436 where there are standards, and where those 
standards address safety.  
 
Goods supplied to a consumer are guaranteed to be reasonably fit for any particular purpose 
for which a consumer makes known to a supplier, expressly or by implication, as the purpose 
for which goods are being acquired, or for any purpose that the supplier represents that the 
goods will be fit for.437 This guarantee of fitness for a particular purpose applies whether or 
not the goods supplied to a consumer contain NMs.  
 
The CGA provides remedies when these guarantees are not met. However, they are self-
enforcing, meaning the consumer has to take action him/herself, such as returning the good to 
the retailer.  
 
 
Approval Prior to Regulated Activity  
 
The MCA is not required to grant approval or authorisation prior to the regulated activity.  







Human and Environmental Safety Assessment  
 
The MCA is not required to undertake a case-by-case safety or hazard assessment of goods on 
the New Zealand market.   
 
 
Post-market Monitoring  
 
The MCA does not investigate breaches of the CGA. Consumers have rights of redress 
against suppliers and manufacturers in respect of the supply of goods,438 for example, where 
goods do not comply with guarantees.439  
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The MCA can, and does, undertake monitoring mainly on a project type basis or in response 
to information received that indicates a potential consumer product safety issue might exist.  
If the an issue arose whereby there was prima facie evidence on a NM related product safety 
concern, then MCA could, if appropriate, instigate action in relation to the Minister’s powers 
under FTA.    
 
3.6 NZCS  
 
Scope and Triggers  
 
The New Zealand Customs Service (NZCS)440 is the government agency that facilitates the 
legitimate movement of goods and people across the border. The NZCS has various functions 
such as enforcing import and export prohibitions and restrictions.441 The NZCS works closely 
with other agencies such as the New Zealand Food Safety Authority, Ministry of Economic 
Development and the ERMA.  
 
The primary statute which regulates the movement of goods, craft and people crossing New 
Zealand border is the Customs and Excise Act 1996 (CEA). This Act is administered by the 
NZCS. The CEA seeks to create a modern customs regime by concentrating on essential 
matters, leaving administrative detail to regulations.442   
 
The NZCS also enforces import and export prohibitions and restrictions under other statutes 
such as the HSNO Act and the FTA.443 Customs officers have powers to seize the goods 
under the CEA if they have reasonable cause to believe that a hazardous substance is being, or 
has been, imported in breach of the HSNO Act.444 Sections 26 and 33 of the FTA deem 
certain goods (such as goods bearing false trade descriptions) to be prohibited imports for the 
purposes of section 54 of the CEA. All of the provisions of the CEA apply to these goods.  
 
New Zealand’s CEA and other relevant legislation are designed to protect national borders by 
controlling the import and export of goods. Within this function, New Zealand’s legislation 
prohibits the importation of certain harmful goods and substances, including weapons, 
explosives and narcotics, unless the importer has approval to import from the relevant 
authority. Products containing NMs (such as cosmetics) are being imported and exported 
across New Zealand’s borders. The number of engineered nanoparticles and goods containing 
NMs entering New Zealand is likely to increase.     
 
All goods imported into New Zealand are required by the CEA to be cleared through the 
NZCS. ‘Goods’ means all kinds of moveable personal property, including animals.445 Goods 
containing NMs will fall within this definition. For example, goods such as hair straighteners 
                                                     
440 Under s 5(1) of the Customs and Excise Act 1996, the previous Customs Department is 
reconstituted as the NZCS.  
441 New Zealand Customs Service http://www.customs.govt.nz/about/What+We+Do.htm 
442 Laws of New Zealand Customs and Excise (online ed) para 4. Relevant regulations include the 
Customs and Excise Regulations 1996 (SR 1996/232) and Customs and Excise (Fees) Regulations 
2004 (SR 2004/367).  
443 See Laws of New Zealand Customs and Excise para 5 for a list of other statutes under which NZCS 
operates. This report only identifies a number of statutes which are of relevance to the importation of 
goods containing NMs.   
444 HSNO Act, s 122. See also Laws of New Zealand Customs and Excise para 5.  
445 CEA, s 2.  
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containing nano silver, tennis rackets, or cosmetic products incorporating NMs will be caught 
by the statutory definition. These goods will be included in the CEA’s definition by virtue of 
being goods imported into New Zealand, and not as a result of incorporating NMs. The good 
itself, not the fact that the good contains NMs, is the trigger.     
 
 
Approval Prior to Regulated Activity  
 
The NZCS’s role in managing the border includes the responsibility of enforcing or assisting 
in the enforcement of the wide range of import prohibitions.446 The prohibitions are enforced 
on behalf of a number of government departments and agencies that administer, or have the 
policy responsibility for, the controls. 
 
There are three ways in which prohibitions can be implemented:  
 
1. Section 54 and/or the First Schedule of the CEA  
Section 54(1) of the CEA may place a prohibition on the import of a certain good. At present, 
it places an absolute prohibition (that is, approval to import cannot be given) on the import of: 
• All publications as defined in section 2 of the Films, Videos and Publications 
Classification Act 1993 that are objectionable within the meaning of that Act in 
the hands of all persons for all purposes.  
• The following goods listed in the First Schedule of the CEA:  
o False or counterfeit money; 
o Goods made by prison labour; 
o Goods whose sale in New Zealand would be an offence under the Food 
Act 1981 or the Food (Safety) Regulations 2002; and  
o Cannabis and methamphetamine utensils.  
 
Under section 54(1), a prohibition on the import of a certain good may be made, whether or 
not the good contains NMs.  
 
2. Orders in Council under section 54(2) of the CEA   
Section 54(2) of the CEA provides that the Governor-General may, by Order in Council, 
prohibit the importation of any specified goods, or goods of a specified class or classes, if it is 
necessary in the public interest to do so.  
The import prohibition may: 
• Be absolute (that is, approval to import cannot be given);  
• Be conditional in that it may apply only under particular circumstances (production of 
a certificate); or  
• Allow the import only with the approval of the Chief Executive of the NZCS or other 
person named in the Order.  
 
The Orders in Council may only be in effect for up to three years. At the end of this period the 
Governor-General may extend them for another three years. Orders in Council under the CEA 
are in effect for the following import prohibitions:  
 
Orders in Council Goods Expires on 
Customs Import 
Prohibition (Trout) Order 
Trout and trout products 11 November 2010  
                                                     
446 Our sincere thanks to David Ryan, Mike Wotherspoon and Kirsty Marshall (NZCS) for their 
extensive assistance with this section of the review.  
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 








Prohibition Order 2008 
Offensive weapons; 
Motor vehicles with incorrect 
odometer readings or no odometer 




Toothfish 10 May 2012 
 
There are currently no Orders in Council under the CEA for specific goods containing NMs. 
An Order in Council prohibiting the import of goods may be made if it is necessary in the 
public interest to do so, whether or not the goods contain NMs.  
 
3. Import prohibitions in other legislation  
Import prohibitions are also contained in other legislation, for example:  
 
• Import and Exports (Restrictions) Act 1988 for hazardous wastes tyres and certain 
dangerous chemicals - administered by the Ministry of Economic Development; 
• United Nations Act 1949 for United Nations import sanctions - administered by the 
Ministry of Foreign Affairs and Trade; 
• Trade in Endangered Species Act 1989 for controls on the import of endangered 
species, for example ivory, coral and New Zealand parrots (kakapo, kaka and kea) - 
administered by the Department of Conservation; 
• Dog Control Act 1996 for controls on the importation of dangerous dogs - 
administered by the Department of Internal Affairs.   
 
 
Prohibitions and restrictions on the importation of many goods are mandated by statutes and 
regulations other than the CEA. The specific statutes place prohibitions and restrictions on the 
importation of certain goods.447 Many goods are controlled in this way and may only be 
imported with the consent of the relevant authority.448 For example, import prohibitions and 
restrictions are enforced at the border for goods such as the following: 
• bulk importations of ozone depleting substances;449  
• chemical weapons;450 
• firearms;451 
• food whose sale in New Zealand would be an offence against the Food Act 1981;452 
• goods bearing a label which contains false or misleading representation;453  
• hazardous wastes;454  
                                                     
447 New Zealand Customs Service Import Prohibitions and Restrictions Schedule 
http://www.customs.govt.nz/library/Fact+Sheets/Fact+Sheet+5++Import+Prohibitions+and+Restriction
s.htm?pageType=print 
448 Laws of New Zealand (online ed) at para 85.  
449 Ozone Layer Protection Act 1996; New Zealand Customs Service Import Prohibitions and 
Restrictions Schedule, at 1.   
450 Chemical Weapons (Prohibition) Act 1996; New Zealand Customs Service Import Prohibitions and 
Restrictions Schedule, at 2.   
451 Arms Act 1983; New Zealand Customs Service Import Prohibitions and Restrictions Schedule, at 3.   
452 CEA, s 54 and First Schedule; New Zealand Customs Service Import Prohibitions and Restrictions 
Schedule, at 3.   
453 FTA; New Zealand Customs Service Import Prohibitions and Restrictions Schedule, at 3.   
454 Hazardous waste may be imported if the Minister of Commerce has consented to the importation. 
Imports and Exports (Restrictions) Prohibition Order (No. 2) 2004; New Zealand Customs Service 
Import Prohibitions and Restrictions Schedule, at 4.   
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• prescription medicines;455  
• hazardous substances including explosives and certain toxic substances.456 
 
The importation of hazardous substances such as explosives and toxic substances will only be 
allowed with an approval issued under the HSNO Act.457 Approval for the importation will be 
based on the importer fulfilling the obligations for importation of the goods as required by the 
HSNO Act, and not whether the goods incorporate NMs.  
 
Goods that do not comply with a relevant product safety standard or have been declared 
unsafe by the Minister of Consumer Affairs may not be imported.458 
 
Various goods containing NMs such as medicines and hazardous substances may fall within 
these statutes outside the customs regime. However, the importation of such goods will be 
prohibited or restricted not on the basis of whether the goods contain NMs, but because the 
goods are caught by the relevant statute.     
 
 
Human and Environmental Safety Assessment  
 
The NZCS does not conduct case-by-case safety or hazard assessment of goods that are 
imported into New Zealand. However, import prohibitions can take human and environmental 
safety into account.  
 
Post-Market Monitoring  
 
The CEA does not grant the NZCS the power to undertake post-importation monitoring or 
safety testing in relation to imported goods in order to ensure the long term human and/or 
environmental safety of imported goods. The NZCS cannot monitor or test goods containing 
NMs after they have been imported.  
 
3.7 NZFSA & FSANZ  
 
 
It is perhaps not surprising that, at the time of writing, ‘FSANZ has (still) not yet received a 
single application to amend the Code in relation to novel nanotechnologies.’459 Though it is 
difficult to be certain, it appears that, for the moment, applications of novel nanotechnology to 
food are fairly minimal. However, the UK House of Lords Science and Technology 
Committee Report has recently predicted that ‘this may well change over the next five years 
or so as the technology develops’.460 The Select Committee identified a number of potential 
future applications of nanotechnology to food.  
                                                     
455 Medicines Act 1981; New Zealand Customs Service Import Prohibitions and Restrictions Schedule, 
at 5.   
456 HSNO Act; New Zealand Customs Service Import Prohibitions and Restrictions Schedule, at 4.   
457 HSNO Act, ss25-73.  
458 FTA, ss 33 and 29-31.  
459 Personal correspondence with FSANZ, 11 August 2010. 
460 UK House of Lords Science and Technology Committee Report, Nanotechnologies and Food 
(January 2010). See also Chaudhry, Q., et al. ‘Applications and implications of nanotechnologies for 
the food sector.’ Food Additives and Contaminants (2008); 25(3): 241-258 ‘The applications of 
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i. Food content: whereby NMs are incorporated directly into food; the Committee 
acknowledged that ‘[n]anotechnologies create the possibility of foods with new 
flavours and textures, and also healthier food products with reduced salt, fat or sugar 
content or increased vitamin and nutrient content’461  
ii. Packaging: the Committee predicted that ‘[f]ood packaging involving the use of 
nanomaterials seems to be the most likely application to appear first in the mass 
market’. The Committee noted that a ‘plastic beer bottle made using clay nanoparticles 
as a gas barrier to improve shelf-life is currently on the market in the EU … and the 
US’.462 Evidence to the Committee also pointed out the possibility of nano-scale 
sensors incorporated in food packaging to detect deterioration in food quality, 
resulting in more accurate sell-by dates for perishable foods which would, in turn, 
improve food safety and reduce wastage’.463 
iii. Preparation: ‘Nano-coatings for food preparation surfaces and machinery are also 
predicted in the next five years’. Examples included ‘chopping boards and food 
containers infused with nanosilver because of its anti-microbial properties.464 
 
FSANZ has also referred to the possibility that ‘nanotechnology could be used to produce 
cheap and highly effective filters to eliminate contaminants and bacteria from water for 
drinking’.465 The Monash Report also noted that substances such as processing aids or 
agricultural and veterinary chemicals, which may incorporate nanoparticles, may also be 
added to or left in food. 
 
It is widely recognised that the applications of nanotechnology to food and food preparation, 
packaging and storage promises a range of benefits to human health and to the environment. 
Most obviously, food that can maintain its flavour while having reduced salt, sugar and fat 
content promises a range of health benefits with regard to, inter alia, obesity, diabetes and 
hypertension. However, it has also been suggested that environmental benefits could also 
accrue through more effective packaging, by reducing: 
 
• food waste through spoilage; 
• energy expended in keeping food refrigerated; 
• packaging waste, thanks to thinner and lighter packaging materials. 
However, as the Committee recognised, ‘[n]anotechnologies may also present new risks, as a 
result of their novel properties. ... Persistent nanomaterials are of particular concern, since 
they do not break down in the stomach and may have the potential to leave the gut, travel 
throughout the body, and accumulate in cells with long-term effects that cannot yet be 
determined.’466 
Concern has also been expressed as to the overall impact of the application of nanotechnology 
to food:  
                                                                                                                                                        
nanotechnology in the food sector are only now emergent, but they are predicted to grow rapidly in the 
coming years.’  
461 Ibid, at para 3.8 
462 Ibid, at para 3.16 
463 Ibid, Q 158. 
464 Id. 
465 FSANZ, ‘Small Particles, Nanotechnology and Food’ (2008) 
466 House of Lords Science and Technology Committee, Nanotechnologies and Food, op. cit., 
Summary 
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‘I think we need to ask: will nanotechnology as a whole result, for example, in greater 
consumption of highly processed food and less consumption of fruit and vegetables? 
Will the addition of nano-additives to junk foods enable them to be marketed for 
health values, for example increased nano-encapsulated omega-3 or iron fortification? 
Will this perhaps further confuse people and lead to a further loss in terms of people's 
diet choices? If the answers to those things are “Yes” then it is possible that nano will 
actually result in poorer health outcomes.’467  
It should, perhaps, be acknowledged that the presence of nano-sized particles in food is not, in 
any sense, new. It has been acknowledged that ‘Some traditional food manufacturing 
processes result in the creation of nano-sized particles—for example, production of ricotta 
cheese involves allowing whey proteins to aggregate into protein nanoparticles and 
production of chocolate and ice cream using natural ingredients involves changes to food 
structures at the nanoscale.’ This led the Select Committee to recommend that ‘for regulatory 
purposes, any definition of “nanomaterials” should exclude those created from natural food 
substances, except for nanomaterials that have been deliberately chosen or engineered to take 
advantage of their nanoscale properties.’468  
 
Scope and Triggers  
 
The examples considered should make it clear, then, that for a regulatory scheme in New 
Zealand to be adequate, it should apply to mNMs that are incorporated directly into processed 
food (as in example i. above), but also to those that are contained in food packaging or 
processes, from where they may migrate into food.  
 
The FSANZ Act defines ‘food’ as: 
 
(a) any substance or thing of a kind used, capable of being used, or represented as being for 
use, for human consumption (whether it is live, raw, prepared or partly prepared); and  
(b) any substance or thing of a kind used, capable of being used, or represented as being for 
use, as an ingredient or additive in a substance or thing referred to in paragraph (a); and  
(c) any substance used in preparing a substance or thing referred to in paragraph (a); and  
(d) chewing gum or an ingredient or additive in chewing gum, or any substance used in 
preparing chewing gum; and  
(e) any substance or thing declared to be a food under a declaration in force under section 
3B.469  
 
The section makes clear that it does not matter whether the substance, thing or chewing gum 
is in a condition fit for human consumption. As the Monash Report explained, this definition 
of food also makes it clear that the FSANZ regulatory framework applies to food and food-
related products incorporating NMs in the same way as it applies to ‘conventional’ food. 
There are no Standards in the Code that specifically regulate mNMs.  
 
In addition to ‘food’, the Code also imposes standards for food additives, defined as ‘any 
substance not normally consumed as a food in itself and not normally used as an ingredient of 
food, but which is intentionally added to a food to achieve one or more of the technological 
functions specified in Schedule 5.’470 Only additives expressly permitted under this section of 
                                                     
467 Georgia Miller, Friends of the Earth Australia, Oral evidence to HL Select Committee, Q286 
468 Nanotechnologies and Food, at para 5.32 
469 FSANZ Act, Section 3A(1) 
470 FS Code, Standard 1.3.1 
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the Code may be added to food, and the use of these additives will be restricted to the 
purposes specified in the Code, e.g. as colourings, preservatives, or flavourings.471  
 
Some of the additives listed in Standard 1.3.1 are permitted subject to quantitative 
restrictions; specifically, some colourings are permitted subject to maximum levels of 290 
mg/kg in foods and 70 mg/L in beverages. The Monash Report identified this as a potential 
regulatory gap, noting that this ‘may not be an appropriate trigger if that additive is added in a 
nano-form and therefore less material is included.’472  
 
mNMs that may find their way into foodstuffs via packaging will be covered by Standard 
1.4.3, while other contaminants that find their way into foodstuffs may be regulated by 
Standard 1.4.1.473 As with Standard 1.3.1, both contain Maximum Limits (MLs), ‘set at levels 
that are consistent with public health and safety’.474 Again, this was flagged by the Monash 
Report as a potential gap: ‘the trigger levels may need to be reviewed if nanoforms of the 
specifically referenced contaminants begin being used and the nanoform of the contaminant 
means the weight threshold is inappropriate.’475 
 
FSANZ has responded to these concerns about the inappropriateness of quantitative triggers 
in the following terms:  
 
‘FSANZ has the capacity to establish relevant restrictions in the Code should it 
become aware of a risk posed by a nanoscale material of an existing substance 
approved under existing Standards, and also for proposed  new or novel nanoscale 
materials that may represent additional safety concerns. All relevant information will 
be rigorously assessed by FSANZ using the best available science. The risk 
assessment process will necessarily consider the most appropriate dose-metric for the 
material being assessed, and this could conceivably result in different maximum 
levels depending on product form.’476  
 
With regard to new nanoscale additives, the most recent edition of FSANZ Application 
Handbook – while not referring specifically to NMs – does make it clear that ‘where particle 
size is important to achieving the technological function or may relate to a difference in 
toxicity, the applicant must provide information on particle size, size distribution, and 
morphology, as well as any size-dependent properties’477 (a requirement that applies also to 
processing aids, nutritive substances and novel foods). Some of the potential difficulties with 
classifying food additives as ‘new’ will be considered in the next section, but at least where 
                                                     
471 ‘A food additive may only be added to food where expressly permitted in this standard.’ (Std. 1.3.1) 
472 Monash Report, at p.72. See also chart at p.98. 
473 As has been drawn to our attention by one of the regulators, any nano-scale contaminants would 
have been unlikely to have been intentionally produced, and are thus arguably ultra vires of our report. 
However, we submit that a discussion of food standards and mNMs would seem incomplete without at 
least some reference to how potential nano-contaminants could be covered. 
474 Standard 1.4.1, Purpose. Standard 1.4.3 uses the same maximum levels as are in Std 1.4.1. 
475 Monash Report, at p.72; see also chart at p.98. We note that at least one regulator objected to this 
being designated as even a potential ‘gap’, but rather, as an example of the sort of periodic revision to 
which the Code is already subject. We would suggest that it does not require a great semantic leap in 
order to categorise a rule that is likely to require revision as a ‘potential gap’. However, we do not wish 
this report to become overly focused on disagreements about terminology; the main point we would 
emphasise is that the potential need for revision is paid due attention, regardless of precisely how this 
need is designated. 
476 Personal correspondence with FSANZ, 11 August 2010 
477 FSANZ Application Handbook (1 July 2020), at p.55. 
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additives are acknowledged to require an amendment to the Code, the insistence on providing 
information on particle size is welcome. 
 
With regard to new information about risks posed by existing additives, it would appear that 
any such additional restrictions as are required could be implemented by the regulator, rather 




New food additives, then, will not be permitted without prior regulatory approval, in the form 
of an amendment to the FS Code (Std. 1.3.1). New packaging materials, on the other hand, 
need only comply with Standard 1.4.3, which specifies that: 
 
‘Articles and materials may be placed in contact with food, provided such articles or 
materials, if taken into the mouth, are not - 
(a) capable of being swallowed or of obstructing any alimentary or respiratory passage; and 
(b) otherwise likely to cause bodily harm, distress or discomfort.’ 
 
The Monash Report expressed concern about this regulatory trigger, in that ‘[d]eficiencies in 
current knowledge regarding the effects of NMs means this provision is unlikely to prevent 
the use of NMs at this time because it could not be shown to be “likely” to harm.’ FSANZ’s 
view on this point is that ‘the current risk assessment framework and toxicological testing 
methodologies are generally sufficient for assessing new or novel nanoscale materials.’ 
However, it ‘accepts that modifications to current protocols may be warranted as the state of 
the science, and sophistication of the nanotechnologies, advance.’478  
 
It seems to us that the interpretation of the adjective ‘likely’ is key to the applicability of this 
regulatory mechanism; indeed, determining applicable standards of proof is essential to the 
operation of many of the regulatory mechanisms considered in this report. 
 
 
Rules specific to New Zealand 
 
As we have explained, most food sold in New Zealand is regulated under the Australia New 
Zealand Food Standards Code. An exception relates to ‘supplemented foods’. Previously 
covered by the Dietary Supplement Regulations 1985, these are (as of 31 March 2010) now 
regulated under the Supplemented Food Standard, which is administered by the New Zealand 
Food Safety Authority (NZFSA). The Supplemented Food Standard (SFS) is seen as an 
intermediary measure by NZFSA, which will govern such products until agreement can be 
reached as to their inclusion in the FS Code. 
 
The SFS defines ‘supplemented food’ as ‘a product that is represented as a food that has a 
substance or substances added to it or that has been modified in some way to perform a 
physiological role beyond the provision of a simple nutritive requirement’.479 Examples 
include ‘muesli bars, juices, sports foods and sports powders with levels of added vitamins, 
minerals, and other substances higher than those permitted by, or not permitted by, the Food 
Standards Code’.480 Dietary supplements, medicines, controlled drugs, formulated meal 
replacements and formulated caffeinated beverages are not covered by the SFS, but by other 
                                                     
478 Personal correspondence with FSANZ, 11 August 2010 
479 Supplemented Food Standard, Clause 6(1) 
480 NZFSA. New Zealand Supplemented Food Standard: New Zealand user guide on implementing the 
requirements. (30 March 2010), at p 
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regulations and pieces of legislation. If a food fits the definition of ‘supplemented food’ but 
also meets the permissions in the Food Standards Code, then it will be governed by the Code 
and not the SFS.481  
 
The SFS requires supplemented foods to comply with the majority of the standards in the 
FSC.482 For example, the food additives permitted in Standard 1.3.1 can all be used in 
supplemented foods, subject to any restrictions on their use imposed by Std 1.3.1. 483 A 
number of exceptions from the FS Code do, however, apply; for example, ‘vitamins or 
minerals may be added at higher levels than in the Food Standards Code, or to foods to which 
they are not permitted to be added’.484  Unless specifically prohibited or restricted in the SFS, 
any vitamin, mineral, botanical or bioactive substance may be added to a supplemented food 
provided it is ‘safe and suitable for the purpose that it is being added.’485  
 
In New Zealand, food substances are also required to comply with the Food Act 1981. Section 
9(4) of the 1981 Act specifies that: 
 No person shall prepare or pack for sale, or sell,— 
(a) Any food that is unsound or unfit for human consumption or contaminated; or 
(b) Any food containing, or having attached to it or enclosed with it or in contact with 
it, any extraneous thing— 
(i) That is injurious to health or harmful; or 
(ii) That is offensive; or 
(iii) The presence of which would be unexpected and unreasonable in food of 
that description prepared or packed for sale in accordance with good trade 
practice; or 
(c) Any food in any package, or any package intended to contain food, if that package 
is made wholly or partly of a material that may render the food injurious to health or 
that may taint the food; or 
(d) Any appliance that may render the food injurious to health or that may taint the 
food. 
 
As with the Food Standards Code discussed above, doubts may be expressed about the likely 
efficacy of this section with regard to nano-risks. For example, Section 9(4)(b) of the Food 
Act does not qualify the phrase ‘injurious to health or harmful’, so it is unclear whether it 
would apply only where an extraneous material enclosed with or in contact with food is 
known to possess such qualities, or whether the offence could be committed by the presence 
of such extraneous materials that are likely to be harmful – and if so, how ‘likely’ would be 
                                                     
481 NZFSA. SFS User Guide, at p.6 
482 Ibid, at p.9. 
483 Ibid, at p.15. 
484 Ibid, at p.12. 
485 Ibid, at p.12. 
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interpreted.  While this ambiguity is not in any way unique to mNMs, the current uncertainty 
about risks posed by mNMs may render further clarity in this area desirable. 
 
 
Approval Prior to Regulated Activity  
 
New food additives, then, will not be permitted without prior regulatory approval, in the form 
of an amendment to the FS Code (Std. 1.3.1). New packaging materials, on the other hand, do 
not need pre-market approval, but must comply with Standard 1.4.3. Food itself will require a 
pre-market safety assessment if it is classified as ‘novel’ (Standard 1.5.1).  
 
The determination of whether a food qualifies as ‘novel’ is made by FSANZ. Following a 
review of the Novel Food Standard in 2007, FSANZ’s decisions will be informed by the 
Advisory Committee on Novel Foods (the ACNF), which will provide recommendations in 
response to enquiries about whether particular foods meet the definitions of ‘non-traditional 
food’ and whether or not an assessment of public health and safety is required.486 It is not 
mandatory for potential applicants to seek the view of the ACNF; instead, they may proceed 
directly to submitting an application seeking to amend Standard 1.5.1 of the Code to permit a 
particular food that they believe meets the definition of novel food in Standard 1.5.1.487 
 
Under the revised Standard, a two-stage assessment must be undertaken, according to which it 
is decided whether a food is (a) a non-traditional food, and (b) whether a public health and 
safety assessment is required.  A ‘non-traditional food’ is defined as: 
  
(a) a food that does not have a history of human consumption in Australia or New Zealand; 
or 
(b) a substance derived from a food, where that substance does not have a history of human 
consumption in Australia or New Zealand other than as a component of that food; or 
(c) any other substance, where that substance, or the source from which it is derived, 
does not have a history of human consumption as a food in Australia or New Zealand. 
 
Key areas influencing the interpretation of the term ‘history of human consumption’ are: 
length of use; extent of use; quantity (level of intake) of use; and purpose or context of use.488 
 
If a food is deemed to be ‘non-traditional’, it will only be classified as a ‘novel food’ if it 
‘requires an assessment of the public health and safety considerations having regard to - 
 
(a) the potential for adverse effects in humans; or  
(b) the composition or structure of the food; or  
(c) the process by which the food has been prepared; or  
(d) the source from which it is derived; or 
(e) patterns and levels of consumption of the food; or  
(f) any other relevant matters. 489 
 
FSANZ has made it clear that the order of these considerations corresponds to their perceived 
importance; therefore, the potential for adverse effects in humans is the primary consideration 
in any recommendation from the ACNF. Information relevant to a determination of the 
potential for adverse effects might include:  
                                                     
486 http://www.foodstandards.gov.au/consumerinformation/novelfoods/advisorycommitteeonn3927.cfm 
487 FSANZ, ‘Guidance Tool for Determining Whether a Food is Novel or Not’ 
488 Id. 
489 Standard 1.5.1(1). N.B. this definition therefore differs from that discussed in the Monash Report. 
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• reports of adverse reactions from food use in other countries;  
• demonstration of safe use in other countries;  
• reports of adverse reactions from medicinal use;  
• animal toxicity studies;  
• observations in humans participating in clinical trials;  
• or the presence of a particular component known to cause adverse reaction or 
illness.490 
 
With regard to composition and structure – which the Monash Report identified as a factor 
that could lead to food incorporating NMs being treated as ‘novel’ - relevant information 
could include:  
 
• the presence of a particular component known to cause adverse reaction or illness 
(e.g. a natural toxicant, contaminant or allergen);  
• analyses of the amount of any such substances known to cause adverse reaction or 
illness;  
• structural similarity of any of the components to substances for which there are 
known safety concerns;  
• special preparation required to enable safe use; or whether the structure of the 
substance is completely new such that its safety for human consumption has not been 
established. 491 
 
It appears, then, that FSANZ has made considerable efforts to render this area more 
transparent. FSANZ has, however, acknowledged that ‘some degree of subjectivity is 
unavoidable due to the broad nature of novel foods’,492 and it may be that the question of 
whether such an application will be required for food may inevitably remain an area of some 
‘fuzziness’ for producers or sellers. A similar concern has been expressed about the European 
novel foods framework: 
  
‘If a company responsible for placing a nanofood product on the market did not 
recognise it to be novel (e.g. because the ingredients already have a history of use at 
the macro-scale) and/or did not consider the properties of the nanofood to be 
substantially different from its macro-scale counterpart (e.g. because of a lack of 
information to the contrary or the lack of a precise definition of the term 
”substantially altered”), then it is possible that a safety evaluation under (EC) 258/97 
will not be carried out.’493  
 
Sue Davies, of the consumer organization Which?, expressed similar concerns to the House of 
Lords Select Committee: ‘we are concerned, about how you can be sure that people who are 
potentially looking at producing these types of products actually understand what applies to 
them and what route they need to go through’494  
 
                                                     
490 FSANZ, ‘Guidance Tool for Determining Whether a Food is Novel or Not’ 
491 Id. 
492 FSANZ, Final Assessment Report, Proposal P291, Review of Novel Food Standard, October 2007 
493 Chaudhry, Q;  Scotter, M;  Blackburn, J;  Ross, B; Alistair, A;  Castle, L;  Aitken, R;  Watkins, R. 
‘Applications and implications of nanotechnologies for the food sector’ Food Additives & 
Contaminants: Part A, (2008) 25(3): 241 - 258 
494 Sue Davies, Oral evidence to House of Lords Select Committee, Q291 
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The option of seeking a recommendation from the ACNF on whether a food should be 
regarded as ‘novel’ may be a considerable step towards clarifying manufacturers’ 
responsibilities in this regard. Nonetheless, it is worthy of note that the novel foods regulatory 
process will only be triggered when a manufacturer recognizes the need to apply to FSANZ. 
Although FSANZ has confirmed that the presence of ‘any nano-sized particle’ must be 
included in an application,495 whether an application will even be made will depend on the 
manufacturer recognising that the food is prospectively novel.  
 
Any residual uncertainty as to whether manufactured nano-forms of existing foods, or indeed 
new processing techniques that actually or potentially produce nanomaterials, should be 
regarded as ‘novel’ should therefore be clarified. FSANZ’s most recent factsheet on the 
subject496 clearly spells out that: 
 
Applications for food additives, processing aids, novel foods and nutritive substances 
must include particle size, size distribution and morphology, where the substance(s) is 
particulate in nature and will remain so in the final food. 
 
The question of when a nanoform of an existing food will be regarded as ‘novel’, however – 
and hence, whether such an application will be required – is not made entirely clear to 
prospective manufacturers or importers. Furthermore, the Authority’s reference to ‘an 
application for a new type of engineered nanometre scale particle in food’ (our emphasis) may 
be taken to imply that the particle’s nanometre size alone would not be sufficient to lead to a 
finding of novelty, an impression confirmed to us by FSANZ.  
 
If manufacturers are unclear about the necessity to apply to FSANZ, then the relevant 
regulatory mechanisms – however thorough – will not be triggered, and a regulatory gap may 
be identified. To avoid this possibility, FSANZ could stipulate more precisely in what 
circumstances nanoscale food ingredients should be regarded as prospectively ‘novel’ (for 
example, when the nanoform has no history of presence in the human food chain), or 
alternatively, that all manufacturers of such foods should contact the ACNF for an opinion on 
the status of such foods. A third option would involve a change to the Code analogous with 
that recently implemented in the European Union with regard to food additives, whereby: 
 
When a food additive is already included in a Community list and there is a 
significant change in its production methods or in the starting materials used, or there 
is a change in particle size, for example through nanotechnology, the food additive 
prepared by those new methods or materials shall be considered as a different 
additive and a new entry in the Community lists or a change in the specifications shall 
be required before it can be placed on the market.497  
 
It should be noted that even this may not be regarded as satisfactory. The European 
Parliament recently called for further clarification as to when food should be regarded as 
novel; in particular, ‘novel food’ should ‘include foods derived from plants and animals, 
produced by non-traditional breeding techniques, and foods modified by new production 
                                                     
495 http://www.foodstandards.gov.au/consumerinformation/newfoodsandtechnolog4358.cfm 
496 FSANZ, Nanotechnology and Food, December 2010, at 
http://www.foodstandards.gov.au/consumerinformation/nanotechnologyandfoo4542.cfm 
497 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 
2008 on food additives, Article 12 
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processes, such as nanotechnology and nanoscience, which might have an impact on 
food.’498 
 
As noted above, recent amendments to the FSANZ Application Handbook have stressed the 
importance of providing information about, e.g., particle size when applying to amend the 
Code.499 The possible concern here, though, is about the perception among manufacturers, etc, 
as to whether such an amendment to the Code is required.   
 
                                                     
498http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&reference=A7-2010-
0152&language=EN&mode=XML Original emphasis. 
499 FSANZ Application Handbook (1 July 2020), at p.55. 
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Standard 1.2 sets out manufacturers’ obligations with regard to labelling of food. Standard 
1.2.2 requires that the label on a package of food must include either the prescribed name of 
the food, where listed in the Code, or in any other case, a name or a description of the food 
sufficient to indicate the true nature of the food. Standard 1.2.4 requires that, subject to some 
exceptions of minor relevance for present purposes, the label on a package of food must 
include a statement of ingredients, listing every ingredient in the food. Ingredients generally 
should be declared using their common name or a name that describes their true nature, while 
additives should be declared by the specific name or number provided in the Schedule to 
Standard 1.2.4.  
 
The Monash Report pointed to ‘uncertainty as to whether the name (for example, titanium 
oxide as listed in the Schedule) would include that additive in a nano form,’ identifying this as 
‘a possible gap here if this regulation is relied on as a means to alert consumers to the 
presence of NMs for the purposes of protecting their health and safety’.500  
 
The mandatory labelling of ‘nanofoods’ has been called for by, among others, Friends of the 
Earth, whose 2008 report claimed that ‘Mandatory labelling of all nanofoods is required to 
enable people to make an informed choice about whether or not to eat them.’501 Furthermore, 
it is currently the subject of ongoing debate in the European Union. The European Parliament, 
Commission and Council of Ministers are, at the time of writing, engaged in conciliation talks 
about amendments to EU novel food regulations.502 The European Parliament has voted for 
nano-specific labelling,503 and in March 2010, the European Parliament’s Committee on the 
Environment, Public Health and Food Safety (ENVI) approved a series of recommendations 
pertaining to regulation of novel foods, which included the following: 
 
‘All ingredients present in the form of nanomaterials shall be clearly indicated in the 
list of ingredients. The names of such ingredients shall be followed by the word 'nano' 
in brackets.’504 
 
The EU Council, in contrast, has rejected the argument for nano-specific labelling: 
‘systematic specific labelling of ingredients in the form of nanomaterials is excessive; there is 
a requirement to consider specific labelling requirements on a case-by-case basis.’505 
                                                     
500 Monash Report, at p.74. q.v. K. Ludlow, ‘The Readiness of Australian Food Regulation for the use 
of Nanotechnology in Food and Food Packaging’, The University of Tasmania Law Review (2007); 
26(2): 177, at p.198.  
501 Friends of the Earth, Out of the Laboratory and Onto Our Plates: Nanotechnology in Food & 
Agriculture, March 2008, at p.45, at http://www.foe.org/pdf/nano_food.pdf 
502 ‘MEPs reiterate opposition to food from cloned animals,’ 1 October 2010, at 
 http://www.europarl.europa.eu/sides/getDoc.do?type=IM-
PRESS&reference=20101019IPR88128&format=XML&language=EN 
503 ‘The European Parliament adopted by 362 votes to 4, with 5 abstentions, a resolution on regulatory 
aspects of nanomaterials … The Parliament also reiterates its call for the provision of information to 
consumers on the use of nanomaterials in consumer products: all ingredients present in the form of 
nanomaterials in substances, mixtures or articles should be clearly indicated in the labelling of the 
product (e.g. in the list of ingredients, the name of such ingredients should be followed by the word 
'nano' in brackets).’ ‘Regulatory aspects of nanomaterials’, INI/2008/2208, at 
http://www.europarl.europa.eu/oeil/file.jsp?id=5680552.,  
504http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+COMPARL+PE-
428.273+03+DOC+PDF+V0//EN&language=EN, Amendment 81 
505 Position (EU) No 6/2010 of the Council at first reading with a view to the adoption of a Regulation 
of the European Parliament and of the Council on novel foods, amending Regulation (EC) No 
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FSANZ has acknowledged that ‘[a]t present, there are no specific labelling requirements in 
the Code for food products which contain nanoscale material.’506 With regard to the 
possibility of implementing such a requirement, it has said the following: 
 
‘Labelling requirements in the Code can be amended either through an application to 
FSANZ or through a proposal raised by FSANZ. In amending food regulatory 
measures, such as mandatory labelling, FSANZ must consider the matter based on a 
rigorous assessment process, including a thorough risk analysis and cost-benefit 
analysis, and following public consultation. Such analyses and consultation processes 
apply to any application or proposal to change the Code.’507  
  
Whether foods containing mNMs should be labelled as such is, of course, a multi-faceted 
question, which extends beyond the risk-based remit of this report, encompassing questions of 
consumer choice and fairness to producers. It could, for example, be argued that requiring 
producers to draw attention to mNMs risks prejudicing potential consumers against their 
produce, without any justification in terms of health and safety. Following the passing of the 
new EU Cosmetics Regulation, the German government asked to be minuted a statement of 
concern that ‘using the term “nano” might be misunderstood by consumers as a warning’508  
 
It could also be noted, of course, that similar arguments have been advanced against the 
compulsory labelling of genetically modified produce. Yet the FS Code requires that the 
presence of genetically modified (GM) foods, ingredients, additives, etc requires to be 
notified on a label.509 FSANZ has referred to this requirement as ‘represent[ing] a balance 
between the needs of consumers and what governments can realistically enforce.’510 This 
might reasonably invite speculation as to whether an analogous rationale could be advanced 
for an analogous requirement for foods, ingredients, additives, etc containing manufactured 
NMs. 
 
We note that a ‘comprehensive review of food labelling law and policy’, commissioned by 
the Australia and New Zealand Food Regulation Ministerial Council, is currently approaching 
completion (the final report is due to be provided to Government through the Ministerial 
Council in December 2010 and to the Council of Australian Governments in early 2011.)511 
The Terms of Reference for the review do not make explicit reference to nano-food, but the 
general questions it has set out to confront are likely to be indicative of the sort of balancing 
of interests that will inform the approach taken to that area: 
 
‘There are tensions between the varying objectives sought to be achieved from food 
labelling laws by the different stakeholders in the food regulatory system. Calls are 
regularly being made for new labelling requirements to address a range of issues of 
                                                                                                                                                        
1331/2008 and repealing Regulation (EC) No 258/97 and Commission Regulation (EC) No 1852/2001 
(15 March 2010), http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:122:0038:01:EN:HTML 
 
506 Personal correspondence with FSANZ, 11 August 2010 
507 Personal correspondence with FSANZ, 12 October 2010 
508 Statement for the minutes by the Federal Republic of Germany on the proposal for a Regulation of 
the European Parliament and of the Council on cosmetic products, Brussels, 17 November 2009. At 
http://register.consilium.europa.eu/pdf/en/09/st12/st12682-ad01re01.en09.pdf 
509 FS Code, Standard 1.5.2 
510 FSANZ, GM Foods: Safety Assessment of Genetically Modified Foods (2005) 
511 http://www.foodlabellingreview.gov.au/internet/foodlabelling/publishing.nsf/Content/home 
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concern to diverse groups within the community. Increasingly these do not relate to the 
characteristics of the food itself, but are about food production systems or attributes.  
 
However, all food labelling requirements impose costs. Therefore it is important that all 
food labelling laws –  
i. are evidence based and effective at achieving their policy purpose;  
ii. do not impose unjustifiable regulatory burdens on business; and  
iii. are capable of being enforced in an effective, proportionate and consistent manner.’512 
An evaluation of the arguments around, and the options for, nano-specific labelling may well 
justify another report. For present purposes, we note only that:  
 
• there is a body of opinion to the effect that failure to inform prospective consumers as 
to the presence of mNMs constitutes a significant regulatory gap. We note, however, 
the existence of a contrary argument, expressed to us on several occasions by FSANZ 
regulators, that this is not properly considered a ‘gap’ at all, but rather a ‘position, or 
preferred policy’. As stated earlier in the report, we are less concerned about the 
terminology used in this area than about trying to ensure that it receives due attention; 
• ‘the provision of adequate information relating to food to enable consumers to make 
informed choices’ is a statutory objective of FSANZ;513  
• as FSANZ has noted, ‘Food labelling, whether it is for consumer information related 
to health matters, food safety and/or to enable consumers to make informed food 
choices, requires that consumers will understand the information on the label and that 
it assists them in choosing appropriate food.’514 Were it to be decided that mandatory 
labelling of nano-ingredients, additives, etc were desirable, attention would require to 
be paid to the form of such labelling, especially given the widely presumed low level 
of public awareness of nanotechnology. 
 
In considering these options for developing and amending food standards, it should be borne 
in mind that FSANZ also has obligations under the Inter-Governmental Agreement (IGA) 
established by the Council of Australian Governments (COAG) in 2008. This requires 
minimum effective regulation be used in the provision of a safe food supply; that regulatory 
decision-making be based on science; and that a cost-benefit approach be employed where 
there may be impost on industry.515 
 
Human and Environmental Safety Assessment  
 
If a food is not specifically regulated by the Code, no human or environmental safety 
assessment is required prior to sale, though it must, as explained above, comply with the 
provisions of the Food Act 1981. Where the food is specifically listed in the Code, a human 
safety assessment will either have occurred, or must occur. Where an unlisted food is 
regarded as novel, a safety assessment will be required in terms of Standard 1.5.1. In 
conducting such an assessment, FSANZ must pursue the following objectives (in descending 
priority order): 
 
(a) the protection of public health and safety; and 
                                                     
512 http://www.foodlabellingreview.gov.au/internet/foodlabelling/publishing.nsf/Content/terms 
513 FSANZ Act 1991, Section 18(1)(b) 
514 FSANZ, The Analysis of Food-Related Health Risks (2008), at p.42 
515 Ibid, at p.65 
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






(b) the provision of adequate information relating to food to enable consumers to make 
informed choices; and 
(c) the prevention of misleading or deceptive conduct.516 
As the Monash Report noted, ‘[t]here is no objective directly relevant to protecting the 
environment.’ – move to main text 
 
FSANZ must ensure that standards are ‘based on a risk analysis using the best available 
scientific evidence’.517 If FSANZ considers that the best available scientific evidence is 
insufficient, it may provisionally adopt ‘sanitary or phytosanitary measures on the basis of 
available pertinent scientific information.’518 FSANZ is therefore empowered to take 
measures to protect human or animal life or health from risks arising from additives, 
contaminants, toxins or disease-causing organisms in foods, beverages or feedstuffs; 
(10(4)(b)). Such measures may apply to, inter alia, ‘any relevant law, decree, regulation, 
requirement or procedure’;519 testing, inspection, certification and approval procedures;520 and 
packaging and labelling requirements directly related to food safety.521 If FSANZ takes action 
on this basis, it ‘must take all reasonable steps to obtain the information necessary for a more 
objective risk analysis and a review of the sanitary and phytosanitary measures, to be 
undertaken within a reasonable period of time.’522 
 
The process of risk analysis undertaken by FSANZ will involve consideration of: 
 
• the context of the problem (e.g. whether it is urgent or likely to be wide-spread in 
nature and involve a range of foods); 
• the nature of the risk (e.g. low versus high and the toxicological endpoint); 
• the likelihood and severity of the risk (e.g. low risk and low severity vs. high risk and 
high severity); 
• uncertainty associated with the risk assessment; and  
• the most  appropriate options (e.g. regulatory or non-regulatory).523 
 
A Regulatory Impact Statement (RIS) addressing the issue of cost effectiveness of various 
options (regulatory and non-regulatory) will also be prepared.  
 
 
Post-Market Monitoring  
FSANZ may undertake monitoring to examine the current state of the food supply in order:  
• to assess the impact of the change to the Code on consumers over time;  
• to determine changes in the status of particular foods in the market; or 
• to verify the conclusions from pre-market risk assessment regarding the estimated 
dietary exposure levels or absence of unexpected health effects.524 
                                                     
516 FSANZ Act 1991 section 10(1).  
517 FSANZ Act 1991, Section 10(2)(a) 
518 FSANZ Act 1991, Section 10(4) 
519 Section 10(5)(e) 
520 Section 10(5)(g) 
521 Section 10(5)(j) 
522 Section 10(4) 
523 FSANZ, The Analysis of Food-Related Health Risks, 2008, at p.40 
524 Ibid, at p.53 
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As Ludlow has noted, however, ‘because any Standard amendment is so resource intensive, it 
is likely only to occur if evidence of new public health and safety considerations arises.’525 
                                                     
525 K. Ludlow, ‘The Readiness of Australian Food Regulation …’, loc. cit., at p.199 
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4 REGULATORY TRIGGERS, GAPS AND ADDITIONAL COMMENTS  
 
The Monash Report concluded that, in Australia, ‘there was no case where a particular 
regulatory framework generally did not apply to a nanofamily as a result of the presence of 
NMs.’526 In general, our report has reached the same conclusion with regard to New Zealand. 
The regulatory mechanisms applicable to conventional products will, in broad terms, apply to 
mNMs, and to products containing and incorporating mNMs (though a possible gap was 
identified where the product actually creates nanoparticles, subsequent to sale.) 
 
It follows, then, that in those areas where regulatory coverage is comprehensive for 
conventional products, it will often be comprehensive for mNMs too. The corollary, of 
course, is that areas of weakness in the regulatory frameworks will also provide weak 
regulation for mNMs. For example, perceived deficiencies identified in the Medicines Act, 
while not always specific to nano-products, will apply as much to them as to any other 
products (see Section 3.2).  
 
We have, however, identified a number of possible regulatory gaps that are more specific to 
products containing mNMs. As explained at the outset of our report, we have distinguished 
between gaps that occur at different levels: respectively, at the level of legislation, at the level 
of regulatory policy, and at the level of compliance and enforcement. The options for 
addressing those gaps will often depend upon which of these categories they are considered to 
fall within.  
 
We have also followed the methodology of the Monash Report in grouping the gaps under 
headings, though our headings do not map precisely onto those utilised in the earlier report. 
 
4.1 Is a nanoform ‘new’? 
 
Identified by the Monash Report as ‘the most significant potential gap’,527 we have also found 
points within New Zealand’s regulatory framework where the identification of nanoforms of 
existing products as new or ‘novel’ is potentially uncertain.  A safety assessment under the 
HSNO Act, for example, will only be triggered if ‘the hazards differ between the 
“conventional” substance and the nano substance’.  
 
Similar uncertainty may be seen to exist with regard to the regulation of food; in many 
circumstances, an item will be subject to a pre-market safety assessment only if it satisfies the 
criteria for a ‘novel food’ set out in Standard 1.5.1 of the FS Code. Although particle size and 
form will be relevant considerations for FSANZ in making a determination as to novelty, 
there is no specific provision to the effect that nanoforms of existing foodstuffs must be 
regarded as novel foods. 
 
Uncertainties about the unique properties, and potential long-term effects of mNMs have led 
to a growing consensus that, for example, chemicals528 or foods529 containing mNMs should 
                                                     
526 Monash Report, at para. 5.1.  
527 Monash Report, at p.5. 
528 ‘We believe that chemicals in the form of nanoparticles and nanotubes should be treated separately 
to those produced in a larger form.’ The Royal Society and the Royal Academy of Engineering, 
Nanoscience and nanotechnologies: opportunities and uncertainties (July 2004), at paragraph 22 
529 ‘Given the uncertainty about the potential risks of nanomaterials, it is essential that any 
nanomaterial used in a food product … should to be subject to a formal risk assessment process’ House 
of Lords Select Committee, Nanotechnologies and Food (January 2010), at 8.11.  
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be treated as new, and accordingly subject to their own risk assessment. Indeed, as noted 
above, the new EC regulation on food additives requires that a food additive that has 
undergone a significant change in particle size will be regarded, for regulatory purposes, as a 
new additive.530  
 
Although the establishment of the Advisory Committee on Novel Foods to offer guidance on 
whether a food is novel is a commendable step, that process of recommendation and decision 
will only be triggered where a manufacturer understands the need to make an application or 
seek advice. Although FSANZ appears to have made considerable efforts to provide detailed 
advice to prospective food manufacturers, that guidance may be seen as somewhat lacking in 
clarity and precision with regard to the status of ‘nanofood.’ 
 
We have suggested that, with regard both to the HSNO and FSANZ Acts, these gaps could 
potentially be addressed by the regulators, without need to amend the legislation. ERMA 
could, for example, modify its Group Standards to require that nano-forms of existing 
substances could be subject to new assessments, or at least that they must be notified to 
ERMA. A partial precedent already exists in the form of the Cosmetic Products Group 
Standard, which requires notification of any cosmetic product containing nanomaterials. It 
seems possible to us that Group Standards could be used to require not only notification, but a 
separate risk assessment for nanoforms of existing substances. 
  
With regard to food, we have suggested that the least burdensome step for the regulator would 
be to stipulate unambiguously that all foods (additives, contact materials, etc) containing 
manufactured NMs should be submitted either to the ACNF for a recommendation as to 
novelty, or to FSANZ for an approval.   
 
4.2 Regulatory scope 
 
Some questions have also arisen with regard to the remit of some of the regulatory bodies. As 
discussed at 3.4, the applicability of the HSNO Act to nano-silver washing machines, and – in 
future – other items such as nano-silver fridges is an area of uncertainty, in view of the likely 
designation of such items as ‘manufactured articles’. The potential difficulty lies in the fact 
that manufactured articles – even those containing or incorporating hazardous substances – 
are not considered to be ‘substances’ for purposes of the HSNO Act, and are therefore (for the 
most part) ultra vires of ERMA. 
 
It has been suggested by the Sustainability Council that a ‘common sense’ approach to the 
definition of ‘hazardous substances’ would encompass manufactured articles that contain 
nano-silver. It is unclear to us whether the wording of the HSNO Act is flexible enough to 
admit of such an interpretation. Certainly, ERMA’s own view appears to be that such items 
lie outwith its regulatory remit. 
 
A more promising mechanism to extend ERMA’s reach to such items (assuming that to be 
desirable) may lie with section 96B(2)(d) of the HSNO Act, which allows a Group Standard 
to be applied to ‘a product (including, but not limited to, a manufactured article ...) that is, 
contains, incorporates, or includes a hazardous substance.’ Before doing so, the Authority 
would need to be satisfied that such a Group Standard was justified; the environmental and 
health benefits, for example, would need to outweigh the economic costs associated with 
complying with the group standard. It lies beyond the remit of this report to advise ERMA on 
whether it should use this power to regulate a particular manufactured item, but its availability 
                                                     
530 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 
2008 on food additives, Article 12, discussed above at 3.7. 
 
A Review of the Adequacy of New Zealand’s Regulatory Systems to Manage the Possible Impacts of Manufactured 






suggests that – once again – this is a regulatory gap that could be addressed without the 
necessity of amending the relevant legislation. 
 
A more intractable problem may be thought to exist with regard to products – such as 
Samsung’s nano-silver washing machine – that do not, at the time of pre-market assessment, 
contain any mNMs whatever, but which nonetheless possesses the capacity to create 
nanoparticles. As we noted above, while it may seem somewhat arbitrary for the law to 
distinguish between items designed to produce potentially hazardous substances, and items 
which already contain such substances, it may be that the wording of the legislation requires 
just such a regulatory distinction. If so, this would be one of the few examples of a regulatory 
gap that can only be addressed at the statutory level.  
 
 
4.3 Appropriateness of quantity-based triggers and conditions 
 
The existence of quantity-based regulatory triggers was identified in the Monash Report as a 
significant regulatory gap. Indeed, its conclusions have led NICNAS, the Australian industrial 
chemicals regulator, to propose ‘to administratively exclude nanomaterials which are new 
chemicals from low volume/low concentration exemptions, thereby shifting a post-market 
audit activity to a pre-market assessment (i.e. new nanomaterials to be assessed under permit 
or certificate categories prior to commercialisation).’531 This relates to an exemption from the 
requirement for assessment certification for persons importing or manufacturing less than 100 
kilograms of the substance per calendar year. As no analogous exemptions exist in New 
Zealand, this particular proposal is not applicable to the New Zealand regulatory framework. 
 
The one quantity-based exception that does exist under the HSNO Act relates to ‘small-scale 
use of hazardous substances in research and development or teaching’ (HSNO Act, Section 
33). Whether training and practice within laboratory environments is adequate to ensure safe 
handling of mNMs is not a question we have been able independently to explore, but we note 
that a number of issues of concern were raised in Sally Gaw’s review of the current state of 
practice for handling nanomaterials in NZ university laboratories (discussed at 3.4). 
 
In general, however, we have found quantity-based triggers to be less a cause for concern in 
New Zealand than the Monash report found to be the case in Australia. Quantity-based 
conditions, however, are present in the New Zealand regulatory scheme. For example, in 
terms of food regulation, some additives and contaminants are permitted only subject to 
quantitative restrictions. Doubts have been raised regarding the suitability of such limits to 
nanoforms. Again, it appears to us as though the regulator – in this case, FSANZ – has the 
capacity to vary these limits, either with regard to nanoforms of existing materials or 
new/novel nanoscale materials (see Section 3.7). 
 
As this report is a regulatory scoping exercise, rather than detailed review of, for example, 
toxicological data, we make no particular finding or recommendation about any particular 
quantitative condition. More generally, we note that the suitability of each of these conditions 
to mNMs is something that requires further and ongoing evaluation, especially as more 
detailed evidence becomes available regarding the unique or distinctive properties of particles 
at the nano-scale.  
 
 
                                                     
531 NICNAS, Proposal for Regulatory Reform of Industrial Nanomaterials. Public Discussion 
Paper – November 2009 
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4.4 Nano-specific labelling 
 
The European Union has recently legislated for compulsory labelling of cosmetics containing 
NMs, while a proposal to require nano-specific labelling of novel foods is currently the 
subject of conciliation proceedings involving the EU Parliament, Council and Commission. 
At present, there are no nano-specific labelling requirements in New Zealand, either for 
cosmetics, foodstuffs, or for any other products containing manufactured NMs.  
 
This could be argued, in some contexts, to be a regulatory gap. In relation to food regulation, 
for example, we have noted that one of FSANZ’s objectives, as laid down in the FSANZ Act, 
is ‘the provision of adequate information relating to food to enable consumers to make 
informed choices’.  
 
Insofar as this is properly seen as a regulatory gap, it may be one that could be addressed at a 
regulatory, as opposed to statutory level. FSANZ could, for example, vary the FS Code to 
require nano-specific labelling, while it would seem to be open to ERMA to use Group 
Standards to impose a similar condition on manufacturers of, e.g., cosmetics containing NMs. 
As we noted above, however, due consideration would have to be paid to the appropriate 
wording of such labels, so as to impart useful information to prospective consumers without 
causing unjustified alarm. 
 
4.5 Regulating uncertainty 
 
The limited state of current knowledge about the risks posed by some nanoscale particles 
presents a number of obstacles to any attempt to regulate in this area. In some cases, 
regulatory triggers require the identification of a product as being likely to present a risk. 
Under the Waste Minimisation Act, for example, the absence of documented cases of adverse 
environmental effects directly attributable to NMs may mean that products containing NMs 
may not be singled out as products likely to harm the environment when disposed of as waste. 
Likewise, in relation to food regulation, the wording of Standard 1.4.3 of the FS Code uses 
the concept of ‘likely to cause bodily harm, distress or discomfort.’ Again, the relative 
absence of reliable nanotoxicological data may mean that it will be difficult to designate such 
a risk as ‘likely’, meaning that the power to prohibit the food which has been in contact with 
an NM may not be useable.  
 
It is therefore obviously important that regulators remain apprised of the most recent reliable 
information with regard to the possible hazards presented by NMs; indeed, we are reassured 
that many of the regulators had already acknowledged this obligation. More challenging, 
however, is the question of how to proceed in situations of uncertainty. As lawyers, we are 
inclined to view this problem as relating to burdens and standards of proof. With regard to 
burden of proof, should regulators, for example, assume that a nanoform of an existing 
product is safe until reliable evidence shows otherwise? Or should they operate the contrary 
assumption: that a new product is unsafe until the contrary can be demonstrated? 
 
Some of the regulatory frameworks we have examined offer some guidance in this regard. 
Section 7 of the HSNO Act, for example, adopts a ‘precautionary approach’, which 
emphasises ‘the need for caution in managing adverse effects where there is scientific and 
technical uncertainty about those effects’.532 In similar terms, the Hazardous Substances and 
New Organisms (Methodology) Order 1998 provides that, where there is technical uncertainty 
or dispute as to the risks posed by a substance, which is not resolved to ERMA’s satisfaction, 
                                                     
532 HSNO Act, section 7 
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ERMA ‘must take into account the need for caution in managing the adverse effects of the 
substance’.533 
 
However, a range of opinions can be found as to how ‘caution’ is to be understood. ERMA’s 
view is that ‘while the HSNO Act provides for decisions to be precautionary where there is 
scientific or technical uncertainty (section 7), it does not empower ERMA to act when there 
are suspicions but little or no evidence.’534 This understanding of s.7 is likely to be 
controversial, not least because it may be thought that many of the situations in which there is 
‘scientific or technical uncertainty’ will arise precisely because ‘there are suspicions but little 
or no evidence’.  
 
Unsurprisingly, some commentators have advocated a more risk-averse understanding of this 
obligation. The Sustainability Council, for example, has called for the withdrawal of 
cosmetics containing NMs ‘until sufficient nanosafety research has been undertaken to assess 
them’. The Council’s report argued that ‘the test of HSNO’s relevance to nanotech is not 
whether it can finger the known, worst offenders (given adequate information), but how it 
caters for the vast number of nanomaterials about which very little is known, some of which 
may turn out to be harmful long after they have been allowed into commercial circulation.’535 
ERMA has rejected this approach: 
 
‘In effect the Sustainability Council arguments are of the “guilty until proven innocent” 
nature.  Our interpretation of the HSNO Act and broader regulatory principles is that while 
novel products are not “innocent until proven guilty” restricting a product through regulation 
requires evidence of risk to be above a minimum threshold (The hard part is determining 
where that threshold is in practice)’536 
 
This is far from a straightforward matter. As one leading commentator on the regulation of 
emerging technologies has said, ‘there is scope for endless argument about just how strong 
the evidence needs to be before precaution kicks in.’537 However, we would submit that 
regulators will require to adopt one or other of these presumptions when dealing with NMs 
about which the evidence of hazard is still uncertain. That is, in the absence of compelling 
evidence either way, NMs must either be presumed to be safe or unsafe. It is unclear what an 
approach avoiding either of those presumptions might look like, even in theory. 
 
Having said that, more nuanced options may exist within those broad presumptions. For 
example, an approach could perhaps be adapted from criminal law, whereby anyone objecting 
to an NM would bear an evidentiary burden of demonstrating some risk of harm – of ‘putting 
the issue into play’, as it has been described – but having passed that threshold, the burden of 
proof would then transfer to the manufacturer to prove that the risk was unfounded or 
adequately managed. This could potentially avoid the possibility of an NM being banned 
because of a mere suggestion of hazard, but would perhaps avoid the danger of regulatory 
paralysis until some harm has actually occurred. 
 
The question of standard of proof has also been identified as an area of possible uncertainty, 
for example, the ‘likelihood’ trigger in Standard 1.4.3 of the FS Code, or the designation as 
‘hazardous’ in terms of the HSE or HSNO Acts. How compelling must the evidence be before 
                                                     
533 Methodology Order, Section 30 
534 Personal correspondence, 9 July 2010 
535 Sustainability Council, The Invisible Revolution, op. cit. 
536 Personal correspondence, 9 July 2010 
537 Roger Brownsword, Rights, Regulation, and the Technological Revolution. Oxford: Oxford 
University Press, 2008, at p.106 
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such triggers are activated? Whether carbon nanotubes would fall within the terms of the 
HSNO Act, for example – and thus, within ERMA’s regulatory remit – would depend upon 
whether ‘they have hazardous properties per HSNO and what test 
methodologies are used to determine those hazardous properties.’538 Since at the time of writing, no 
applications have been received by ERMA for approval of CNTs, this must remain a hypothetical 
question.  
 
It seems likely, however, that CNTs will be a manifestation of mNMs that will generate most 
controversy, at least in the near future. The view has several times been expressed to us, for 
example, that existing evidence about the risks they pose should be sufficient to justify a 
moratorium on their use, or at least on certain uses to which they could be put. ERMA’s view, 
on the other hand, is that the studies published to date are preliminary and inconclusive. 
 
Insofar as existing regulations are not specific about the level of proof that would be required 
to trigger regulatory action, we must agree with the Monash Report that these may be seen as 
potential regulatory gaps. 
 
4.6 Compliance and enforcement 
 
Finally, it should be borne in mind that even the most comprehensive regulatory framework 
will be an ineffective safeguard of public health if no effective mechanism exists to monitor 
and enforce compliance with it. This is what we identified as a third level regulatory gap. For 
example, the notification requirement of the presence of NMs in cosmetics relies upon the 
voluntary compliance of manufacturers. It appears, however, that this requirement has been 
widely ignored. As stressed earlier in the report, we wish to imply no criticism of ERMA 
when we note that such a requirement serves negligible purpose if there is no mechanism in 
place even to ascertain whether it is being complied with.  
 
We therefore make the general recommendation that, before implementing any rule or 
measure to address nano-safety concerns, consideration should be given to the practical 
necessity of monitoring, and where need be, enforcing compliance with that rule or measure. 
This may involve a range of measures, from merely reminding manufacturers in clear terms 
of their obligations, to invoking such legal sanctions as are considered appropriate – though it 
should be noted that, to date, voluntary notification approaches ‘have had limited success both 
nationally and internationally’.539 
 
 Where regulators are not empowered to conduct such monitoring and enforcement roles, 
amendment of their foundation statutes may be required. More often, we suspect, the gaps 
will be the result of policy decisions by the regulators themselves, and the resource realities 




                                                     
538 Personal correspondence with ERMA, 21 December 2010.  
539 NICNAS, Proposal for Regulatory Reform of Industrial Nanomaterials: Public Discussion Paper – 
November 2009, at p.12 
 
 












Agency Triggers Potential Gaps Additional comments 
DoL • The HSE Act applies to places of work. 
Duties are imposed on employers (and others) to 
take all practicable steps to ensure healthy and safe 
workplaces. The concept of ‘hazard’ is central to 
the Act. Employers must identify hazards and 
eliminate, isolate or minimise them. Employers 
must follow this process for hazards, whether or 
not the hazards involve NMs.  
 
• The Code applies to all workplaces in 
which hazardous substances are being used or 
produced, whether or not they contain NMs. 
• There is a potential regulatory gap in that the 
“current state of knowledge” regarding harm 
attributed to many NMs is deficient.  
 
• Although many of the OSH implications of 
NMs and nanoparticles are unknown, scientific 
studies indicate that adverse health consequences are 
possible from NM and nanoparticle use and 
exposure. For some nanoparticles, such as carbon 
nanotubes, the small size and fibre shape has led to 
speculation that carbon nanotubes may have similar 
adverse health effects to asbestos fibres. Workers in 
workplaces are potentially being exposed to 
nanoparticles, hazardous substances and dangerous 
goods containing NMs. The main exposure routes are 
inhalation and dermal absorption. 
 
• A potential regulatory gap may exist if the 
deficiencies in nanotoxicology prevent a potentially 
harmful NM from being identified as a significant 
hazard. However, significant hazard is defined in the 
HSE Act as an actual or potential cause or source of 
serious harm… (section 2, our emphasis). If the NM 
is a potential cause of harm, it could be identified as 
a significant hazard and, therefore, trigger the 
Although there is no 
environmental safety assessment 
under the HSE Act, this is 
intentional and a result of the 
scope of the Act and because of 
coverage under the HSNO Act.  
 
The HSE Act drafters wanted to 
separate regulating safety at 
work from general regulation of 
product liability issues. 
Therefore, the regulation of 
product liability issues (including 
products containing NMs) falls 
outside the scope of the HSE 
Act.However, the HSE Act 
applies to places of work in 
which hazards (which means 
inter alia, substances) and/or 
significant hazards are identified, 
whether or not those hazards 
and/or significant hazards 
involve NMs.   
 
 






Agency Triggers Potential Gaps Additional comments 
hierarchy of action. In addition, the HSNO Act is the 
primary legislative instrument for dealing with 
hazardous substances.   
 
• There is no approval prior to the regulated 
activity. However, the HSNO Act is the primary 
legislative instrument for dealing with hazardous 
substances.  
 
• There is no environmental safety assessment 
under the HSE Act. However, the HSNO Act is the 
primary legislative instrument for dealing with 
hazardous substances.    
 
• Current processes may not consider the high 
surface area and increased reactivity of NMs. 
Therefore, the current methods and procedures may 
be inadequate for the safety of workers. Hazard 
assessment for nanoparticles needs to consider shape, 
chemical properties, the role of particle size, 
functionality and dose. 
 
• There is no national or international agreed 
definition to describe nanoparticles. Second, 
equipment and methods to enable routine 
measurements of nanoparticles are not yet 
available.   
 
• It is unclear whether designers, manufacturers 
and suppliers of plant, not specifically concerned 
with NMs, would or should be aware of the presence 
 






Agency Triggers Potential Gaps Additional comments 
of NMs and their risks.   
 
• Identification of the hazardous substance 
requires suppliers to detail the chemical identity and 
CAS Number of the substance. This identification 
will not necessarily reflect the fact that the chemical 
is in nanoform.  
 
• The physical and chemical properties of the 
substance are to be included in SDS. Particle size is 
not specifically noted as a relevant property. The 
SDS may also describe other properties and 
additional information (at the supplier’s option). The 
supplier could describe the particle size of the 
substance in these sections of the SDS, but the 
supplier is not required to do so. However, SDS are 
required under the HSNO Act.   
 
 
• Health hazard information is required. 
However, there are deficiencies in the toxicological 
data for NMs, particularly for chronic exposure.    
 
• SDS could alert users to the presence of NMs 
and the risks posed by them, but there is no guarantee 
that this will occur.  
 
• The Code, generally, and health hazard 
information specifically, does not expressly 
distinguish between nano and conventional forms of 
chemicals.   
 






Agency Triggers Potential Gaps Additional comments 
 
• SDS do not impose obligations on suppliers to 
disclose whether a substance is, or originated as, a 
NM and may, thus, have special properties. Given 
deficiencies in current knowledge regarding the 
safety of NMs, SDS requirement that health hazard 
information should be included is unlikely to trigger 
the provision of nanotoxicological information. 
These gaps mean that users may not receive adequate 
information on the possible hazards of substances to 
workers. However, these aspects are more applicable 
to HSNO Act requirements.   
   
• Minimisation of the risk of substances 
hazardous to health may be achieved by a variety of 
practices such as personal protective equipment 
(PPE). However, it is likely that nanoparticles will be 
able to penetrate the material from which the 
protective clothing is made more readily than macro 
particles.  
 
• Ecotoxicity assessment is not required but this 
is covered by the HSNO Act.  
 
ERMA • HSNO Act applies only to ‘substances’ that 
are ‘hazardous’. Substance is ‘hazardous’ if 
it meets or exceeds one of the thresholds set 
down in the Hazardous Substances 
(Minimum Degrees of Hazard) Regulations 
2001 
• If a substance reaches one of these, ERMA 
• Doubts exist regarding designation of 
nanoform as a new hazardous substance. Otherwise, 
would be covered by existing approval, and no new 
assessment required. 
 
• Manufactured products containing mNMs 
(e.g. nano-silver in washing machines, or products 
• Gap re low volume 
permits, identified in Monash 
Report, not applicable to New 
Zealand. R&D exemptions, 
however, do apply, and perhaps 
merit closer examination. 
 
 






Agency Triggers Potential Gaps Additional comments 
approval will be required before it can be 
imported, manufactured or used. ERMA 
will decide whether the substance’s likely 
benefits outweigh any risks and costs. 
 
containing carbon nanotubes) may be ultra vires of 
ERMA’s regulatory remit.  
 
• No requirement for nano-specific labelling, or 
public register of products containing mNMs. 
 
• ERMA’s interpretation of precautionary 
approach – as required by HSNO Act – subject to 
some criticism. How much and how clear must 
evidence be before a substance can be treated as 
‘hazardous’ (e.g. in the contentious example of 
carbon nanotubes)? 
 
• Some doubts have been raised about the 
exemption for ‘small-scale use of hazardous 
substances in research and development or teaching’ 
• Appears to be open to 
ERMA to use Group Standards 
to extend regulatory remit to 
manufactured articles 
containing, incorporating or 
including hazardous substances. 
(HSNO Act, s. 96B(2)(d)). 
Doubts, however, concern 
certain manufactured items that 
appear to create mNMs 
subsequent to sale; do they 
‘contain, incorporate or 
include’ a hazardous substance 
at the point of pre-market 
assessment?   
 
FSANZ • Food will require a pre-market safety 
assessment if it is classified as ‘novel’ (FS 
Code, Standard 1.5.1). New food additives  will 
not be permitted without prior regulatory 
approval, in the form of an amendment to the 




• Some potential room for uncertainty around 
whether food, food additives or contact materials  
should be classified as ‘new’/‘novel’.  
 
• Absence of nano-specific labelling 
requirement regarded by some as unsatisfactory.  
 
 
• Some additives, etc permitted subject to 
quantative restrictions (e.g. some colourings 
permitted subject to maximum levels of 290 mg/kg in 
foods and 70 mg/L in beverages.) Doubts have been 
raised regarding suitability of such limits to 
nanoforms. 
• As with other regulatory areas, doubts have 
• ‘comprehensive review 
of food labelling law and 
policy’, commissioned by the 
Australia and New Zealand 
Food Regulation Ministerial 
Council, is currently 
approaching completion. 
 






Agency Triggers Potential Gaps Additional comments 
been expressed regarding adequacy of current risk 
assessment methodologies in view of limited 






• If products (including medicines, medical 
devices, related products, herbal remedies) are 
used for a therapeutic purpose,  whether or not they 
contain NMs.  
• Exemptions  
 
• Definitions such as medicine and medical 
devices are inconsistent with international norms.  
 
• There is no approval process for medical 
devices.   
 
• There is no human safety assessment for 
medical devices.  
 
• As combination therapies, such as 
nanotherapeutics, confuse the boundaries between 
‘medicine’ and ‘medical device’, it is doubtful 
whether the Meds Act definitions can manage the 
challenges posed by these combinations. 
 
• Risk assessment is only concerned with 
human health and safety. Medsafe is not required to 
consider broader environmental risks associated with 
therapeutic products (e.g. those with NMs).  
 
• The human safety assessment process under 
the Meds Act is concerned with the principles of 
benefit/risk analysis, rather than solely the 
technology per se. This assessment method may not 
• Exemptions and exempt 
products 
 
• Potential for increase in 
products which blur the 
boundary between ‘medicine’ 
and ‘medical device’.  
 
• Potential for increase in 
number of products which sit at 
the NZFSA, ERMA/MfE and 
Medsafe interface.  
 






Agency Triggers Potential Gaps Additional comments 
be appropriate for nanomedicines where there exists 
a deficiency of long-term exposure and 
nanotoxicology data. There may be long-term effects 
which present benefit/risk assessments fail to 
consider.  
MfE • The disposal & minimisation of waste, 
whether or not some of the constituents of waste 
contain NMs. 
 
• If products are considered waste, whether 
or not they contain NMs or are produced using 
nanotechnology.  
 
• The actions of territorial authorities (e.g. 
s42). 
• While some products containing NMs will be 
considered ‘waste’, it is unclear whether this control 
will be adequate for classifying risks associated with 
products containing NMs. 
 
• The WMA encourages waste minimisation. 
Therefore, the Act deals with some events before 
they occur. There are powers in the Act to prohibit 
the disposal of certain types of waste.  However, 
there will be challenges in applying the Act to NMs. 
Although there are potential health and 
environmental risks associated with NMs, to date 
there have been no documented cases of adverse 
environmental effects directly attributable to NMs. 
The current lack of data on exposure and 
ecotoxicological properties of some NMs means that 
products containing NMs may not be singled out as 
products likely to harm the environment when 
disposed of as waste.   
• Under WMA, the Ministry for the 
Environment does not undertake safety assessments. 
But ERMA does conduct safety assessments.  
• The WMA includes monitoring, compliance 
• It is unlikely that the 
monitoring techniques under the 
WMA are adequate for 
detecting NMs that are released 
into the environment. This issue 
is not limited to NZ.   
 
• Section 23(1)(b) 
concerns controlling or 
prohibiting the manufacture or 
sale of products that contain 
specified materials. This section 
could potentially cover products 
with NMs. 
 
• There is currently no 
national policy statement or 
national environment standard 
covering NM disposal 
management.540 
                                                     
540 We are grateful to Ceri Warnock for asking whether a RMA NPS or NES is required for NM disposal management, or whether the WMA (with revision) could provide 
appropriate national consistency.  
 






Agency Triggers Potential Gaps Additional comments 
and enforcement provisions in relation to managing 
environmental harm. However, few of the 
enforcement and auditing powers are likely to be 





• FTA:  
o ‘Goods’ and ‘unsafe goods’ whether or not 
they contain NMs.  
o The FTA will be triggered if a person in 
trade engages in conduct that is misleading or 
deceptive, whether or not that conduct is 
misleading or deceptive in relation to goods 








o ‘Goods’ whether or not they contain NMs.  
o The statutory guarantees in the supply of 
goods apply to goods whether or not they 
contain NMs. 
o Specifically, the statutory acceptable 
quality (safety) guarantee applies to all 
‘goods’ that are supplied to a consumer, 
whether or not they contain NMs.   
o Specifically, the guarantee of fitness for a 
particular purpose applies whether or not the 
goods supplied to a consumer contain NMs.  
 
• FTA:  
o There is no approval prior to the regulated 
activity, therefore the statutory regime is primarily 
reactive rather than proactive.  
o There are no human and environmental safety 
assessments. 
o However, these comments apply to all goods, 
including those containing NMs, due to the 
deliberate scope, and reactive nature of, the 
legislation.  
• CGA: 
o There is no approval prior to the regulated 
activity.  
o There are no human and environmental safety 
assessments.  
o There is no post-market monitoring.  
o However, these comments apply to all goods, 
including those containing NMs, due to the 
deliberate scope of the legislation. 
• There are no nano-
specific product safety 
standards. 
 






Agency Triggers Potential Gaps Additional comments 
NZCS  • Applies to the importation of goods, whether 
or not they contain NMs. 
• The NZ government may place prohibitions 
and restrictions on the importation of goods. At 
present, the goods will be prohibited or restricted 
by virtue of falling within one of the three general 
sources of prohibitions and controls on imports, 
and not as a consequence of the goods containing 
NMs. 
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5 CONCLUSION  
 
It may be seen, then, that some of the potential gaps we have identified are quite specific to a 
particular regulatory area. Others – such as the challenge of deciding what burden and 
standard of proof, or attitude towards precaution, is most appropriate in the face of uncertain 
evidence – are likely to be common to all regulators, and probably in all jurisdictions. Insofar 
as specific gaps have been identified, we have tried where possible to consider some possible 
strategies whereby they could be closed, or at least narrowed. Where we have done so, these 
should be seen merely as options for further consideration, rather than explicit 
recommendations on our part.  
 
As the Monash Report concluded, it is now for each of the regulatory agencies to consider in 
detail the potential gaps we have identified, and to consider whether these potential gaps 
require some action on their part. If some action is regarded as appropriate, detailed 
consideration should then be given to what form of action would be most appropriate to the 
gap in question, giving consideration to the scale and urgency of the possible problem, and to 
issues of proportionality. 
 
This report, then, in no ways purports to be the last word on the subject of regulation of 
nanoproducts in New Zealand. It is hoped, however, that it will make a worthwhile 
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APPENDIX TWO: ABBREVIATIONS USED FOR LEGISLATION  
 
Abbreviation  Statute  
 
CEA Customs and Excise Act 1996 
CGA Consumer Guarantees Act 1993  
Food Act   Food Act 1981 
FS Code  Australia New Zealand Food Standards Code  
FTA Fair Trading Act 1986 
HRC Act  Health Research Council Act 
HSNO Act  Hazardous Substances and New Organisms 
Act 1996 
 
HSE Act  Health and Safety in Employment Act 1992 
 
Meds Act  Medicines Act 1981  
RMA Resource Management Act  1991  
WMA Waste Minimisation Act 2008 
 
       
 
       
 
    
     
 
  
